Cryptosporidium antigens

Administering specific cryptosporidial antigens like Gp900 and Cp23, either as proteins or encoded by self-replicating RNA, induces protective immunity against Cryptosporidium, addressing the lack of a vaccine for cryptosporidiosis and reducing infection risk and severity.

WO2024243278A1PCT designated stage expired Publication Date: 2024-11-28UNIV OF VIRGINIA +6
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/030512
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-22
Filing Date
2024-05-22
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

There is no effective vaccine available to protect against cryptosporidiosis, a leading cause of diarrhea in infants in low- and middle-income countries, and current methods fail to comprehensively identify parasite antigens associated with protection from reinfection.

Method used

A method involving the administration of cryptosporidial antigens such as Gp900, CpMuc8, CpSMP1, CpCCDC, CpCorA, Cp23, and Cp17, either as proteins or encoded by self-replicating RNA, to induce protective immunity, potentially combined with an adjuvant like GLA-3M052, to inhibit or prevent Cryptosporidium infections.

Benefits of technology

The proposed method elicits an immune response that reduces the risk and severity of Cryptosporidium infections, providing protection against reinfection and potentially delaying the onset of infections.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000021_0001
    Figure IMGF000021_0001
  • Figure IMGF000031_0001
    Figure IMGF000031_0001
  • Figure IMGF000051_0001
    Figure IMGF000051_0001
Patent Text Reader

Abstract

The present invention is directed to methods and compositions to protect against a Cryptosporidium infection, comprising one or more cryptosporidial antigens selected from Gp900, CpMuc8, CpSMP1, CpCCDC, and / or CpCorA, optionally Cp23 and / or Cp17.
Need to check novelty before this filing date? Find Prior Art

Description

[0001]PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 CRYPTOSPORIDIUM ANTIGENS PRORITY This application claims the benefit of priority of U.S. Provisional Patent Application No. 63 / 503,580, filed on May 22, 2023, and is incorporated by reference herein in its entirety. GOVERNMENT GRANT SUPPORT This invention was made with government support under AI043596 awarded by the National Institutes of Health. The government has certain rights in the invention. BACKGROUND Cryptosporidium parasites are a common cause of diarrhea in infants and children in low- and middle-income countries, globally are the most common cause of outbreaks of waterborne disease, and in immunocompromised individuals can cause protracted infections. SUMMARY There is no vaccine to protect from cryptosporidiosis, a leading cause of diarrhea in infants in low- and middle-income countries. A comprehensive identification of parasite antigens associated with protection from reinfection is provided herein. A Cryptosporidium protein microarray was constructed by in vitro transcription and translation of 1761 C. parvum, C. hominis or C. meleagridis antigens, including proteins with a signal peptide (376) and / or a transmembrane domain (327). Plasma IgG and / or IgA from Bangladeshi children longitudinally followed for cryptosporidiosis from birth to three years of age, identified 233 seroreactive proteins. Seven of these were associated with protection from reinfection. These included Cp23, Cp17, Gp900, CpSMP1, CpMuc8, CpCorA and CpCCDC1. Provided herein is antigen selection for an immune modulating composition, such as a vaccine. One embodiment provides a method to inhibit or prevent a Cryptosporidium infection, including a reinfection, comprising administering an effective amount of a cryptosporidial antigen to a subject, wherein said cryptosporidial antigen comprises one or more of Gp900, CpMuc8, CpSMP1, CpCCDC and / or CpCorA or portion thereof which elicits an immune response. In one embodiment, the cryptosporidial antigen further comprises Cp23 and / or Cp17. In another embodiment, the cryptosporidial antigen further comprises Cp_Claudin_Pf or CpPGM. In one embodiment, RNA encoding the cryptosporidial antigen, such as self-replicating / self-amplifying RNA, DNA encoding the cryptosporidial antigen, or cryptosporidial antigen protein is administered. In one embodiment, the DNA and / or RNA code for two more cryptosporidial antigen proteins. One embodiment further comprises administering an adjuvant, such as GLA-3M052. In one embodiment, the cryptosporidial antigen is administered more than once. PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 One embodiment provides a method for inducing protective immunity against Cryptosporidium infection in a human comprising administering an effective amount of cryptosporidial antigen to the human, wherein said cryptosporidial antigen comprises one or more of Gp900, CpMuc8, CpSMP1, CpCCDC and / or CpCorA or portion thereof which elicits an immune response. In one embodiment, the cryptosporidial antigen further comprises Cp23 and / or Cp17. In another embodiment, the cryptosporidial antigen further comprises Cp_Claudin_Pf or CpPGM. In one embodiment, RNA encoding the cryptosporidial antigen, such as self-replicating / self-amplifying RNA, DNA encoding the cryptosporidial antigen, or cryptosporidial antigen protein is administered. In one embodiment, the DNA and / or RNA codes for two more cryptosporidial antigen proteins. One embodiment further comprises administering an adjuvant, such as GLA-3M052. In one embodiment, the cryptosporidial antigen is administered more than once. In one embodiment, the protective immunity reduces a risk of Cryptosporidium infection. In another embodiment, the protective immunity delays onset of Cryptosporidium infection and / or reduces the severity of Cryptosporidium infection. One embodiment provides a method to provide passive immunity to a subject comprising administering one or more antibodies to said subject, wherein said one or more antibodies are directed to at least one of Gp900, CpMuc8, CpSMP1, CpCCDC, CpCorA or portion thereof or optionally comprising Cp23, Cp17 or portion thereof. I one embodiment, the antibody is a monoclonal antibody. The method of making and using antibodies is well known in the art and carried out methods available to an art worker. One embodiment provides a composition comprising at least one of Gp900, CpMuc8, CpSMP1, CpCCDC and / or CpCorA or portion thereof and an adjuvant, and optionally comprising Cp23 and / or Cp17. In one embodiment, the cryptosporidial antigen protein is any one of SEQ ID NOs: 10 to 23 or a sequence that has at least about 80% sequence identity thereto. BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1C. Humoral immunity to Cryptosporidium antigens was isotype specific. Immune responses are shown for (A) IgA and (B) IgG antibodies. The Y-axis is signal intensity after normalization and the X- axis shows Cryptosporidium antigens ranked by median signal intensity. Bars represent the interquartile range of each antibody response and are shown as red if antibodies were present in > 10% of infants (seroprevalent). (C) The Venn diagram shows seroprevalent Cryptosporidium antigens with IgA- and IgG-specific and overlapping immune responses. FIG. 2. Cryptosporidium antigens recognized by IgA and IgG antibodies. The proteomic microarray was used to measure the parasite specific antibody response in the infants enrolled into PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 the study cohort at one year in age. Previously infected children (columns) and the Cryptosporidium antigens (rows) that stimulated a strong IgG and / or IgA antibody response (present in > 10% of the children; n=232 antigens) are shown. The spot signals were normalized by first determining the specific background component by use of mixture models and setting this value to 0. Bar at the top of each heat map indicates the total number of Cryptosporidium antigens each child responds to (Antibody Breadth). The side bars indicate a) the seroprevalence of each antigen and b) presence of a membrane targeting signal peptide (SP). FIGS. 3A-3F. Antibody responses waned with time after a Cryptosporidium infection. (A) The t-SNE plot identified a subset of children with a similar antibody profile. Each point corresponds to the immune profile of a child. Gray squares indicate children where no previous Cryptosporidium infections had been identified by qPCR in clinical or surveillance stool samples ("qPCR-”), and orange circles represent children that had previous infections detected by qPCR (“qPCR+”), with the intensity of the overlaid color indicating the days since the last Cryptosporidium qPCR+ stool sample was identified. A group of infants had similar antibody profiles and a high density of recent infections (R1). (B) The split violin plot of antibody signals against the 100 most reactive antigens (Y-axis) for each isotype (X-axis) shows the responses of children within the R1 region of the t-SNE plot compared to the remainder of the samples in R2. The median and quartile values are shown as horizontal lines in each split violin. (C) The split violin plot shows the same comparison as (B) using the antibody breadth (count of seropositive responses) among the 100 most reactive antigens. P- values above each split violin were calculated using linear mixed effects regression (LMER) and Wilcoxon’s rank sum tests for (B) and (C), respectively. (D) Antibody breadth among the 100 most reactive antigens for each isotype is shown on the Y-axis after log10 transformation with the interval (days) between the last Cryptosporidium qPCR positive diagnostic assay and the time of antibody measurement shown on the X-axis. Linear regression P-values and R2 values are shown for IgG and IgA, as well as a line and confidence intervals (colored bands) fit to each. (E) and (F) PLS-DA is shown for IgA and IgG responses respectively. Each point corresponds to the immune profile of a child. The purple circles indicate the antibody response obtained from plasma that was collected from children where none of the stool samples (diarrheal or surveillance) collected during the first year of life, prior to the plasma sampling time point, were ever qPCR positive for Cryptosporidium parasites (“Yr0-1 qPCR-”). Green triangles indicate that the child had a verified Cryptosporidium sub-clinical or symptomatic infection (“Yr-0-1 qPCR+”). The percentage of the variation in the child’s antibody profile accounted for by each axis is indicated. FIGS.4A-4C. The breadth of the anti-Cryptosporidium immune response was not correlated with protection from infection. (A) Split violin plot of antibody breadth in plasma among the 100 PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 most reactive antigens (Y-axis) for each isotype (X-axis) is shown for the comparison between children that had no stool samples (diarrheal or surveillance) qPCR positive for Cryptosporidium parasites (purple) and children who had a verified Cryptosporidium infection (green). (B) Data is shown from one year old infants who had prior qPCR-confirmed Cryptosporidium infections (“Yr0- 1 qPCR+”) that were subsequently uninfected (blue) or reinfected (orange) during the next two years. (C) Data is shown from one year old infants that included both the immunologically naïve infants with no prior Cryptosporidium infections detected by qPCR in stool samples (diarrheal or surveillance) as well as those with qPCR+ stool samples during the first year of life. Medians and quartiles are indicated by horizontal lines in each split violin. Significant P-values from Wilcoxon’s rank sum tests are shown above violins. N.S.: not significant. FIGS.5A-5F. Children with antibodies that targeted the C. hominis peptides encoded by the gp60 gene and Cp23 protein were associated with protection from reinfection. In the protein array data, IgA and IgG antibodies against the protein encoded by the C. hominis gp60 gene (Chro.60183) and IgG against Cp23 (Chro.40414) were associated with a delay in Cryptosporidium reinfection among children with a qPCR verified Cryptosporidium infection during the first year of life (A, C, E) or among all children in the study (B, D, F). The X-axis shows days after the end of year one (when the assayed plasma samples were collected). The Y-axis shows the proportion of children who remained uninfected. Red lines represent children seronegative for the antigen, and blue lines represent seropositive children. The Kaplan-Meier curves show the probability of survival free of Cryptosporidium species, and the tables below the graphs indicate the number of children in the seropositive or seronegative categories at select time points. (A-B) IgG against Gp60 (Chro.60183). (C-D) IgA against Gp60 (Chro.60183). (E-F) IgG against Cp23 (Chro.40414). Hazard ratios (HR), confidence intervals and p-values were calculated using multivariable Cox proportional hazards models. FIGS. 6A-6C. gp60 Genotype immune response. (A) Cartoon illustrating the proteins encoded by the gp60 gene. Heat map showing the intensity and breadth of the (B) IgA and (C) IgG antibody responses to the polymorphic region of the Gp40 protein. The different alleles of the peptide encoded by the gp60 allele (columns), and the signal obtained when using the plasma with antibodies raised in response to infection of parasite with different gp60 genotypes (rows). Lines at the top of each heat map indicate the protein type and on the side the genotype of the infecting parasite. Parasite genotypes: rows 1-8 IaA18R3; 9; IaA19R3; 10-16 IaA25R3; 17-20 IbA9G3R2; 21-29 IdA15G1; 30 IfA13G1; 31-34 C. parvum IIdA15G1R1. Protein alleles columns A IaA27R3, B IaA26R3, C IaA25R3, D IaA22R3, E IaA19R3 F IaA18R3, G IbA9G3R2, H IdA14G1, I IdA15G1, J IeA11G3T3, K IfA13G1, L IfA16G1, M IIcA5G3a N IIdA13G1. Side panels show the intensity scale for the PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 amount of antibody binding to alleles expressed by IVTT and spotted on the array. Antibody binding to the purified recombinant relatively conserved Cp17 peptide was included on the array as a positive control. Its signal intensity was higher than that of the IVTT values. FIGS. 7A-7G. Random Forest analysis for selection of important antigens and analysis of risk during the first year after sampling. (A) The scatter plot represents antigens and clinical variables ranked by variable importance (“VIMP”) scores in random forest (“RF”) using 1,000 trees constructed per model. Models were fit to survival data during one year of follow-up after sampling on seropositive and seronegative children that all previously had qPCR-confirmed Cryptosporidium infections. Models using the entire cohort of children and two-year follow-up periods are shown in FIG.16. Each model was repeated 100 times, and the VIMP score was averaged across all runs (Y- axis). For each antigen, the percentage of runs where VIMP was greater than 0 (i.e., important to the model) was calculated (X-axis). The red horizontal dashed lines represent the mean of all VIMP scores plus one standard deviation. The vertical dashed red lines represent antigens with at least 80% positive VIMP scores. The upper right quadrant shows the antigens selected as important variables in the model. (B) The horizontal bar plot represents VIMP scores for each antigen with at least 80% positive VIMP scores. The vertical red dashed line represents the cutoff for selection of important variables (equivalent to the horizontal lines in (A). Hazard ratios calculated in the survival analysis were shown as protective (HR < 1, teal) or not (HR > 1, magenta). (C) Only protective antigens with at least 80% positive VIMP scores and VIMP scores above the importance cutoff were selected for individual antigen analysis. (D-G) The Kaplan Meier plots represent the two most significant novel antigens associated with protection in children with prior qPCR+ stool samples or all children, respectively, after feature selection using random forest. FIGS. 8A-8E. Cryptosporidium antigens associated with the development of a protective immune response. (A) The survival curve illustrates the two subgroups of children and two follow- up periods after plasma was collected (end of year one) that were analyzed for protection. The blue line follows only children who had a qPCR-verified Cryptosporidium infection (sub-clinical or symptomatic) during the first year of life, prior to sampling plasma. The red line follows all children in the array study and includes the immunologically naïve children that remained uninfected at one year of age as well as those known to be previously infected. Dotted and dashed lines indicate the time points (year 2 and year 3) selected for analysis of the differences between uninfected and infected groups looking specifically at the protective candidate antigens identified in Table 1. (B and C) PLS-DA on the antibody profiles of the candidate antigens shown in Table 1 associated with either reinfection or protection. Each point represents the immune profile from one year old children with prior qPCR-verified Cryptosporidium infections who were subsequently uninfected (blue circles) or PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 reinfected (orange triangles) during the one-year follow-up period (B) or two-year follow-up period (C) after plasma samples were collected. (D and E) Predictor loadings derived from the PLS-DA analysis in (B) and (C) are shown, respectively. Antibody targets are shown on the Y-axis, and the X-axis shows the absolute value of the loading weights (or PLS-DA regression coefficients); the absolute value was used to focus attention on the importance of each antigen in maximizing the covariance between antibodies and Cryptosporidium infection outcomes. Orange bars indicate antibodies more abundant in the children who subsequently had a new Cryptosporidium infection, and blue bars indicate the antibodies more abundant in the uninfected children. FIG. 9. Frequency of new Cryptosporidium infections over the first three years of life. Positive samples (Cq values <40) were grouped into one infection if collected at < 65-day intervals. The day when the first positive sample was collected was used for tabulation purposes and reported as the child’s age in days. The number of new infections (diarrheal or sub-clinical) in each 30.4 days window is displayed on the Y axis. On the X axis is the child’s age. FIG. 10. Cryptosporidium Protein Microarray Design. The array included 522 conserved antigens derived from proteins (n=376) that contained a signal peptide (C. parvum: antigens 382; C. hominis: 155 antigens (134 derived from the C. hominis orthologues of “high value” C. parvum proteins already on the array); C. meleagridis: 6 antigens (also represented by other orthologues on the array). Additional antigens from proteins (n=327) without a signal peptide, but which nevertheless had a transmembrane domain, were included on the array (total antigens: 457; C. parvum antigens: 365; C. hominis antigens: 90 (66 were derived from the C. hominis orthologues of C. parvum proteins already on the array); C. meleagridis 2 (both also represented by other orthologues on the array). The Cryptosporidium parasites have a complex life cycle. Within the host life-stages are either extracellular or intracellular and differ in their protein repertoire. Proteins expressed in the sporozoite / oocyst life stages Cryptosporidium proteome (mass spectrometry data) number of proteins represented on array: 451; reactive proteins: IgG: n=64; IgA: n=28) (38, 77). Differentially expressed transcripts were included in the array design although antigens may only be translated and interact with the host immune system in the successive life stages (41, 78). Transcriptional changes in C. parvum oocyst / sporozoites: total number of proteins represented on array: 409; reactive antigens: IgG: n=34; IgA: n=22. Transcriptional data Meront / trophozoites enriched (24h after infection) (total number of proteins represented on array: 248; reactive antigens: IgG: n= 29; IgA: n= 29) Merozoite enriched (48h after infection) (total number of proteins represented on array: 548; reactive antigens: IgG: n= 62; IgA: n= 39). Gametocytes (in vivo and in vitro female gamonts) (37) (total number of proteins represented on array: 544; reactive antigens: IgG: n= 62; IgA: n= 42). PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 FIG. 11. Selection criteria for C. parvum antigens from proteins containing either a Signal Peptide and / or a Transmembrane Domain. The final array included 382 conserved C. parvum antigens from proteins that contained a signal peptide. An additional 365 C. parvum antigens included on the array were from proteins without a signal peptide, but which nevertheless had a transmembrane domain. FIGS. 12A-12B. Normalization of the signal from the IgG antibodies binding to the C. hominis antigen encoded by the gp60 gene. (A) The density plot shows the distribution of the array normalized fluorescence signal intensity (SI) values of each antigen on the X-axis. Red line: Gaussian distribution of negative signals determined by mixture model; Green line: Gaussian distribution of positive signals determined by mixture model; Blue line: antigen specific seropositivity cut-off value determined using the mean plus 3 standard deviations of the background (red line); Yellow line: high intensity signal representing signals 4-fold higher than the entire array background. (B) The ROC graph compares the ability of different background cut-off values to predict which children had been previously infected (fecal DNA positive using a diagnostic qPCR assay). Dotted lines indicate the performance of the threshold cut-off values predicted by mixture model (Mx-Mdl) and median signal intensity (median). FIGS.13A-13C. Correlation between and within IgG and IgA responses. The correlograms show Spearman’s correlation coefficients on a color scale for antibody responses between reactive Cryptosporidium antigens. Antigens are ordered using hierarchical clustering. The color scale for Spearman’s correlation coefficients is located below each correlogram with red values indicating negative correlation and blue values indicating positive correlations. (A) antigens reactive against IgG (n=176); (B) antigens reactive against IgA (n=93); (C) antigens reactive against both IgG and IgA (n=36). FIGS.14A-14E. T-SNE plot of antigen responsiveness overlaid with biomarkers of immune function. (A) The overlaid color indicates child HAZ score at the end of three years as described in the figure legend. Square boxes indicated children with cryptosporidiosis. The HAZ score was not linked to any particular immunological profile. Correlation was also not observed between the immune profile and any of the biomarkers of inflammation measured in the child’s plasma at one year of age (B) sCD14 (C) IL-1b (D) CRP or (E) IL-4 the biomarker of the activation of the subpopulation of T-cells which are the most biologically active helper cells for B-cells (values indicated by the appropriate figure legend). FIG.15. Discordant results evidenced by the IVTT spot on the array. Antibody signals are shown for the antigen encoded by the IbA9G3a allele of the gp60 gene. The left Y-axis shows the signals obtained from the IgA antibodies (blue points). The right Y-axis shows the signals obtained PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 with the IgG antibodies (black spots). The X-axis shows the gp60 genotypes of the parasites known to have infected the child prior to blood collection (IbA9G3a genotype in bold with*): 1-8 IaA18R3; 9; IaA19R3; 10-16 IaA25R3; 17-20 IbA9G3R28; 21-29 IdA15G1; 30 IfA13G1; 31-34 C. parvum IIdA15G1R1. FIGS.16A-16F. Random Forest analysis for selection of antigen variables and analysis of risk. (A, C, E) The scatter plots represent antigens and clinical variables ranked by variable importance (“VIMP”) scores in random forest (“RF”) using 1,000 trees constructed per model. Models were fit to survival data during (A) one year of follow-up after sampling on all seropositive and seronegative children in the cohort, (C) two years of follow-up in children that had all been previously infected with Cryptosporidium, and (E) two years of follow-up in all children in the cohort. Each model was repeated 100 times, and the VIMP score was averaged across all runs. For each antigen, the percentage of runs where VIMP was greater than 0 (i.e., important to the model) was calculated. The red horizontal dashed lines represent the mean of all VIMP scores plus one standard deviation. The vertical dashed red lines represent antigens with at least 80% positive VIMP scores. The upper right quadrants show the antigens selected as important variables in the model. (B, D, F) The horizontal bar plots represents VIMP scores for each variable with at least 80% positive VIMP scores. The vertical red dashed lines represent the cutoff for selection of important variables (equivalent to the horizontal lines in A, C, E, respectively). Hazard ratios calculated in the survival analysis were shown as protective (HR < 1) or not (HR > 1). Generally protective antigens with at least 80% positive VIMP scores and VIMP scores above the importance cutoff were selected for specific antigen analysis. FIGS.17A-17D. Survival analysis of all antibodies against all reactive antigens. The volcano plots display the log hazard ratio (“HR”) of multivariable Cox proportional hazards models of each reactive Cryptosporidium antigen (IgG or IgA seropositive vs. seronegative antibody responses) associated with time until Cryptosporidium infection (All Children) or reinfection (among subset of children with qPCR+ stool samples collected during the first year of life; “Yr0-1 qPCR+” Children) during the 1 year or 2-year follow-up periods after sampling at 1 year of age. Points represent antigens, and triangles represent antigens that have been identified as important variables associated with risk of infection in random forest analysis for each of the four survival analyses: (A) 1 year follow-up in previously infected children, (B) 1 year follow-up in all children in the cohort, (C) 2- year follow-up in previously infected children, and (D) 2 year follow-up in all children in the cohort. Values below 0 represent a reduction in risk (HR < 1), whereas values above 0 represent an increase in risk with seropositive antibody responses (HR > 1). The y-axis shows -log10 p-values from the Cox models adjusted for demographic and environmental variables. The horizontal red line PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 represents a raw p-value of 0.05. The gene IDs of the proteins identified in each respective random forest analysis, as well as proteins that had raw p-values < 0.05, are labeled next to respective points. Among the antigens not identified in random forest analysis, no p-values remained significant after correction for the false discovery rate when adjusting for all comparisons. FIG.18. Correlation between protective antibodies identified in random forest analysis and antibodies associated with higher risk of reinfection. The correlogram shows the correlation between signals for antigens with IgG responses associated with protection (hazard ratio < 1) and those associated with increased risk of infection (hazard ratio > 1) that were identified as important variables in random forest analysis. Protective antibodies: Gp60, Cp23, Gp900, CpSMP. Antibodies associated with increased risk: cgd4_1910, Chro.10174, cgd8_3610 and cgd3_4190. The X-axis shows normalized IgG signals for the antigen above the column, and the Y-axis shows the normalized IgG signals for the antigen to the right of the row. Data points are colored by children that had qPCR+ stool samples during the first year of life (Yr0-1 qPCR+, purple) and those without qPCR+ stool samples (Yr0-1 qPCR-, green). A smooth line is shown for all of the samples in red. FIG.19. Correlation of protective antibodies and antibodies associated with increased risk of reinfection with inflammatory and T cell activation markers for B cell help. The correlogram shows the Spearman’s correlation coefficients for the comparisons between antibody levels against antigens identified in random forest analysis and HAZ scores, IL4, CRP, IL1β and sCD14 levels. Protective antigens: Gp60, Cp23, Gp900 and CpSMP; antigens associated with increased risk of subsequent infection: cd4_1910, Chro.10174, cgd8_3610 and cgd3_4190. FIGS.20A-20R. (A-R) Antigens associated with a delay in infection in the survival analysis but not selected by random forest analysis. The Kaplan-Meier curves show associations of seropositivity to cryptosporidial antigens with a delay in Cryptosporidium infection during the 1 year and 2-year follow-up periods following plasma sampling at 1 year of age. The X-axis shows days after the end of year one (when the assayed plasma sample was collected). The Y-axis shows the proportion of children who remained uninfected as defined by qPCR+ clinical or surveillance stool samples during follow-up. The tables below the graphs indicate the number of children in the seropositive (blue lines) or seronegative (red lines) category at select time points. Antigens are indicated at the top of each panel, along with the follow-up period and the antibody isotype associated with risk of infection. Hazard ratios (β), confidence intervals (CI), P-values and P-values adjusted for the false discovery rate (BH) are shown in each graph from univariate models and multivariable models adjusted for covariates (βadj, CIadj, Padj and BH Padj). FIG.21. CONSORT Diagram of the Cryptosporidiosis and Enteropathogens in Bangladesh Study, with a starting enrollment of n=500 patients. PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 FIG.22. Incidence of Diarrheal Cryptosporidiosis in the Mirpur cohort. Data shown is only from the children in Subgroup 1 where monthly stool samples and yearly blood collection continued until year 4. Surveillance samples collected during this period were used to calculate child participation in each 6-month window (a participating child should have six surveillance stools collected in each 6 months). Infections occurring within each 6-month interval were grouped. Child age in years at the end of each grouped period is shown on the X axis. A positive sample was classified as part of a separate infection only if it occurred greater than 65 days after the preceding positive sample. To account for the possibility that the diarrhea was caused by another co-infecting pathogen Cryptosporidium -associated diarrheal infection was classified as such only when symptom onset was coincident with the qPCR detection of Cryptosporidium in fecal DNA. The frequency of diarrheal cryptosporidiosis (red symbols and line) is shown on the right Y axis and sub-clinical cryptosporidiosis (blue symbol and line) on the left axis. FIG. 23. Cryptosporidiosis and fecal anti-Cp17 and anti-Cp23 in a subset of children followed from birth to age 3 years. FIG. 24. Variation in the child anti-Cryptosporidium Cp17 and Cp23 antibody responses were associated with changes in different biological variables (child age and infection history) and environmental (seasons of the year) variables. Results from a Mixed Model Regression Analysis. X axis indicates the estimated effect on relative antibody levels. (A-C; anti-Cp17 antibodies) (D-F; anti- Cp23 antibodies) (A, D; Fecal IgA) (B, E Plasma IgA) (C, F; Plasma IgG). Y axis indicates the different variables included in this analysis. Red symbols and error bars indicate the effect is statistically significant (p>0.05). FIGS. 25A-25B. Increase of anti-Cp17 antibody avidity in 4-year-old children living in a high-transmission area. Avidity was measured by ELISA with the chaotropic reagent ammonium thiocyanate (NH4SCN). (A) Cp17 Grouped two-way ANOVA to compare previously infected samples from one- or one and a half paired with samples collected when they were four-years old. Anti-Cp17 IgG avidity; one or one and a half compared to paired 4 year old samples n=57 p<0.0001, between children n.s. p=0.4725; amount of variation accounted by age of child 14.18%, and between children 43.31%; Analysis was repeated using a mixed-effects analysis correcting for multiple comparisons separating the data from one year olds n=40; paired with their samples collected when 4 year olds p <0.0001: and samples from one and a half years old n=17; paired with their samples collected when 4 year olds p = 0.039 (B) The avidity of anti-Cp23 was not significantly affected by child age p=0.3 and the differences between children p=0.0217: amount of variation accounted by age of child 0.94% and between children 65.2%. PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 FIG. 26. Similar Decline in diarrheal cryptosporidiosis in Sub-group 1 and 2. After year 3 children were split into the 2 groups. Sub-Group1 (red symbols and line) children with uninterrupted bi-weekly diarrheal surveillance and monthly asymptomatic stool collection and Sub-Group2 (purple symbols and line) children where diarrheal sample continued to be collected but only bi-annual asymptomatic stools were collected. Infections occurring within each 6-month interval were grouped and the number shown on the Y axis. X axis indicates child age in years. FIGS.27A-27F. Analysis of the IgA (A-D: fecal A&B; plasma C &D) and plasma IgG (E & F) antibodies to the Cp17 (A, C, E) and Cp23 (B, D, F) antigens. Relative antibody levels are shown on the Y-axis with the children’s age in days shown on the X-axis. Linear regression P and R2values are shown as well as confidence intervals (gray bands) and the limit of assay detection (dotted red line). FIG.28. Expectation of parasite burden and antibody response in a wild-type mouse infected with Cryptosporidium. Parasite burden measured by qPCR (Cq) and anti-Cp17 antibody levels measured by ELISA (Relative Units) in fecal samples. Parasitic burden after initial (yellow triangle markers) and secondary infections (blue triangle markers) is monitored from days 0-18. Monitoring of fecal anti-Cp17 levels from initial infection (orange circle markers) and subsequent infection (blue square markers) extended from days 0-36. FIG.29. Closer examination of parasitic burden and anti-Cp17 antibodies in wild-type mouse fecal samples showcases a transitory period between days 8-15 post-infection. At day 8, parasitic burden (in yellow) begins to decrease in unison with the elevation of anti-Cp17 antibodies (in orange). At peak antibody load (day 20), parasitic burden in feces becomes undetectable by qPCR. FIG. 30. Engineered Cryptosporidium vaccine construct 1 (p531) includes transcripts of previously identified immunoprotective antigens Cp23 (light blue), Cp17 (green) and Cgd4_1970 (dark blue) as well as T2A linkers (yellow) and T2A proteolytic sites (red). The DNA transcript (SEQ ID NO: 1) and translated residues (SEQ ID NO: 2) are presented. FIG. 31. Engineered Cryptosporidium vaccine construct 2 (p532) includes transcripts of previously identified immunoprotective antigens Cgd8_420 (green), Cgd6_4870 (orange) as well as T2A linkers (yellow) and T2A proteolytic sites (red). The DNA transcript (SEQ ID NO: 3) is presented. FIG. 32. Protocol diagram depicts mice infected with Cryptosporidium at W0. Mice are injected with control or experimental vaccine at weeks W0, W2 and W6 (denoted by syringe icons). Fecal samples are collected at W0 (pre-vaccination), W8 (post-vaccination) and W23 (post- vaccination, post-challenge). Animals are challenged with Cryptosporidium at W10. PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 FIG. 33. Results of anti-Cp23 antibody detection (ELISA) in fecal samples from infected mice pre-immunization (W0), post-immunization (W8, surrounded by orange bars), and post- Cryptosporidium challenge (W23), as well as immunized naïve mice. Circles denote the GST protein controls (black), the self-amplifying RNA (saRNA) control vector (blue), and the saRNA vaccine carrying rCp23 (red). In the pre-immune state, no differences in anti-Cp23 antibody levels were detected between groups and remained nearly undetectable at baseline. Post-vaccination, the control- vaccinated mice displayed marginal increases in anti-Cp23, while the rCp23 saRNA vaccination led to a comparatively larger increase in anti-Cp23 that extended beyond the assay’s limit of detection. Post-challenge, anti-Cp23 levels returned to baseline. Naïve mice administered control or saRNA vaccines did not experience elevations in anti-Cp23 compared to infected animals. FIG.34. qPCR assay detects parasite burden in mice from days 0-22 post-Cryptosporidium infection and immunization sequence. Experimental groups are shown sequentially from left to right: IM saRNA SEAP control, IM saRNA Crypto. vaccine (constructs p531+p532), intranasal (IN) saRNA SEAP control, and IN Crypto. vaccine (constructs p531+p532). Notably increased Crypto. burden is highlighted at days 11 and 14 post-infection, with no significant differences in burden measured between control (IM or IN) and Crypto. (IM or IN) immunized mice at day 11. At day 14 post-infection, the IM injected, Crypto. vaccinated mice had significantly decreased parasitic burden in comparison to mice injected with either IM control or IN Crypto. vaccines. FIG. 35. Protocol diagram depicts mice infected with Cryptosporidium at W0. Mice are injected with control or experimental vaccine at weeks W0, W4 and W8 (denoted by syringe icons). Blood is collected at W10, and mice are challenged with Crypto. at W16. The vaccination experimental groups were denoted as Gp1, Gp2, Gp3, Gp4, and Gp5. FIG.36. Post-infected and post-vaccinated blood is collected from mice at W10. Significant differences in plasma anti-Cp23 IgG are noted between the control (Gp2) and Cryptosporidium vaccinated animals (Gp1, Gp3, Gp4, and Gp5). FIG.37. Post-infected and post-vaccinated blood is collected from mice at W10. Significant increases in plasma anti-Cp17 IgG are detected in Crypto. protein vaccinated animals (Gp4 and Gp5) compared to controls (Gp2). Animals vaccinated with Crypto. saRNA alone (Gp3 or Gp1) did not display significant changes in anti-Cp17 compared to controls (Gp2). FIGS. 38A-38B. Inverse correlation detected between anti-Cp17 fecal antibody levels and Cryptosporidium burden (log DNA) in vaccinated animals at days 10 and 13 post-challenge. (A) Animals receiving adjuvant alone (control, Gp2, green dots) tended to have increased Crypto. burden at day 10 in comparison to animals vaccinated with adjuvanted Crypto. proteins (Cp17+Cp23, Gp5, PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 blue dots). (B) A significant inverse correlation between anti-Cp17 levels and Cryptosporidium burden in vaccinated animals is graphed at R2=0.5074, p=0.0043. FIGS. 39A-39B. Increased fecal anti-Cp17 antibody levels are associated with decreased parasite burden in animals vaccinated with adjuvanted Cryptosporidium proteins. (A) Fecal anti- Cp17 antibody levels are detected in vaccinated mice challenged with Cryptosporidium. A significant increase in anti-Cp17 was noted in mice vaccinated with adjuvanted Cp17 and Cp23 proteins (Gp5) compared to controls (Gp2, adjuvant-only). (B) Amongst five groups of vaccinated animals, fecal parasite burden (detected by qPCR) was significantly reduced only in animals initially vaccinated with adjuvanted Crypto. proteins Cp17 and Cp23 (Gp5). Initial vaccination with Crypto. Cp23 saRNA vector was not sufficient to control parasite burden (Gp1, Gp3, and Gp4), even when later boosted with Crypto. proteins (Gp4). DESCRIPTION Provided herein is the identification of antigens that are associated with protection from reinfection of Cryptosporidium and the results from testing of vaccines for Cryptosporidium. Identification of Cryptosporidium proteins recognized by the humoral immune system of children and associated with immunity to reinfection provides a rational approach to vaccine development. Definitions The following definitions are included to provide a clear and consistent understanding of the specification and claims. As used herein, the recited terms have the following meanings. All other terms and phrases used in this specification have their ordinary meanings as one of skill in the art would understand. Such ordinary meanings may be obtained by reference to technical dictionaries, such as Hawley's Condensed Chemical Dictionary 14th Edition, by R.J. Lewis, John Wiley & Sons, New York, N.Y., 2001. References in the specification to "one embodiment," "an embodiment," etc., indicate that the embodiment described may include a particular aspect, feature, structure, moiety, or characteristic, but not every embodiment necessarily includes that aspect, feature, structure, moiety, or characteristic. Moreover, such phrases may, but do not necessarily, refer to the same embodiment referred to in other portions of the specification. Further, when a particular aspect, feature, structure, moiety, or characteristic is described in connection with an embodiment, it is within the knowledge of one skilled in the art to affect or connect such aspect, feature, structure, moiety, or characteristic with other embodiments, whether or not explicitly described. The singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a compound" includes a plurality of such compounds, so that a compound X includes a plurality of compounds X. It is further noted that the PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for the use of exclusive terminology, such as "solely," "only," and the like, in connection with any element described herein, and / or the recitation of claim elements or use of "negative" limitations. The term "and / or" means any one of the items, any combination of the items, or all of the items with which this term is associated. The phrase "one or more" is readily understood by one of skill in the art, particularly when read in context of its usage. For example, one or more substituents on a phenyl ring refers to one to five, or one to four, for example if the phenyl ring is di-substituted. As used herein, “or” should be understood to have the same meaning as “and / or” as defined above. For example, when separating a listing of items, “and / or” or “or” shall be interpreted as being inclusive, e.g., the inclusion of at least one, but also including more than one of a number of items, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as “only one of” or “exactly one of,” or, when used in the claims, “consisting of,” will refer to the inclusion of exactly one element of a number or list of elements. In general, the term “or” as used herein shall only be interpreted as indicating exclusive alternatives (i.e., “one or the other but not both”) when preceded by terms of exclusivity, such as “either,” “one of,” “only one of,” or “exactly one of.” As used herein, the terms “including,” “includes,” “having,” “has,” “with,” or variants thereof, are intended to be inclusive similar to the term “comprising.” The term "about" can refer to a variation of ± 5%, ± 10%, ± 20%, or ± 25% of the value specified. For example, "about 50" percent can in some embodiments carry a variation from 45 to 55 percent. For integer ranges, the term "about" can include one or two integers greater than and / or less than a recited integer at each end of the range. Unless indicated otherwise herein, the term "about" is intended to include values, e.g., weight percentages, proximate to the recited range that are equivalent in terms of the functionality of the individual ingredient, the composition, or the embodiment. The term about can also modify the endpoints of a recited range as discuss above in this paragraph. As will be understood by the skilled artisan, all numbers, including those expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth, are approximations and are understood as being optionally modified in all instances by the term "about." These values can vary depending upon the desired properties sought to be obtained by those skilled in the art utilizing the teachings of the descriptions herein. It is also understood that such values inherently contain variability necessarily resulting from the standard deviations found in their respective testing measurements. As will be understood by one skilled in the art, for any and all purposes, particularly in terms of providing a written description, all ranges recited herein also encompass any and all possible sub- PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 ranges and combinations of sub-ranges thereof, as well as the individual values making up the range, particularly integer values. A recited range (e.g., weight percentages or carbon groups) includes each specific value, integer, decimal, or identity within the range. Any listed range can be easily recognized as sufficiently describing and enabling the same range being broken down into at least equal halves, thirds, quarters, fifths, or tenths. As a non-limiting example, each range discussed herein can be readily broken down into a lower third, middle third and upper third, etc. As will also be understood by one skilled in the art, all language such as "up to," "at least," "greater than," "less than," "more than," "or more," and the like, include the number recited and such terms refer to ranges that can be subsequently broken down into sub-ranges as discussed above. In the same manner, all ratios recited herein also include all sub-ratios falling within the broader ratio. Accordingly, specific values recited for radicals, substituents, and ranges, are for illustration only; they do not exclude other defined values or other values within defined ranges for radicals and substituents. One skilled in the art will also readily recognize that where members are grouped together in a common manner, such as in a Markush group, the invention encompasses not only the entire group listed as a whole, but each member of the group individually and all possible subgroups of the main group. Additionally, for all purposes, the invention encompasses not only the main group, but also the main group absent one or more of the group members. The invention therefore envisages the explicit exclusion of any one or more of members of a recited group. Accordingly, provisos may apply to any of the disclosed categories or embodiments whereby any one or more of the recited elements, species, or embodiments, may be excluded from such categories or embodiments, for example, for use in an explicit negative limitation. The terms "treating," "treat" and "treatment" include (i) preventing a disease, pathologic or medical condition from occurring (e.g., prophylaxis); (ii) inhibiting the disease, pathologic or medical condition or arresting its development; (iii) relieving the disease, pathologic or medical condition; and / or (iv) diminishing symptoms associated with the disease, pathologic or medical condition. Thus, the terms "treat", "treatment", and "treating" can extend to prophylaxis and can include prevent, prevention, preventing, lowering, stopping or reversing the progression or severity of the condition or symptoms being treated. As such, the term "treatment" can include medical, therapeutic, and / or prophylactic administration, as appropriate. An "effective amount" refers to an amount effective to treat a disease, disorder, and / or condition, or to bring about a recited effect. For example, an effective amount can be an amount effective to reduce the progression or severity of the condition or symptoms being treated. Determination of a therapeutically effective amount is well within the capacity of persons skilled in PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 the art, especially in light of the detailed disclosure provided herein. The term "effective amount" is intended to include an amount of a compound described herein, or an amount of a combination of compounds described herein, e.g., that is effective to treat or prevent a disease or disorder, or to treat the symptoms of the disease or disorder, in a host. Thus, an "effective amount" generally means an amount that provides the desired effect. The term "contacting" refers to the act of touching, making contact, or of bringing to immediate or close proximity, including at the cellular or molecular level, for example, to bring about a physiological reaction, a chemical reaction, or a physical change, e.g., in a solution, in a reaction mixture, in vitro, or in vivo. As used herein, a “subject” or “subject in need thereof” is a patient, animal, mammal, or human, who will benefit from the method of this invention, including adult and children (including 0 to 4 years of age) subjects. The term “symptom,” as used herein, refers to any morbid phenomenon or departure from the normal in structure, function, or sensation, experienced by the patient and indicative of disease. In contrast, a “sign” is objective evidence of disease. For example, a bloody nose is a sign. It is evident to the patient, doctor, nurse and other observers. A “compound,” as used herein, refers to any type of substance or agent that is commonly considered a drug, or a candidate for use as a drug, as well as combinations and mixtures of the above. As used herein, the term “pharmaceutically acceptable carrier” means a chemical composition with which an appropriate compound or derivative can be combined and which, following the combination, can be used to administer the appropriate compound to a subject. “Pharmaceutically acceptable” means physiologically tolerable, for either human or veterinary application. As used herein, “pharmaceutical compositions” include formulations for human and veterinary use. The use of the word “detect” and its grammatical variants refers to measurement of the species without quantification, whereas use of the word “determine” or “measure” with their grammatical variants are meant to refer to measurement of the species with quantification. The terms “detect” and “identify” are used interchangeably herein. The term “standard,” as used herein, refers to something used for comparison. For example, it can be a known standard agent or compound which is administered and used for comparing results when administering a test compound, or it can be a standard parameter or function which is measured to obtain a control value when measuring an effect of an agent or compound on a parameter or function. Standard can also refer to an “internal standard”, such as an agent or compound which is added at known amounts to a sample and is useful in determining such things as purification or recovery rates when a sample is processed or subjected to purification or extraction procedures before PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 a marker of interest is measured. Internal standards are often a purified marker of interest which has been labeled, such as with a radioactive isotope, allowing it to be distinguished from an endogenous marker. The term “nucleic acid” typically refers to large polynucleotides. By “nucleic acid” is meant any nucleic acid, whether composed of deoxyribonucleosides or ribonucleosides, and whether composed of phosphodiester linkages or modified linkages such as phosphotriester, phosphoramidate, siloxane, carbonate, carboxymethylester, acetamidate, carbamate, thioether, bridged phosphoramidate, bridged methylene phosphonate, bridged phosphoramidate, bridged phosphoramidate, bridged methylene phosphonate, phosphorothioate, methylphosphonate, phosphorodithioate, bridged phosphorothioate or sulfone linkages, and combinations of such linkages. The term nucleic acid also specifically includes nucleic acids composed of bases other than the five biologically occurring bases (adenine, guanine, thymine, cytosine and uracil). As used herein, the term “nucleic acid” encompasses RNA as well as single and double-stranded DNA and cDNA. Furthermore, the terms, “nucleic acid,” “DNA,” “RNA” and similar terms also include nucleic acid analogs, i.e., analogs having other than a phosphodiester backbone. For example, the so-called “peptide nucleic acids,” which are known in the art and have peptide bonds instead of phosphodiester bonds in the backbone, are considered within the scope of the present invention. By “nucleic acid” is meant any nucleic acid, whether composed of deoxyribonucleosides or ribonucleosides, and whether composed of phosphodiester linkages or modified linkages such as phosphotriester, phosphoramidate, siloxane, carbonate, carboxymethylester, acetamidate, carbamate, thioether, bridged phosphoramidate, bridged methylene phosphonate, bridged phosphoramidate, bridged phosphoramidate, bridged methylene phosphonate, phosphorothioate, methylphosphonate, phosphorodithioate, bridged phosphorothioate or sulfone linkages, and combinations of such linkages. The term nucleic acid also specifically includes nucleic acids composed of bases other than the five biologically occurring bases (adenine, guanine, thymine, cytosine, and uracil). Conventional notation is used herein to describe polynucleotide sequences: the left-hand end of a single-stranded polynucleotide sequence is the 5’- end; the left-hand direction of a double-stranded polynucleotide sequence is referred to as the 5’- direction. The direction of 5’ to 3’ addition of nucleotides to nascent RNA transcripts is referred to as the transcription direction. The DNA strand having the same sequence as an mRNA is referred to as the “coding strand”; sequences on the DNA strand which are located 5’ to a reference point on the DNA are referred to as “upstream sequences”; sequences on the DNA strand which are 3’ to a reference point on the DNA are referred to as “downstream sequences.” PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 The term “nucleic acid construct,” as used herein, encompasses DNA and RNA sequences encoding the particular gene or gene fragment desired, whether obtained by genomic or synthetic methods. Unless otherwise specified, a “nucleotide sequence encoding an amino acid sequence” includes all nucleotide sequences that are degenerate versions of each other and that encode the same amino acid sequence. Nucleotide sequences that encode proteins and RNA may include introns. The term “oligonucleotide” typically refers to short polynucleotides, generally, no greater than about 50 nucleotides. It will be understood that when a nucleotide sequence is represented by a DNA sequence (i.e., A, T, G, C), this also includes an RNA sequence (i.e., A, U, G, C) in which “U” replaces “T.” By describing two polynucleotides as “operably linked” is meant that a single-stranded or double-stranded nucleic acid moiety comprises the two polynucleotides arranged within the nucleic acid moiety in such a manner that at least one of the two polynucleotides is able to exert a physiological effect by which it is characterized upon the other. By way of example, a promoter operably linked to the coding region of a gene is able to promote transcription of the coding region. A “coding region” of a gene consists of the nucleotide residues of the coding strand of the gene and the nucleotides of the non-coding strand of the gene which are homologous with or complementary to, respectively, the coding region of an mRNA molecule which is produced by transcription of the gene. “Encoding” refers to the inherent property of specific sequences of nucleotides in a polynucleotide, such as a gene, a cDNA, or an mRNA, to serve as templates for synthesis of other polymers and macromolecules in biological processes having either a defined sequence of nucleotides (i.e., rRNA, tRNA and mRNA) or a defined sequence of amino acids and the biological properties resulting therefrom. Thus, a gene encodes a protein if transcription and translation of mRNA corresponding to that gene produces the protein in a cell or other biological system. Both the coding strand, the nucleotide sequence of which is identical to the mRNA sequence and is usually provided in sequence listings, and the non-coding strand, used as the template for transcription of a gene or cDNA, can be referred to as encoding the protein or other product of that gene or cDNA. “Complementary” as used herein refers to the broad concept of subunit sequence complementarity between two nucleic acids, e.g., two DNA molecules. When a nucleotide position in both of the molecules is occupied by nucleotides normally capable of base pairing with each other, then the nucleic acids are considered to be complementary to each other at this position. Thus, two nucleic acids are complementary to each other when a substantial number (at least 50%) of corresponding positions in each of the molecules are occupied by nucleotides which normally base PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 pair with each other (e.g., A:T and G:C nucleotide pairs). Thus, it is known that an adenine residue of a first nucleic acid region is capable of forming specific hydrogen bonds (“base pairing”) with a residue of a second nucleic acid region which is antiparallel to the first region if the residue is thymine or uracil. Similarly, it is known that a cytosine residue of a first nucleic acid strand is capable of base pairing with a residue of a second nucleic acid strand which is antiparallel to the first strand if the residue is guanine. A first region of a nucleic acid is complementary to a second region of the same or a different nucleic acid if, when the two regions are arranged in an antiparallel fashion, at least one nucleotide residue of the first region is capable of base pairing with a residue of the second region. In one embodiment, the first region comprises a first portion and the second region comprises a second portion, whereby, when the first and second portions are arranged in an antiparallel fashion, at least about 50%, including at least about 75%, at least about 90%, or at least about 95% of the nucleotide residues of the first portion are capable of base pairing with nucleotide residues in the second portion. In some embodiments, all nucleotide residues of the first portion are capable of base pairing with nucleotide residues in the second portion. “Recombinant polynucleotide” refers to a polynucleotide having sequences that are not naturally joined together. An amplified or assembled recombinant polynucleotide may be included in a suitable vector, and the vector can be used to transform a suitable host cell. A recombinant polynucleotide may serve a non-coding function (e.g., promoter, origin of replication, ribosome- binding site, etc.) as well.A host cell that comprises a recombinant polynucleotide is referred to as a “recombinant host cell.” A gene which is expressed in a recombinant host cell wherein the gene comprises a recombinant polynucleotide, produces a “recombinant polypeptide.” A “recombinant polypeptide” or protein is one which is produced upon expression of a recombinant polynucleotide. A “recombinant cell” is a cell that comprises a transgene. Such a cell may be a eukaryotic or a prokaryotic cell. Also, the transgenic cell encompasses, but is not limited to, an embryonic stem cell comprising the transgene, a cell obtained from a chimeric mammal derived from a transgenic embryonic stem cell where the cell comprises the transgene, a cell obtained from a transgenic mammal, or fetal or placental tissue thereof, and a prokaryotic cell comprising the transgene. A “vector” is a composition of matter which comprises an isolated nucleic acid and which can be used to deliver the isolated nucleic acid to the interior of a cell. Numerous vectors are known in the art including, but not limited to, linear polynucleotides, polynucleotides associated with ionic or amphiphilic compounds, plasmids, and viruses. Thus, the term “vector” includes an autonomously replicating plasmid or a virus. The term should also be construed to include non-plasmid and non- viral compounds which facilitate transfer or delivery of nucleic acid to cells, such as, for example, polylysine compounds, liposomes, and the like. Examples of viral vectors include, but are not limited PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 to, adenoviral vectors, adeno-associated virus vectors, retroviral vectors, recombinant viral vectors, and the like. Examples of non-viral vectors include, but are not limited to, liposomes, polyamine derivatives of DNA and the like. “Expression vector” refers to a vector comprising a recombinant polynucleotide comprising expression control sequences operatively linked to a nucleotide sequence to be expressed. An expression vector comprises sufficient cis-acting elements for expression; other elements for expression can be supplied by the host cell or in an in vitro expression system. Expression vectors include all those known in the art, such as cosmids, plasmids (e.g., naked or contained in liposomes) and viruses that incorporate the recombinant polynucleotide. The term “amino acid” is used interchangeably with “amino acid residue,” and may refer to a free amino acid and to an amino acid residue of a peptide / protgien. It will be apparent from the context in which the term is used whether it refers to a free amino acid or a residue of a peptide / protein. The expression “amino acid” as used herein is meant to include both natural and synthetic amino acids, and both D and L amino acids. “Standard amino acid” means any of the twenty standard L-amino acids commonly found in naturally occurring peptides / proteins. “Nonstandard amino acid residue” means any amino acid, other than the standard amino acids, regardless of whether it is prepared synthetically or derived from a natural source. As used herein, “synthetic amino acid” also encompasses chemically modified amino acids, including but not limited to salts, amino acid derivatives (such as amides), and substitutions. Amino acids contained within the peptides / proteins of the present invention, and particularly at the carboxy- or amino-terminus, can be modified by methylation, amidation, acetylation or substitution with other chemical groups which can change the peptide’s / proteins’s circulating half-life without adversely affecting their activity (e.g., peptidomimetic for making peptides protease resistant). Amino acids have the following general structure: Amino acids may be classified into seven groups on the basis of the side chain R: (1) aliphatic side chains, (2) side chains containing a hydroxylic (OH) group, (3) side chains containing sulfur atoms, (4) side chains containing an acidic or amide group, (5) side chains containing a basic group, PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 (6) side chains containing an aromatic ring, and (7) proline, an imino acid in which the side chain is fused to the amino group. As used herein, amino acids are represented by the full name thereof, by the three-letter code corresponding thereto, or by the one-letter code corresponding thereto, as indicated in the following table: Full Name Three-Letter Code One-Letter Code Aspartic Acid Asp D Glutamic Acid Glu E Lysine Lys K Arginine Arg R Histidine His H Tyrosine Tyr Y Cysteine Cys C Asparagine Asn N Glutamine Gln Q Serine Ser S Threonine Thr T Glycine Gly G Alanine Ala A Valine Val V Leucine Leu L Isoleucine Ile I Methionine Met M Proline Pro P Phenylalanine Phe F Tryptophan Trp W The term “basic” or “positively charged” amino acid as used herein, refers to amino acids in which the R groups have a net positive charge at pH 7.0, and include, but are not limited to, the standard amino acids lysine, arginine, and histidine. As used herein, the term “conservative amino acid substitution” is defined herein as an amino acid exchange within one of the following five groups: I. Small aliphatic, nonpolar or slightly polar residues: Ala, Ser, Thr, Pro, Gly; II. Polar, negatively charged residues and their amides: PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 Asp, Asn, Glu, Gln; III. Polar, positively charged residues: His, Arg, Lys; IV. Large, aliphatic, nonpolar residues: Met Leu, Ile, Val, Cys V. Large, aromatic residues: Phe, Tyr, Trp. The nomenclature used to describe the peptide / protein compounds of the present invention follows the conventional practice wherein the amino group is presented to the left and the carboxy group to the right of each amino acid residue. In the formulae representing selected specific embodiments of the present invention, the amino-and carboxy-terminal groups, although not specifically shown, will be understood to be in the form they would assume at physiologic pH values, unless otherwise specified. As used herein, “protecting group” with respect to a terminal amino group refers to a terminal amino group of a peptide / protein, which terminal amino group is coupled with any of various amino terminal protecting groups traditionally employed in peptide synthesis. Such protecting groups include, for example, acyl protecting groups such as tert-butyl, formyl, acetyl, benzoyl, trifluoroacetyl, succinyl, and methoxysuccinyl; aromatic urethane protecting groups such as benzyloxycarbonyl; and aliphatic urethane protecting groups, for example, tert-butoxycarbonyl or adamantyloxycarbonyl. See Gross and Mienhofer, eds., The Peptides, vol. 3, pp. 3-88 (Academic Press, New York, 1981) for suitable protecting groups. “Homologous” as used herein, refers to the subunit sequence similarity between two polymeric molecules, e.g., between two nucleic acid molecules, e.g., two DNA molecules or two RNA molecules, or between two polypeptide molecules. When a subunit position in both of the two molecules is occupied by the same monomeric subunit, e.g., if a position in each of two DNA molecules is occupied by adenine, then they are homologous at that position. The homology between two sequences is a direct function of the number of matching or homologous positions, e.g., if half (e.g., five positions in a polymer ten subunits in length) of the positions in two compound sequences are homologous then the two sequences are 50% homologous, if 90% of the positions, e.g., 9 of 10, are matched or homologous, the two sequences share 90% homology. By way of example, the DNA sequences 3’ATTGCC5’ and 3’TATGGC5’ share 50% homology. As used herein, “homology” is used synonymously with “identity.” The determination of percent identity between two nucleotide or amino acid sequences can be accomplished using a mathematical algorithm. For example, a mathematical algorithm useful for PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 comparing two sequences is the algorithm of Karlin and Altschul (1990, Proc. Natl. Acad. Sci. USA 87:2264-2268), modified as in Karlin and Altschul (1993, Proc. Natl. Acad. Sci. USA 90:5873-5877). This algorithm is incorporated into the NBLAST and XBLAST programs of Altschul, et al. (1990, J. Mol. Biol.215:403-410), and can be accessed, for example at the National Center for Biotechnology Information (NCBI) world wide web site having the universal resource locator using the BLAST tool at the NCBI website. BLAST nucleotide searches can be performed with the NBLAST program (designated “blastn” at the NCBI web site), using the following parameters: gap penalty = 5; gap extension penalty = 2; mismatch penalty = 3; match reward = 1; expectation value 10.0; and word size = 11 to obtain nucleotide sequences homologous to a nucleic acid described herein. BLAST protein searches can be performed with the XBLAST program (designated “blastn” at the NCBI web site) or the NCBI “blastp” program, using the following parameters: expectation value 10.0, BLOSUM62 scoring matrix to obtain amino acid sequences homologous to a protein molecule described herein. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al. (1997, Nucleic Acids Res.25:3389-3402). Alternatively, PSI- Blast or PHI-Blast can be used to perform an iterated search which detects distant relationships between molecules (Id.) and relationships between molecules which share a common pattern. When utilizing BLAST, Gapped BLAST, PSI-Blast, and PHI-Blast programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. The percent identity between two sequences can be determined using techniques similar to those described above, with or without allowing gaps. In calculating percent identity, typically exact matches are counted. As used herein, a “substantially homologous amino acid sequences” includes those amino acid sequences which have at least about 95% homology, at least about 96% homology, at least about 97% homology, at least about 98% homology, or at least about 99% or more homology to an amino acid sequence of a reference antibody chain. Amino acid sequence similarity or identity can be computed by using the BLASTP and TBLASTN programs which employ the BLAST (basic local alignment search tool) 2.0.14 algorithm. The default settings used for these programs are suitable for identifying substantially similar amino acid sequences for purposes of the present invention. “Substantially homologous nucleic acid sequence” means a nucleic acid sequence corresponding to a reference nucleic acid sequence wherein the corresponding sequence encodes a peptide having substantially the same structure and function as the peptide encoded by the reference nucleic acid sequence, e.g., where only changes in amino acids not significantly affecting the peptide function occur. In some embodiments, the substantially identical nucleic acid sequence encodes the peptide encoded by the reference nucleic acid sequence. The percentage of identity between the PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 substantially similar nucleic acid sequence and the reference nucleic acid sequence is at least about 50%, 65%, 75%, 85%, 95%, 96%, 97%, 98%, 99% or more. Substantial identity of nucleic acid sequences can be determined by comparing the sequence identity of two sequences, for example by physical / chemical methods (i.e., hybridization) or by sequence alignment via computer algorithm. Suitable nucleic acid hybridization conditions to determine if a nucleotide sequence is substantially similar to a reference nucleotide sequence are: 7% sodium dodecyl sulfate SDS, 0.5 M NaPO4, 1 mM EDTA at 50°C with washing in 2X standard saline citrate (SSC), 0.1% SDS at 50°C; including in 7% (SDS), 0.5 M NaPO4, 1 mM EDTA at 50°C with washing in 1X SSC, 0.1% SDS at 50°C; including 7% SDS, 0.5 M NaPO4, 1 mM EDTA at 50°C with washing in 0.5X SSC, 0.1% SDS at 50°C; and including in 7% SDS, 0.5 M NaPO4, 1 mM EDTA at 50°C with washing in 0.1X SSC, 0.1% SDS at 65°C. Suitable computer algorithms to determine substantial similarity between two nucleic acid sequences include GCS program package (Devereux et al., 1984 Nucl. Acids Res. 12:387), and the BLASTN or FASTA programs (Altschul et al., 1990 Proc. Natl. Acad. Sci. USA. 199087:14:5509-13; Altschul et al., J. Mol. Biol.1990215:3:403-10; Altschul et al., 1997 Nucleic Acids Res. 25:3389-3402). The default settings provided with these programs are suitable for determining substantial similarity of nucleic acid sequences for purposes of the present invention. Methods involving conventional molecular biology techniques are described herein. Such techniques are generally known in the art and are described in detail in methodology treatises, such as Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, ed. Sambrook et al., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989; and Current Protocols in Molecular Biology, ed. Ausubel et al., Greene Publishing and Wiley-Interscience, New York, 1992 (with periodic updates). Methods for chemical synthesis of nucleic acids are discussed, for example, in Beaucage and Carruthers, Tetra. Letts.22: 1859-1862, 1981, and Matteucci et al., J. Am. Chem. Soc. 103:3185, 1981. As used herein, an “instructional material” includes a publication, a recording, a diagram, or any other medium of expression which can be used to communicate the usefulness of the peptide / protein of the invention in the kit for effecting alleviation of the various diseases or disorders recited herein. Optionally, or alternately, the instructional material may describe one or more methods of alleviating the diseases or disorders in a cell or a tissue of a mammal. The instructional material of the kit of the invention may, for example, be affixed to a container which contains the identified compound invention or be shipped together with a container which contains the identified compound. Alternatively, the instructional material may be shipped separately from the container with the intention that the instructional material and the compound be used cooperatively by the recipient. Immunization / Immune Modulating Composition / Vaccine PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 As described herein, the inventors have discovered compositions, methods and immunization regimens whereby a subject is protected against cryptosporidiosis, a leading cause of diarrhea, through administration of one or more anti-Cryptosporidium immune response inducing agents / compositions. As used herein, one or more anti-Cryptosporidium immune response inducing agents / compositions are any agents / compositions that are suitable for administration to a mammal and are effective to induce active immunity or boost an immune response, including a protective immune response, against cryptosporidiosis. The one or more anti-Cryptosporidium immune response inducing agents / compositions will provide one or more Cryptosporidium antigens, and can be in the form of, for example, a composition comprising a Cryptosporidium protein antigen, a nucleic acid that encodes a Cryptosporidium protein antigen, a viral replicon particle (VRP) that contains a nucleic acid that encodes a Cryptosporidium protein antigen, or recombinant viral vectors. The Cryptosporidium antigen can be one or more of those disclosed herein. The one or more anti- Cryptosporidium immune response inducing agents / compositions can comprise a Cryptosporidium protein or a portion thereof (e.g., a membrane protein or portion thereof that is exposed to the immune system). More than one anti-Cryptosporidium immune response inducing agents / compositions can be administered. If multiple agents / compositions are administered, they can be in the same composition, in separate compositions, they can be administered at the same time, at different times, at the same concentration, different concentrations (such as increasing or decreasing concentrations with each repeated booster / follow on administration), and / or they can be in the same or different forms (e.g., one can be administered as protein and another can be administered as nucleic acid). In some embodiments, there is provided a one dose regimen, in other embodiments, there is a 2 or more dose regimen, such as 2, 3, 4, 5, 6, or more doses. In some embodiments, the doses / boosters are spaced out over time. Administration of the one or more anti-Cryptosporidium immune response inducing agents / compositions can be at substantially the same time as other vaccines (e.g., during the same medical consultation or visit to a healthcare professional or vaccination center). In some embodiments, the one or more anti-Cryptosporidium immune response inducing agents / compositions comprise proteins, DNA molecules, self-replicating RNA molecules or VRPs. The one or more anti-Cryptosporidium immune response inducing agents / compositions can further comprise a pharmaceutically acceptable carrier and, optionally, an adjuvant. The immune response can comprise a humoral immune response, a cell-mediated immune response, or both. In some embodiments an immune response is induced against each delivered type PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 of Cryptosporidium protein. A cell-mediated immune response can comprise a helper T-cell (Th) response, a CD8+ cytotoxic T-cell (CTL) response, or both. In some embodiments the immune response comprises a humoral immune response. In some embodiments, the antibody response is characterized by IgG and / or IgA antibodies. An immune response can be stimulated by administering one or more anti-Cryptosporidium immune response inducing agents / compositions (a composition comprising proteins, DNA molecules, RNA molecules, such as self-replicating RNA molecules, or VRPs) to a subject. In some embodiments the immune response induced is a protective immune response, i.e., the response reduces the risk of Cryptosporidium infection, delays the onset of Cryptosporidium infection, reduces the risk of Cryptosporidium-caused disease, reduced the severity of Cryptosporidium-caused disease, delays the onset of Cryptosporidium-caused disease, reduces the frequency of Cryptosporidium- caused disease, reduces the sequelae of Cryptosporidium infection or Cryptosporidium-caused disease, or reduces the risk that an Cryptosporidium-infected individual will spread Cryptosporidium to another individual. Any suitable route of administration can be used. For example, an agent and / or composition can be administered intramuscularly, intraperitoneally, subcutaneously, transdermally, or intradermally. If desired, the composition can be administered through an intra-mucosal route such as intra-orally, intra-nasally, intra-vaginally, and intra-rectally. Compositions can be administered according to any suitable schedule. In one embodiment, protective immunity against Cryptosporidium is provided comprising the administration of one or more anti-Cryptosporidium immune response inducing agents / compositions to a subject. Optionally a second, third, fourth, fifth or sixth one or more anti-Cryptosporidium immune response inducing agents / compositions can be administered at a later time as a booster. As described herein, a first one or more anti-Cryptosporidium immune response inducing agents / compositions and a second (or third and so on) one or more anti-Cryptosporidium immune response inducing agents / compositions can be the same or different, such proteins or nucleic acids, including self-replicating RNA. Anti-Cryptosporidium immune response inducing agents / compositions Any desired anti-Cryptosporidium immune response inducing agents / compositions can be used in the invention. For example, Cryptosporidium proteins or fragments can be delivered directly as components of anti-Cryptosporidium immune response inducing agents / compositions, or nucleic acids that encode one or more Cryptosporidium proteins or fragments can be administered to produce the Cryptosporidium protein or fragment in vivo, or recombinant viral vectors expressing Cryptosporidium proteins can be administered. Such as protein formulations and recombinant nucleic PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 acids (e.g., self-replicating RNA) that contain sequences encoding Cryptosporidium proteins or fragments are further described herein. Protein Formulations Immunogenic proteins or fragments thereof used according to the invention will usually be isolated or purified. Thus, they will be separate and discrete from the whole organism with which the molecule is found in nature or is present in the substantial absence of other biological macro- molecules of the same type. Exemplary Cryptosporidium Protein / Antigen sequences CpSMP1 (Accession No: OLQ16986.1, CryptoDB ID Chro.30111; C. parvum Orthologue CryptoDB cgd3_820; C. parvum Orthologue Accession XP_626664.1) Protein Sequence MKLSFFLSLLVLFISYYQVNSQDAYHPFRSTALELADSKNQSSCNENCIQEKNDRSLQESSE NSNSGTSQGSNNSVGNIIQENINNLYKELADHSQEQAKNTWDSLSTGAKAGIIIAIVVVAIIII AGIIHCLCICKLCCCC (SEQ ID NO: 10) Antigen QDAYHPFRSTALELADSKNQSSCNENCIQEKNDRSLQESSENSNSGTSQGSNNSVGNIIQEN INNLYKELADHSQEQAKNTWDSLSTGAK (SEQ ID NO: 11) CpMuc8 (Accession No: PPS95475.1, CryptoDB ID CHUDEA8_700-t30_1; C. parvum Orthologue CryptoDB Cgd8_700; C. parvum Orthologue Accession XP_626980.1) Protein Sequence MIFLRVLITCLTLLIVTHITLFISLNNEIGNHLNDKITKINSQAVFISFLEIPGLKRKKKYSRLSLTNMNIKRMSLNHIN SLISRLLQQISELRKEINDLEAKLKVLKSGLELEKCNNKNKKNKKKHLSKKCQNCENIQKEINNVESKIRKLRLKLNNNK NKLIKAKFRKSRLVSNSNEQEGTEANADTEAYKIKYSTGTSTSTSTSTVTTTCITSTSTHKTTTTTTISTTTSNITITPT ISSKATPTPTPNPTLSELNNSETNMVNEKLKLLDVKMEEIKKLAMGQRETVQFFFEKLLKVFAASELIKLKCELGMVNKL FVIKLKIIKILQSAQNRNNESYRIDESTFLTTQTEKGKQAIKEYEIILLLLKDLISYFSKLLELCEEIFHVSPKIKGKLE KLLINLNECKVEKFNPLLDLTRFLVQNFSKFPINSRYGSKIFLYLLTRLQGFTQIKECLSIKKLQKWVSLKNEYNNKILK YKLKLKSLKCNGHNHLNKPCTRNTCIIESKKYFLMEKIKTYNLIIELLISLLNSCDNLLKKDPSSLEMQAKIHSFTKECG YTYDITKSIKKLGIYKDLNQSQKKQVYQNMYQLIQTIGGFTFIFYSKDCNIETITELFQFISRINQIKELEENNKDLYED PNLDEARKLKIISVKSLIKITLDLISFCLTYYQFEEEVTQKIHFNKEIIKKMDINSELRADLKLFENLQILLSEKYIYST LDCNFKNIMKIIQEKQQSMELLNFYQKELKLKKHLHGKSGNQSIDEIIQKRNILLYEITMNNNHNCSICNSDNVKRNILL EKYYMELLQFILNNCIKIKFPYINKFLDEEISKNNYKMIIGGLFFGIIENLFSEEIILLLNLANKIEMAILNTLLKRFSI NMSGLKDCTVKKIIDFKKSLKEIKILQDRLEERINNNNYEEISYKNIKLEEMMNENELMITKRLHYRLKDILIVLILIIE DIIRRCENVIEIIKKDDDNELLTKILKLPSPQYFTTRIIKGLLLNKNEITSVFFELTSNFDLFGHINSCLETNYLSLLLK YGKLSEEFNMILSNFLNKYSNGIDSSLEYNYYEEFLILIGYSLALEYFCEAIYACILRVEGENGLGIIKKYDPFKKEGVN LIVNKSINDILKQERWGYGLFQENLTIDGSHLLHRFIGNDKIKPESCKISFIKELVQKIKEIENLKKGLKNEELIEAKNL SSILSLYLSIIKFCFKFGIFYILKSQLNKKQEIITTGVVGWEFHPTLMEFDFPSYPLEDGFLSNLELFGFDNLVSSGDYS PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 QLFDLESGDLISRTEMSVGMYIDDLVDENERFGFEGFGVGIGVGIGIGTETGTKGAETGTETGTETETGTKTGAETETGT KTKEAETGTGAEIKAEVKLEAGDEAKKAEFPILTVMPELGPEQHVLDKLDLKTLMNYNLMNYLEMFIKELSNLLLPEILE KAFKFLTGCDLNLLYLINTRISTIEYLLIQILKFNNNKSDYNSVNYELLFETLRNLVSKLKSYLVKCQELNKFKYPWLHI PNLKNFKENIQSLLFSFFQQDKNIPKDCFLINIEEVKKFISFQKLKIERLENMVEKTKLFIQNRDGKNANFKSSSTIFHL ELEKEIIGSAIIRNEQLTAICEEFLNYFQLNSKITIDIFDVLENLFSSLFISDLQISQFNSRISQVFSLGASGAGIGTSP GGNIGPSPSLTPSPGTPTTGAGAVYTPAPAPTPTSAPTPPPAYGEASGFNSPSILLLSDIYTEGTEGPNSPTIQSKPIND ISSQTNQENSEYSFFLNDPEVQNLYSLYLSLNEEPLTLIQLIESSGFDKEFLIQMLLSFLEEN (SEQ ID NO: 12) Antigen MIKAEVKLEAGDEAKKAEFPILTVMPELGPEQHVLDKLDLKTLMNYNLMNYLEMFIKELSNLLLPEILEKAFKFLTGCDL NLLYLINTRISTIEYLLIQILKFNNNKSDYNSVNYELLFETLRNLVSKLKSYLVKCQELNKFKYPWLHIPNLKNFKENIQ SLLFSFFQQDKNIP (SEQ ID NO: 13) CpCCDC (Accession No: OLQ18345.1, CryptoDB ID Chro.80102; C. parvum Orthologue CryptoDB cgd8_830; C. parvum Orthologue Accession XP_626992.1) Protein Sequence MSKGKFSFSLGKSKEKGPNSLGNVFLGEKVFESEKDEKNNAEDLGSKNSDNFQSISTNYEYKKSIKFYDEHPELLEDFDR SNTVKRIEAEDKEEKKDEPKKASLGKSKYLSRIQEYVELRNIEKQEIQEEKIQKEIKEEGNTQVFITDAYKDVLEERKKL KNLLTNRKLSEGEDPRIGGPSSIFEMRLSPSMNELKNEEIDKQIASGSPKEELKIYNVNSANNSTTKDYYVVNNDEVPKT SKDLKLIKIQQARERYLLRKQNKNSA (SEQ ID NO: 14) Antigen MSKGKFSFSLGKSKEKGPNSLGNVFLGEKVFESEKDEKNNAEDLGSKNSDNFQSISTNYEY KKSIKFYDEHPELLEDFDRSNTVKRIEAEDKEEKKDEPKKASLGKSKYLSRIQEYVELRNIE KQEIQEEKIQKEKEEGNTQVFITDAYKDVLEERKKLKNLLTNRKLSEGEDPRIGGPSSIFEM RLSPSMNELKNEEIDKQIASGSPKEELKIYNVNSANNSTTKDYYVVNNDEVPKTSKDLKLI KIQQARERYLLRKQNKNSA (SEQ ID NO: 15) CpCorA (Accession No: XP_666181.1, CryptoDB ID Chro.20166; C. parvum Orthologue CryptoDB cgd2_1520; C. parvum Orthologue Accession XP_626374.1) Protein Sequence MSNNVNESFREIQQPPPSYLVSKDLDSIVVEESMEIFDDRIYDSETQKNEDSSKEMLENVDF LDRVVDQFYGNERTSSIRKVNDEMDEGNPLLFSNNMTRNTEIMNINKRHKIMDNNDQKLG GSREFLDAIQAKTRKYITFEIGRGYKRCLLLQTGELLRLVHSYNKECLLQDTVPGALKLRD LRQVVSMGSSQRPSIEVRRNCILVNVPHFRAIILHQKVLLIASGYSRSPLDYPSSGINYNYSS SNNNKSEKKEDFKEQNNCVNKNAFSLNDVQLEVPAPYLSSIDIPNSPSNYQCKNDVINEVN FDNSMTVQFDSSKVSSFPKTGIEYTPIEGLSDKQIYSKNCQFIPPGIEEGFPLLRKLEHISGIES STPFEYLVLETILVESCNIINRQVRPIRDSVLFILDSFPGRNRETRRLLDAVSELRRRLNAIEEL PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 AQGLFKAITEMLGNEEDMQRLEISFYWNRPEAWEYPKNTPYHEEVENVLECYAQEVEMM LQQIESIGESLEDALEVLTLELSSLRNSIMKADLGLSIIATIVGFCGFFADCFGMNLRNGLEE VGPALFWFITWGLILLCAAGAIVVLTTFRKIDL (SEQ ID NO: 16) Antigen MNLRNGLEEVGPALF (SEQ ID NO: 17) Cp23 (Accession No: XP_666427.1, CryptoDB ID Chro.40414; C. parvum Orthologue CryptoDB cgd4_3620; C. parvum Orthologue Accession XP_625938.1) Protein Sequence MGCSSSKPETKVAENKSAADANKQRELAEKKAQLAKAVKNPAPISNQAQQKPEEPKKSEPASNNPP AADAPAAQAPPAPAEPAPQDKPAEAPAAEAPAAEPAAQQDKPADA (SEQ ID NO: 18) Antigen SSKPETKVAENKSAADANKQRELAEKKAQLAKAVKNPAPISNQAQQKPEEPKKSEPASNN PPAADAPAAQAPPAPAEPAPQDKPAEAPAAEAPAAEPAAQQDKPADA (SEQ ID NO: 19) Cp17 (Accession No: Genotype Ia Sequence (MG694234-MG694238). AEJ22846.1, CryptoDB ID Chro.60138; C. parvum Orthologue CryptoDB cgd6_1070; C. parvum Orthologue Accession XP_627479.1) Protein Sequence MRLSLIIVLLSVIVSAVFSAPAVPLRGTLKDVPVEGSSSSSSSSSSSSSSSSSTSTVAPANKAR TGEDAEGSQDSSGTEASGSQGSEEEGSEDDGQTSAASQPTTPAQSEGATTETIEATPKEECG TSFVMWFGEGTPAATLKCGAYTIVYAPIKDQTDPAPRYISGEVTSVTFEKSDNTVKIKVNG QDFSTLSANSSSPTENGGSAGQASSRSRRSLSEETSEAAATVDLFAFTLDGGKRIEVAVPNV EDASKRDKYSLVADDKPFYTGANSGTTNGVYRLNENGDLVDKDNTVLLKDAGSSAFGLR YIVPSVFAIFAALFVL (SEQ ID NO: 20) Antigen AEENGETVATVDLFAFTLDGGRRIEVAVPKDENADKRSEYSLVADDKPFYTGANSGITNG VYKLDENGNLVDKDNKVLLKD (SEQ ID NO: 21) Gp900 (Accession No: OLQ18067.1, CryptoDB ID Chro.70447; C. parvum Orthologue CryptoDB cgd6_1070; C. parvum Orthologue Accession XP_627479.1) Protein Sequence MVNIKVSSSAIALVAVIMNPLFSLAFKSSNRLEMRIESSGAVSNEKFVIPSLPSDLDPTTFLLIDSTGKK FSPYTGKHDDASTTSSAYSAPFELDVSGVPIEPNTRRMVDPVSLMLFDNSTGVMYDPNTNSILEGSIAGI RSESCVVSELNFTSTTGFTTDTSMNWPVSITSGELKDPNKQATISGSRSCGWKQGYSIDSSTGFRVDSIT PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 GLPTDPYSNCPFNPVTGNLVSRSTGKTIPNTYAGVYRSNETKTTEPSADTNFLLVDPKINAPCNSENSFE QGQIFDMSSKVYIPYTKCVGVKHTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT TTTTTTTTKKPTTTTTTTTTTTTTTTTTTTTTTTTTTTKTTTTTTSAPGKPTTTTTVAPGQPTTTTTEAP GQPTTTTTEAPGQPTTTTTGSPSKPTTTTTTKATTTTTTLNPIITTTTQKPTTTTTTKVPGKPPIATTTT TLKPIVTTTTTKATTTTTTTVPTTTTTTKRDEMTTTTTPPLPDIGDIEITPIPIEKMLDKYTRMIYDYNS GLLLDSNDEPIPGSQAGQIADTSNLFPTQTHKSTGLPIDPMVGLPFDPKSGNLVHPYTNQTMSGLSVSYL AAKNLTVDTDETYGLPIDTLTGYPLDPVSLIPFNPETGELFDPISDEIMNGTIAGIVSGISASESLLSQK SAQIDPATNMVVGEFGGLLNPATGVMIPGSLGPSEQTPFSPEIEDGGIIPPEVAAANADKFKLSIPPSVP ESIPEKDQKIDSISELMYDIESGRLIGQVSKRPIPGSIAGDLNPIMKTPTQTDSVTGKPIDPTTGLPFNP PTGHLINPTNNNTMDSSFAGAYKYAVSNGIKTDNVYGLPVDEITGLPKDPVSDIPFNSTTGELVDPSTGK PIDNSTAGIISGKPGLPPIEDENGNLFDPSTNLPIDGNNQLINPETNSTVPGSTSGTTKPKPGIPVNGGG VVPNEEAKDQADKGKDGLIVPPTNSINKDPVTNAQYSNSTGNIINPETGKVIPGSLPGSLNYPSFNTPQQ TDEITGKPVDTVTGLPYDPSTGEIIDPATKLPIPGSVAGDEILTEVLNITTDEVTGLPIDPETGLPRDPV SGLPQLPNGTLVDPSNKKPIPGSHSGFINGTSGEQSHEKDPGTGKPLDPNTGLPFDEDSGSLINPETGDK LQGSHSGTFMPVPGKPQGENGGIMTPEQILEALNKLPTSNEVNISPKPSSDAVPDKPTNTWWNKISGQTY QVDGEKTIPGSAASVIHTALGTPTQTDPTTGLPSDPSTGLPFIPGFNVLVDPQTGEQMKGSVPYVSLYVK EKNIVTEAAYGLPVDPKTGFPIDPISYLPFAKNGELIDPISGKYFSGSIAGFISGKAGTQSKSSDESGNP IDPSTNMPYDPKTGKLIDPESGIAIDNSISGVFATVPGTAAPKKGGVIPESVAAEAAKKYFAANVEGGEG EKVPPPPESSSNIAIQAAGGASAAVGLVAAGVGAWYASRNRQEGEDDDDYADGFEAEYEEEEEEEGDEAA NETVVTIERDSSFWNES (SEQ ID NO: 22) Antigen GIAIDNSISGVFATVPGTAAPKKGGVIPESVAAEAAKKYFAANVEGGEGEKVPPPPESSSNI AIQAAGGASAAV (SEQ ID NO: 23) Cp_Claudin_Pf (Accession No: XP_668208.1, CryptoDB ID Chro.40265; C. parvum Orthologue CryptoDB cgd4_2350; C. parvum Orthologue Accession XP_625823.1) Protein Sequence MSHNASSRNQGGDTGLGIGWKLLAAVGFTAIVLQIISIILNGWRVAPAITYQYYQKSTLKS WQLQSSEYGLYIYKFNNGASTRPWSTVEQFVCSWIDSYVSISQVEQSLWGSTCSTDCQTAL RTRCTSYVKFANGGYLCLGALVISIIVGIVGVVWLFVFGKSRNFLLFAWSTSSILSSSGIAY WCYTTSQAIKGIIGTQQYPYPSLGYGAYLGILSTVCFIICAFGVLVVHYLESKAAMDARQA ELMKEAAANNEWMGQSGMSPPGMGPPGMGPPWYGSAWYESTWYGSTWYGSTWYGST WYGSTWYGSTWYGSTWYGPAWYGPTWYGSTWYGPAWHGPTRNGK (SEQ ID NO: 24) Antigen FGKSRNFLLFAWSTSSILSSSGIAYWCYTTSQAIKGIIGTQQYPYPSLGYGA (SEQ ID NO: 25) PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 CpPGM (Accession No: XP_667865.1, CryptoDB Chro.40222; C. parvum Orthologue CryptoDB cgd4_1970; C. parvum Orthologue Accession XP_625791.1) Protein Sequence MRSIGNSKLESFSVTYSGNLHKLSAHSSLFSNSQFESCNTMCDDFDPTCDCNTASTTETEITI DQVDSWIEIIKKNAEAAANPILKNDSTSSTTETTDSSNQYVWIGIGVGAIVLIGLIIFFITKSRS NNSQGQDPNANYNMQGGAPGMMPGGMPGMPGMPGMPGGMPGMPGGMPGMPGMPGM PGMPGMPGMPGMPGGMPGGMPGMPGGMPGGMPGGMPGMPGGMPMR (SEQ ID NO: 26) Antigen MRSIGNSKLESFSVTYSGNLHKLSAHSSLFSNSQFESCNTMCDDFDPTCDCNTASTTETEITI DQVDSWIEIIKKNAEAAANPILKNDSTSSTTETTDSSNQ (SEQ ID NO: 27) Cryptosporidium proteins / antigens may contain one or more mutations. Proteins, or fragments thereof, will usually be prepared by expression in a recombinant host system. Generally, they (e.g., Cryptosporidium proteins / antigens) are produced by expression of recombinant constructs that encode the proteins in suitable recombinant host cells, although any suitable methods can be used. Suitable recombinant host cells include, for example, insect cells (e.g., Aedes aegypti, Autographa californica, Bombyx mori, Drosophila melanogaster, Spodoptera frugiperda, and Trichoplusia ni), mammalian cells (e.g., human, non-human primate, horse, cow, sheep, dog, cat, and rodent (e.g., hamster), avian cells (e.g., chicken, duck, and geese), bacteria (e.g., E. coli, Bacillus subtilis, and Streptococcus spp.), yeast cells (e.g., Saccharomyces cerevisiae, Candida albicans, Candida maltosa, Hansenual polymorpha, Kluyveromyces fragilis, Kluyveromyces lactis, Pichia guillerimondii, Pichia pastoris, Schizosaccharomyces pombe and Yarrowia lipolytica), Tetrahymena cells (e.g., Tetrahymena thermophila) or combinations thereof. Many suitable insect cells and mammalian cells are well-known in the art. Suitable insect cells include, for example, Sf9 cells, Sf21 cells, Tn5 cells, Schneider S2 cells, and High Five cells (a clonal isolate derived from the parental Trichoplusia ni BTI-TN-5B1-4 cell line (Invitrogen)). Suitable mammalian cells include, for example, Chinese hamster ovary (CHO) cells, human embryonic kidney cells (HEK293 cells, typically transformed by sheared adenovirus type 5 DNA), NIH-3T3 cells, 293-T cells, Vero cells, HeLa cells, PERC.6 cells (ECACC deposit number 96022940), Hep G2 cells, MRC-5 (ATCC CCL-171), WI-38 (ATCC CCL-75), fetal rhesus lung cells (ATCC CL-160), Madin-Darby bovine kidney (“MDBK”) cells, Madin-Darby canine kidney (“MDCK”) cells (e.g., MDCK (NBL2), ATCC CCL34; or MDCK 33016, DSM ACC 2219), baby hamster kidney (BHK) cells, such as BHK21-F, HKCC cells, and the like. Suitable avian cells include, for example, chicken embryonic stem cells (e.g., EBx® cells), chicken embryonic fibroblasts, chicken embryonic germ PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 cells, duck cells (e.g., AGE1.CR and AGE1.CR.pIX cell lines (ProBioGen) which are described, for example, in Vaccine 27:4975-4982 (2009) and WO2005 / 042728), EB66 cells, and the like. Recombinant constructs encoding Cryptosporidium proteins / antigens can be prepared in suitable vectors using conventional methods. A number of suitable vectors for expression of recombinant proteins in insect or mammalian cells are well-known and conventional in the art. Suitable vectors can contain a number of components, including, but not limited to one or more of the following: an origin of replication; a selectable marker gene; one or more expression control elements, such as a transcriptional control element (e.g., a promoter, an enhancer, a terminator), and / or one or more translation signals; and a signal sequence or leader sequence for targeting to the secretory pathway in a selected host cell (e.g., of mammalian origin or from a heterologous mammalian or non-mammalian species). For expression in mammalian cells, a vector that will drive expression of the construct in the desired mammalian host cell (e.g., Chinese hamster ovary cells) is used. Cryptosporidium proteins / antigens can be purified using any suitable methods. Suitable methods for purifying desired proteins including immunoaffinity chromatography, precipitation and various types of chromatography, such as hydrophobic interaction, ion exchange, affinity, chelating and size exclusion are well-known in the art. Suitable purification schemes can be created using two or more of these or other suitable methods. If desired, the Cryptosporidium proteins / antigens can include a “tag” that facilitates purification, such as an epitope tag or a HIS tag. Such tagged proteins can conveniently be purified, for example from conditioned media, by chelating chromatography or affinity chromatography. Additional purification techniques include diafiltration and tangential flow filtration. The proteins / antigens can be administered in any suitable carrier, including those discussed below for nucleic acid compositions. Nucleic Acid Compositions Recombinant nucleic acid molecules that encode one or more Cryptosporidium proteins or fragments can be administered to induce production of the encoded Cryptosporidium proteins or fragments and an immune response thereto. The recombinant nucleic acid can be based on any desired nucleic acid such as DNA (e.g., plasmid or viral DNA) or RNA, including self-replicating RNA, and can be monocistronic or polycistronic. Any suitable DNA or RNA can be used as the nucleic acid vector that carries the open reading frames that encode Cryptosporidium proteins or fragments thereof, or then they can be free DNA and or RNA. Suitable nucleic acid vectors have the capacity to carry and drive expression of one or more Cryptosporidium proteins or fragments. Such PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 nucleic acid vectors are known in the art. If desired, the recombinant nucleic acid molecule can be modified, e.g., contain modified nucleobases and or linkages. Recombinant nucleic acid molecules that are polycistronic provide the advantage of delivering sequences that encode two or more Cryptosporidium proteins to a cell, and for example driving the expression of the Cryptosporidium proteins. The self-replicating / self-amplifying RNA molecules (non-amplifying RNA molecules are also envisioned for used in the compositions / methods described herein) are capable of being translated to produce Cryptosporidium proteins encoded by the self-replicating RNA. Self-replicating mRNA have at least two open reading frames. One frame, like conventional mRNA, codes for the antigen of interest. The other frame codes for an RNA-dependent RNA polymerase (and its helper proteins) which replicates the mRNA construct in the cell. This allows smaller vaccine doses. The self-replicating RNA can be directly translated after delivery to a cell. A self-replicating RNA molecule useful with the invention has one or more sequences that encode Cryptosporidium proteins or fragments thereof. The sequences encoding the Cryptosporidium proteins or fragments can be in any desired orientation. If desired, the sequences encoding the Cryptosporidium proteins or fragments can be part of a single open reading frame. In some embodiments the RNA may have one or more additional (downstream) sequences or open reading frames e.g., that encode other additional Cryptosporidium proteins or fragments thereof. Self-replicating RNA molecules can contain one or more modified nucleotides and therefore have improved stability and be resistant to degradation and clearance in vivo, and other advantages. As used herein, “modified nucleotide” refers to a nucleotide that contains one or more chemical modifications (e.g., substitutions) in or on the nitrogenous base of the nucleoside (e.g., cytosine (C), thymine (T) or uracil (U)), adenine (A) or guanine (G)). If desired, a self-replicating RNA molecules can contain chemical modifications in or on the sugar moiety of the nucleoside (e.g., ribose, deoxyribose, modified ribose, modified deoxyribose, six-membered sugar analog, or open-chain sugar analog), or the phosphate. The preparation of nucleotides and modified nucleotides and nucleosides are well-known in the art, e.g., from U.S. Pat. Nos. 4,373,071, 4,458,066, 4,500,707, 4,668,777, 4,973,679, 5,047,524, 5,132,418, 5,153,319, 5,262,530, 5,700,642 all of which are incorporated herein by reference in their entirety, and many modified nucleosides and modified nucleotides are commercially available. If desired, self-replicating RNA molecule can contain phosphoramidate, phosphorothioate, and / or methylphosphonate linkages. Self-replicating RNA molecules that comprise at least one modified nucleotide or linkages can be prepared using any suitable method. The self-replicating RNA may be administered with or without an adjuvant. DNA / RNA Delivery Systems PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 DNA / expression vectors and self-replicating RNA described herein are suitable for delivery in a variety of modalities, such as naked RNA (e.g., as an aqueous solution of RNA) delivery or in combination with lipids, polymers or other compounds that facilitate entry into the cells. DNA and self-replicating RNA molecules can be introduced into target cells or subjects using any suitable technique, e.g., by direct injection, microinjection, electroporation, lipofection, biolystics, and the like. The DNA and self-replicating RNA molecules can be delivered into cells via amphiphiles. See e.g., U.S. Pat. No.6,071,890. Typically, a nucleic acid molecule may form a complex with the cationic amphiphile. Mammalian cells contacted with the complex can readily take it up. To enhance entry into cells and also subsequent intercellular effects, the DNA and self- replicating RNA can be administered in combination with a delivery system, such as a particulate or emulsion delivery system. A large number of delivery systems are well known to those of skill in the art. Three such useful delivery systems are (i) liposomes, (ii) non-toxic and biodegradable polymer microparticles, and (iii) cationic submicron oil-in-water emulsions. Liposomes Various amphiphilic lipids can form bilayers in an aqueous environment to encapsulate a RNA-containing aqueous core as a liposome. These lipids can have an anionic, cationic or zwitterionic hydrophilic head group. Formation of liposomes from anionic phospholipids dates back to the 1960s, and cationic liposome-forming lipids have been studied since the 1990s. Some phospholipids are anionic whereas other are zwitterionic. Suitable classes of phospholipid include, but are not limited to, phosphatidylethanolamines, phosphatidylcholines, phosphatidylserines, and phosphatidylglycerols. Useful cationic lipids include, but are not limited to, dioleoyl trimethylammoniumpropane (DOTAP), 1,2-distearyloxy-N,N-dimethyl-3-aminopropane (DSDMA), 1,2-dioleyloxy-N,Ndimethyl-3-aminopropane (DODMA), 1,2-dilinoleyloxy-N,N- dimethyl-3-aminopropane (DLinDMA), 1,2-dilinolenyloxy-N,N-dimethyl-3-aminopropane (DLenDMA). Zwitterionic lipids include, but are not limited to, acyl zwitterionic lipids and ether zwitterionic lipids. Examples of useful zwitterionic lipids are DPPC, DOPC and dodecylphosphocholine. The lipids can be saturated or unsaturated. Liposomes can be formed from a single lipid or from a mixture of lipids. A mixture may comprise (i) a mixture of anionic lipids (ii) a mixture of cationic lipids (iii) a mixture of zwitterionic lipids (iv) a mixture of anionic lipids and cationic lipids (v) a mixture of anionic lipids and zwitterionic lipids (vi) a mixture of zwitterionic lipids and cationic lipids or (vii) a mixture of anionic lipids, cationic lipids and zwitterionic lipids. Similarly, a mixture may comprise both saturated and unsaturated lipids. For example, a mixture may comprise DSPC (zwitterionic, saturated), DlinDMA PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 (cationic, unsaturated), and / or DMPG (anionic, saturated). Where a mixture of lipids is used, not all of the component lipids in the mixture need to be amphiphilic e.g., one or more amphiphilic lipids can be mixed with cholesterol. The hydrophilic portion of a lipid can be PEGylated (i.e., modified by covalent attachment of a polyethylene glycol). This modification can increase stability and prevent non-specific adsorption of the liposomes. For instance, lipids can be conjugated to PEG using techniques such as those disclosed in Heyes et al. (2005) J Controlled Release 107:276-87. Liposomes are usually divided into three groups: multilamellar vesicles (MLV); small unilamellar vesicles (SUV); and large unilamellar vesicles (LUV). MLVs have multiple bilayers in each vesicle, forming several separate aqueous compartments. SUVs and LUVs have a single bilayer encapsulating an aqueous core; SUVs typically have a diameter ≤50 nm, and LUVs have a diameter >50 nm. Liposomes useful with of the invention are ideally LUVs with a diameter in the range of 50- 220 nm. For a composition comprising a population of LUVs with different diameters: (i) at least 80% by number should have diameters in the range of 20-220 nm, (ii) the average diameter (Zav, by intensity) of the population is ideally in the range of 40-200 nm, and / or (iii) the diameters should have a polydispersity index <0.2. Techniques for preparing suitable liposomes are well known in the art e.g., see Liposomes: Methods and Protocols, Volume 1: Pharmaceutical Nanocarriers: Methods and Protocols. (ed. Weissig). Humana Press, 2009. ISBN 160327359X; Liposome Technology, volumes I, II & III. (ed. Gregoriadis). Informa Healthcare, 2006; and Functional Polymer Colloids and Microparticles volume 4 (Microspheres, microcapsules & liposomes). (eds. Arshady & Guyot). Citus Books, 2002. One useful method involves mixing (i) an ethanolic solution of the lipids (ii) an aqueous solution of the nucleic acid and (iii) buffer, followed by mixing, equilibration, dilution and purification (Heyes et al. (2005) J Controlled Release 107:276-87.). RNA and / or DNA can be encapsulated within the liposomes, and so the liposome forms an outer layer around an aqueous DNA- or RNA-containing core. This encapsulation has been found to protect RNA from RNase digestion. The liposomes can include some external RNA or DNA (e.g., on the surface of the liposomes), but in some embodiments, at least half of the nucleic acid (and ideally substantially all of it) is encapsulated. Microparticles / Polymers Various polymers can form microparticles to encapsulate or adsorb DNA or RNA. The use of a substantially non-toxic polymer means that a recipient can safely receive the particles, and the use of a biodegradable polymer means that the particles can be metabolized after delivery to avoid PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 long-term persistence. Useful polymers are also sterilizable, to assist in preparing pharmaceutical grade formulations. Suitable non-toxic and biodegradable polymers include, but are not limited to, poly(α- hydroxy acids), polyhydroxy butyric acids, polylactones (including polycaprolactones), polydioxanones, polyvalerolactone, polyorthoesters, polyanhydrides, polycyanoacrylates, tyrosine- derived polycarbonates, polyvinyl-pyrrolidinones or polyester-amides, and combinations thereof. In some embodiments, the microparticles are formed from poly(α-hydroxy acids), such as a poly(lactides) (“PLA”), copolymers of lactide and glycolide such as a poly(D,L-lactide-co-glycolide) (“PLG”), and copolymers of D,L-lactide and caprolactone. Useful PLG polymers include those having a lactide / glycolide molar ratio ranging, for example, from 20:80 to 80:20 e.g., 25:75, 40:60, 45:55, 55:45, 60:40, 75:25. Useful PLG polymers include those having a molecular weight between, for example, 5,000-200,000 Da e.g., between 10,000-100,000, 20,000-70,000, 40,000-50,000 Da. The microparticles ideally have a diameter in the range of 0.02 μm to 8 μm. Techniques for preparing suitable microparticles are well known in the art e.g., see Functional Polymer Colloids and Microparticles volume 4 (Microspheres, microcapsules & liposomes). (eds. Arshady & Guyot). Citus Books, 2002; Polymers in Drug Delivery. (eds. Uchegbu & Schatzlein). CRC Press, 2006 and Microparticulate Systems for the Delivery of Proteins and Vaccines. (eds. Cohen & Bernstein). CRC Press, 1996. To facilitate adsorption of RNA, a microparticle may include a cationic surfactant and / or lipid e.g., as disclosed in O'Hagan et al. (2001) J Virology 75:9037-9043; and Singh et al. (2003) Pharmaceutical Research 20: 247-251. An alternative way of making polymeric microparticles is by molding and curing e.g., as disclosed in WO2009 / 132206. Microparticles of the invention can have a zeta potential of between 40-100 mV. RNA can be adsorbed to the microparticles, and adsorption is facilitated by including cationic materials (e.g., cationic lipids) in the microparticle. Oil-In-Water Cationic Emulsions Oil-in-water emulsions are known for adjuvating influenza vaccines e.g., the MF59™ adjuvant in the FLUAD™ product, and the AS03 adjuvant in the PREPANDRIX™ product. DNA or RNA delivery can be accomplished with the use of an oil-in-water emulsion, provided that the emulsion includes one or more cationic molecules. For instance, a cationic lipid can be included in the emulsion to provide a positively charged droplet surface to which negatively charged nucleic acid can attach. The emulsion comprises one or more oils. Suitable oil(s) include those from, for example, an animal (such as fish) or a vegetable source. The oil is ideally biodegradable (metabolizable) and biocompatible. Sources for vegetable oils include nuts, seeds and grains. Peanut oil, soybean oil, PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 coconut oil, and olive oil, the most commonly available, exemplify the nut oils. Jojoba oil can be used e.g., obtained from the jojoba bean. Seed oils include safflower oil, cottonseed oil, sunflower seed oil, sesame seed oil and the like. In the grain group, corn oil is the most readily available, but the oil of other cereal grains such as wheat, oats, rye, rice, teff, triticale and the like may also be used. 6-10 carbon fatty acid esters of glycerol and 1,2-propanediol, while not occurring naturally in seed oils, may be prepared by hydrolysis, separation and esterification of the appropriate materials starting from the nut and seed oils. Fats and oils from mammalian milk are metabolizable and so may be used. The procedures for separation, purification, saponification and other means necessary for obtaining pure oils from animal sources are well known in the art. Most fish contain metabolizable oils which may be readily recovered. For example, cod liver oil, shark liver oils, and whale oil such as spermaceti exemplify several of the fish oils which may be used herein. A number of branched chain oils are synthesized biochemically in 5-carbon isoprene units and are generally referred to as terpenoids. Squalane, the saturated analog to squalene, can also be used. Fish oils, including squalene and squalane, are readily available from commercial sources or may be obtained by methods known in the art. Other useful oils are the tocopherols, particularly in combination with squalene. Where the oil phase of an emulsion includes a tocopherol, any of the α, β, γ, δ, ε or ξ tocopherols can be used. D-α-tocopherol and DL-α-tocopherol can both be used. An oil combination comprising squalene and a tocopherol (e.g., DL-α-tocopherol) can be used. The aqueous component of the emulsion can be plain water (e.g., w.f.i.) or can include further components e.g., solutes. For instance, it may include salts to form a buffer e.g., citrate or phosphate salts, such as sodium salts. Typical buffers include: a phosphate buffer; a Tris buffer; a borate buffer; a succinate buffer; a histidine buffer; or a citrate buffer. A buffered aqueous phase can be used, and buffers will typically be included in the 5-20 mM range. The emulsion also includes a cationic lipid. In some embodiments this lipid is a surfactant so that it can facilitate formation and stabilization of the emulsion. Useful cationic lipids generally contain a nitrogen atom that is positively charged under physiological conditions e.g., as a tertiary or quaternary amine. This nitrogen can be in the hydrophilic head group of an amphiphilic surfactant. Useful cationic lipids include, but are not limited to: 1,2-dioleoyloxy-3-(trimethylammonio)propane (DOTAP), 3′-[N—(N′,N′-Dimethylaminoethane)-carbamoyl]Cholesterol (DC Cholesterol), dimethyldioctadecyl-ammonium (DDA e.g. the bromide), 1,2-Dimyristoyl-3-Trimethyl- AmmoniumPropane (DMTAP), dipalmitoyl(C16:0)trimethyl ammonium propane (DPTAP), distearoyltrimethylammonium propane (DSTAP). Other useful cationic lipids are: benzalkonium chloride (BAK), benzethonium chloride, cetramide (which contains tetradecyltrimethylammonium PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 bromide and possibly small amounts of dedecyltrimethylammonium bromide and hexadecyltrimethyl ammonium bromide), cetylpyridinium chloride (CPC), cetyl trimethylammonium chloride (CTAC), N,N′,N′-polyoxyethylene (10)-N-tallow-1,3- diaminopropane, dodecyltrimethylammonium bromide, hexadecyltrimethyl-ammonium bromide, mixed alkyl-trimethyl-ammonium bromide, benzyldimethyldodecylammonium chloride, benzyldimethylhexadecyl-ammonium chloride, benzyltrimethylammonium methoxide, cetyldimethylethylammonium bromide, dimethyldioctadecyl ammonium bromide (DDAB), methylbenzethonium chloride, decamethonium chloride, methyl mixed trialkyl ammonium chloride, methyl trioctylammonium chloride), N,N-dimethyl-N-[2(2-methyl-4-(1,1,3,3tetramethylbutyl)- phenoxy]-ethoxy)ethyl]-benzenemetha-naminium chloride (DEBDA), dialkyldimetylammonium salts, [1-(2,3-dioleyloxy)-propyl]-N,N,N,trimethylammoniumchloride, 1,2-diacyl-3- (trimethylammonio) propane (acyl group=dimyristoyl, dipalmitoyl, distearoyl, dioleoyl), 1,2-diacyl- 3 (dimethylammonio)propane (acyl group=dimyristoyl, dipalmitoyl, distearoyl, dioleoyl), 1,2- dioleoyl-3-(4′-trimethyl-ammonio)butanoyl-sn-glycerol, 1,2-dioleoyl 3-succinyl-sn-glycerol choline ester, cholesteryl (4′-trimethylammonio) butanoate), N-alkyl pyridinium salts (e.g. cetylpyridinium bromide and cetylpyridinium chloride), N-alkylpiperidinium salts, dicationic bolaform electrolytes (C12Me6; C12BU6), dialkylglycetylphosphorylcholine, lysolecithin, L-α dioleoylphosphatidylethanolamine, cholesterol hemisuccinate choline ester, lipopolyamines, including but not limited to dioctadecylamidoglycylspermine (DOGS), dipalmitoyl phosphatidylethanol-amidospermine (DPPES), lipopoly-L (or D)-lysine (LPLL, LPDL), poly (L (or D)-lysine conjugated to N-glutarylphosphatidylethanolamine, didodecyl glutamate ester with pendant amino group (CAGluPhCnN), ditetradecyl glutamate ester with pendant amino group (C14GluCnN+), cationic derivatives of cholesterol, including but not limited to cholesteryl-3 β- oxysuccinamidoethylenetrimethylammonium salt, cholesteryl-3 β-oxysuccinamidoethylene- dimethylamine, cholesteryl-3 β-carboxyamidoethylenetrimethylammonium salt, and cholesteryl-3 β- carboxyamidoethylenedimethylamine. Other useful cationic lipids are described in US 2008 / 0085870 and US 2008 / 0057080, which are incorporated herein by reference. The cationic lipid can be biodegradable (metabolizable) and biocompatible. In addition to the oil and cationic lipid, an emulsion can include a non-ionic surfactant and / or a zwitterionic surfactant. Such surfactants include, but are not limited to: the polyoxyethylene sorbitan esters surfactants (commonly referred to as the Tweens), especially polysorbate 20 and polysorbate 80; copolymers of ethylene oxide (EO), propylene oxide (PO), and / or butylene oxide (BO), sold under the DOWFAX™ tradename, such as linear EO / PO block copolymers; octoxynols, which can vary in the number of repeating ethoxy (oxy-1,2-ethanediyl) groups, with octoxynol-9 PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 (Triton X-100, or t-octylphenoxypolyethoxyethanol) being of particular interest; (octylphenoxy)polyethoxyethanol (IGEPAL CA-630 / NP-40); phospholipids such as phosphatidylcholine (lecithin); polyoxyethylene fatty ethers derived from lauryl, cetyl, stearyl and oleyl alcohols (known as Brij surfactants), such as triethyleneglycol monolauryl ether (Brij 30); polyoxyethylene-9-lauryl ether; and sorbitan esters (commonly known as the Spans), such as sorbitan trioleate (Span 85) and sorbitan monolaurate. Mixtures of these surfactants can be included in the emulsion e.g., Tween 80 / Span 85 mixtures, or Tween 80 / Triton-X100 mixtures. A combination of a polyoxyethylene sorbitan ester such as polyoxyethylene sorbitan monooleate (Tween 80) and an octoxynol such as t-octylphenoxy- polyethoxyethanol (Triton X-100) is also suitable. Another useful combination comprises laureth 9 plus a polyoxyethylene sorbitan ester and / or an octoxynol. Useful mixtures can comprise a surfactant with a HLB value in the range of 10-20 (e.g., polysorbate 80, with a HLB of 15.0) and a surfactant with a HLB value in the range of 1-10 (e.g., sorbitan trioleate, with a HLB of 1.8). Anti-Cryptosporidium Immune Response Inducing Agent / Composition The anti-Cryptosporidium immune response inducing compositions may comprise one or more immunoregulatory agents. In some embodiments, one or more of the immunoregulatory agents include one or more adjuvants, for example two, three, four or more adjuvants. The compositions of the invention may include one or more pharmaceutically acceptable carrier(s) and / or excipient(s), including adjuvants. A thorough discussion of such components is available in Gennaro (2000) Remington: The Science and Practice of Pharmacy.20th edition, ISBN: 0683306472. Compositions will generally be in aqueous form. The composition may include preservatives such as thiomersal or 2-phenoxyethanol. However, that the vaccine should be substantially free from (i.e., less than 5 μg / ml) mercurial material, e.g., thiomersal-free. Immunogenic compositions containing no mercury are more preferred. Preservative-free immunogenic compositions are preferred. To control tonicity, a physiological salt can be included, such as a sodium salt. Sodium chloride (NaCl) is one exmaple, which may be present at between 1 and 20 mg / ml. Other salts that may be present include potassium chloride, potassium dihydrogen phosphate, disodium phosphate dehydrate, magnesium chloride, calcium chloride, and the like. Compositions will generally have an osmolality of between 200 mOsm / kg and 400 mOsm / kg, including between 240-360 mOsm / kg, such as within the range of 290-310 mOsm / kg. Compositions may include one or more buffers. Typical buffers include: a phosphate buffer; a Tris buffer; a borate buffer; a succinate buffer; a histidine buffer (particularly with an aluminum hydroxide adjuvant); or a citrate buffer. Buffers will typically be included in the 5-20 mM range. The PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 pH of a composition will generally be between 5.0 and 8.1, and more typically between 6.0 and 8.0, e.g., between 6.5 and 7.5, or between 7.0 and 7.8. A process of the invention may therefore include a step of adjusting the pH of the bulk vaccine prior to packaging. The composition is preferably sterile. The composition is preferably non-pyrogenic, e.g., containing <1 EU (endotoxin unit, a standard measure) per dose, and preferably <0.1 EU per dose. The composition is preferably gluten free. Human vaccines are typically administered in a dosage volume of about 0.5 ml, although a half dose (i.e., about 0.25 ml) may be administered to children. Compositions of the invention, that contain Cryptosporidium polypeptides, or nucleic acids that encode Cryptosporidium polypeptides, may also include one or more adjuvants, for example two, three, four or more adjuvants, which can function to enhance the immune responses (humoral and / or cellular) elicited in a patient who receives the composition. Adjuvants can include, but are not limited to, Inorganic compounds (potassium alum, aluminium hydroxide, aluminium phosphate, calcium phosphate hydroxide), Oils (paraffin oil, propolis, Adjuvant 65, squalene), Bacterial products (killed bacteria of the species Bordetella pertussis, Mycobacterium bovis, toxoids, MPL (Monophosphorylated lipid A), Plant saponins (from Quillaia, soybean, Polygala senega), Cytokines ( IL-1, IL-2, IL-12), CpG oligonucleotides, and Combinations (Freund's complete adjuvant, Freund's incomplete adjuvant, AS01 (combining MPL and Quillaia saponins), Matrix-M (combining Quillaia saponins and two types of fat)). Methods of Treatment, Use and Administrations Compositions of the invention are suitable for administration to subjects, and the invention provides a method of inducing an immune response in subject, comprising the step of administering a composition (e.g., an anti-Cryptosporidium immune response inducing agent / composition) of the invention to a subject. The compositions (e.g., an anti-Cryptosporidium immune response inducing agent / composition) can be used to produce a vaccine formulation for immunizing a subject. For example, the immune response may be raised following administration of proteins / antigens disclosed herein. The invention also provides a composition of the invention for use as a medicament, e.g., for use in immunizing a patient against Cryptosporidium infection. The invention also provides the use of a polypeptide or nucleic acid as described above in the manufacture of a medicament for raising an immune response in a patient. The immune response raised by these methods and uses will generally include an antibody response, preferably a protective antibody response. Methods for assessing antibody responses after Cryptosporidium vaccination are well known in the art. PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 Compositions of the invention can be administered in a number of suitable ways, such as intramuscular injection (e.g., into the arm or leg), subcutaneous injection, intranasal administration, oral administration, intradermal administration, transcutaneous administration, transdermal administration, and the like. The appropriate route of administration will be dependent upon the age, health and other characteristics of the subject. A clinician will be able to determine an appropriate route of administration based on these and other factors. Treatment can be by a single dose schedule or a multiple dose schedule. Multiple doses may be used in a primary immunization schedule and / or in a booster immunization schedule. In a multiple dose schedule the various doses may be given by the same or different routes, e.g., a parenteral prime and mucosal boost, a mucosal prime and parenteral boost, etc. Administration of more than one dose (typically two doses) is particularly useful in immunologically naïve patients. Multiple doses will typically be administered at least 1 week apart (e.g., about 2 weeks, about 3 weeks, about 4 weeks, about 6 weeks, about 8 weeks, about 10 weeks, about 12 weeks, about 16 weeks, and the like, including once every 6 months or once a year). The invention will be described by the following non-limiting examples. EXAMPLE 1 Introduction Cryptosporidium parasites are a common cause of diarrhea in infants and children in low- and middle-income countries, globally are the most common cause of outbreaks of waterborne disease, and in immunocompromised individuals can cause protracted infections (1). Evidence that a vaccine is an achievable goal includes that the incidence of infection declines with age (2–4) and that antibodies against the surface of the infectious oocyst (5) and invasive sporozoite parasite life stages are associated with partial immunity to reinfection (5,9). While the associated protective immune response involves both cellular and humoral immunity, identification of antibody responses against Cryptosporidium antigens associated with protection from reinfection provides a foundation for the development of an effective anti-Cryptosporidium vaccine. Previously, another study conducted a natural history of cryptosporidiosis in infants longitudinally followed for infection from birth to three years of age (National Clinical Trial Identifier: NCT02764918) (6–9). The infants resided in a low-income community of Dhaka, Bangladesh. Fecal DNA was extracted from monthly surveillance and diarrheal stool samples and symptomatic and asymptomatic cases of cryptosporidiosis were identified using a pan- Cryptosporidium qPCR assay. By the end of year one, 27.5% (n=109) of infants had been infected at least once. The immunity arising from this infection was however incomplete with most of these PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 children reinfected by three years of age (FIG.9) (10). These repeat infections however had a lower burden of parasites and were more likely to be sub-clinical in nature. Herein follows results from probing a Cryptosporidium protein microarray with antisera from one year old infants. The association of antibody responses against specific proteins with immunity to reinfection in years 2 and 3 of life was then tested. Materials and Methods Open Reading Frame Selection for the Cryptosporidium Protein Microarray Although many Cryptosporidium species can infect humans, the most common human pathogens are the zoonotic C. parvum and C. meleagridis and the anthroponotic C. hominis (6). The selected C. parvum proteins included those which had been previously identified as potential vaccine candidates (13–33). Potential vaccine candidates selected for inclusion in the Cryptosporidium protein array PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 The genome sequences of C. parvum and C. hominis are very conserved (95-97%) (56) and C. meleagridis is not very divergent (8.5%; C. parvum versus C. meleagridis) (57) (11, 12). The array included 522 conserved antigens derived from proteins (n=376) that contained signal peptides (C. parvum: antigens 382; C. hominis: 155 antigens ((134 derived from the C. hominis orthologues of “high value” C. parvum proteins already on the array))); and C. meleagridis: 6 antigens ((also represented by other orthologues on the array)) (CryptoDB Database: Release 59(58)). Due to discovery of novel export motifs such as PEXEL in other apicomplexan parasites, it was decided to not restrict the antigen selections to only those with a signal peptide (59, 60). Additional antigens from proteins (n=327) without a signal peptide, but which nevertheless had a transmembrane domain, were included on the array (total antigens: 457; C. parvum antigens: 365; C. hominis antigens: 90 (66 were derived from the C. hominis orthologues of C. parvum proteins already on the array); C. meleagridis 2 (both also represented by other orthologues on the array)). Cryptosporidium Protein Microarray Fabrication The protein microarray used in this study was produced by Antigen Discovery, Inc (ADI) (61, 62). Briefly, the open reading frames selected as described above were subcloned into a T7 expression vector pXI and expressed using an in vitro the Escherichia coli transcription and cell free translation (IVTT) system (Rapid Translation System, Biotechrabbit, Berlin, Germany). After expression the proteins were printed onto nitrocellulose-coated AVID slides (Grace Bio-Labs Inc) using an Omni Grid Accent robotic microarray printer (Digilabs, Inc., Marlborough, MA, USA). As a positive control the purified recombinant Cryptosporidium Cp17 and Cp23 peptides were also spotted onto the array (8, 63). Child cohort A total of 500 children were enrolled within one week of birth from the Mirpur community of Dhaka, Bangladesh beginning in June 2014 through March 2016 (6) (ClinicalTrials.gov NCT02764918). (5) Infants were monitored for cryptosporidiosis through testing of diarrheal and monthly surveillance stool samples, through bi-weekly home visits by trained field investigators. PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 Height and weight were measured quarterly to assess child growth (7). Children who had a HAZ score <-1 were defined as ‘at risk for stunting’ and HAZ < -2 as stunted (64). Select clinical metadata for this study is available on the NCBI’s dbGaP under accession number phs001665.v2.p1. The data for this study is collected as a sub-study of dbGaP phs001475.v2.p1. Sampling and Specimen Testing Fecal DNA was extracted from the diarrheal and monthly surveillance stools and a previously described multiplex qPCR assay which utilizes pan-Cryptosporidium primers and probes targeting the 18 S rDNA gene was used to identify infected infants (6). In select isolates the parasite was genotyped using standard protocols (9). Assays to measure select biomarkers of gut and systemic inflammation (CRP, sCD14, IL-1Beta, IL-4) were performed as previously described (6). A blood sample was drawn at 18 weeks, one year and then every 6 months (dbGAP Accession phs001665.v1.p1). The plasma samples from children which were collected at one year of age were diluted 1:100 and used to probe the Cryptosporidium proteome microarray using standard protocols (56). Samples were incubated on the arrays overnight at 4ºC on a rocker, subsequently washed and incubated with goat anti-human IgG-Fc fragment DyLight650 (Bethyl Laboratories, Cat#A80- 104D5) or Cy3 AffiniPure F(ab')₂ fragment goat anti-human serum IgA, α chain specific (Jackson ImmunoResearch Laboratories, Cat#109-166-011) for one hour at room temperature on a rocker, then washed, dried and stored in the dark until scanning. The exposed arrays were scanned, and the spot and background signal intensities (SI) were exported into R for statistical analysis (65). Spot SIs were adjusted for local background by subtraction, and values were floored to 1. Next, the data were normalized by dividing the Cryptosporidium protein spot values by the median of IVTT control spots (IVTT expression reactions with no Cryptosporidium ORFs), and values were log transformed using the base-2 logarithm. Thus, normalized data represented the log2 signal-to-noise ratio, where a value of 0 represents specific antibody SI equal to the background, 1.0 represented twice the background, 2.0 represented 4-fold over background, etc. For the purified Cp23 protein and Cp17 peptide printed on the microarrays, the data were unaffected by the IVTT background, and thus the normalization procedure was to floor the data to 1 and then transform values using the base-2 logarithm, resulting in normalized data that represent a doubling in fluorescence SI per unit increase. Thus, the scales of purified proteins and IVTT proteins differed due to the former being log-scale SI levels and the latter being log-scale signal-to-noise ratios. Statistical Analysis Cryptosporidium protein responses were classified as seropositive or negative by taking the distribution of each spot individually between all samples to model negative and positive subpopulations using mixture models executed with the “normalmixEM” function in the mixtools PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 package (66), and a seropositivity cutoff was established for each antigen as the mean and three standard deviations of the negative SI distribution. When mixture models failed to converge, a simple seropositivity cutoff of 1.0, or 2-fold over background, was applied. IgG and IgA “reactivity” for each antigen was defined as a proportion of seropositive responses, or seroprevalence, of at least 10% among the study children. Overlap in IgG and IgA responses that recognized individual antigens was assessed using the VennDiagram package in R (68). Antibody breadth scores were calculated as the sum of seropositive responses per individual. Normalized SI and antibody breadth scores were visualized using the ComplexHeatmap package (67). Associations between normalized SI and protein features such as life cycle stage and signal peptides were analyzed using multivariable negative binomial regression for seropositivity classifications and ordinary least squares regression for normalized SI. Univariate groupwise analysis was performed using T-tests. Correlations were assessed using Pearson’s correlation coefficient. Unsupervised data reduction and trends was analyzed using t-distributed stochastic neighbor embedding (tSNE), using a perplexity parameter of 40, 1000 iterations and a theta of 0.0 after testing varying parameters for shape of the data (68, 69). To test differences in profile-wide normalized SI and to control for multiple measurements per subject, linear mixed effects regression (LMER) was performed using the lme4 package (44), allowing for random intercepts at the subject and antigen level—p-values for LMER models were obtained by ANOVA between full models and null variable models. Supervised data reduction and multi-antigen analysis was performed using partial least squares discriminant analysis (PLS-DA) using the mixOmics package (70). PLS-DA results were visualized using plots of PLS-DA scores of first and second latent variables for trends discriminating groups and by plotting the loading weights (i.e., PLS-DA regression coefficients) to highlight the importance of the variables used to define the latent components that maximize the covariance between antibody data and Cryptosporidium infection endpoints (infection prior to sampling and infection 1 and 2 years after sampling). Analysis of antibody breadth was performed using negative binomial regression. Analysis of seropositivity to an antigen and association with risk of infection or reinfection (only among children with infections prior to 1 year of age) during the one-year and two-year follow- up periods following sample collection was performed using Cox proportional hazards models adjusted by the number of episodes a child had, HAZ score at birth, mother’s age, BMI and education level, household income and expenses, principal source of household drinking water, the water treatment method routinely used by the household, and proximity to one of the Dhaka water drainage channels. The two a priori vaccine candidate antigens Gp60 (containing the Cp17 peptide) and Cp23 were analyzed without correction for the false discovery rate (71). PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 To control for false discovery due to the multiple comparisons made, antibody responses were modeled using random forest (“RF”) with survival data using the “randomForestSRC” and “ggRandomForests” packages to perform feature selection (72). All reactive antigens were included in each of four RF models: 1 year follow-up post-sampling among all children or among only children with previous infections, and 2-year follow-up among the two groups of children. Each model performed 1,000 decision trees while allowing deterministic splitting (nsplit = 0) and computation of variable importance (VIMP) using permutation. Each model was repeated 100 times, and VIMP scores were computed for each repeat and then averaged for each antigen target. VIMP scores that were greater than 0 in at least 80% of repeats (80 / 100 RF models) were considered “potentially important variables” for the RF models. Further, a VIMP score cutoff was calculated as one standard deviation above the mean of all VIMP scores returned from the 100 RF model iterations. The survival analysis identified which antibodies were associated with a hazard ratio below 1 (protective response) vs hazard ratios greater than 1 (increased susceptibility). The criteria determined for selection of a minimal number of important variables was: (1) positive VIMP scores in at least 80% of repeats and average VIMP scores above the cutoff, and (2) seropositivity hazard ratios below 1 in all models. The selected features were used in Cox models, reporting both raw p-values and p-values adjusted for the false discovery rate. Detailed information about the R workflow used in this paper is publicly available at https: / / github.com / wikipetria / Cryptosporidium. Analysis of Gp40 / 15 (aka Gp60) sequence variation and antibody associations was performed using the Prism 9 computer program (GraphPad). Results Identification of Immunoreactive Proteins The Cryptosporidium spp. protein microarray created for this study comprised a total of 1761 antigens representing 1250 unique genes from C. parvum (n=980), C. hominis (n=263) and C. meleagridis (n=7). C. parvum sequences were used as the backbone of the protein microarray due to the ready availability of C. parvum DNA and its superior assembly and annotation (11, 12) (FIG.2). The selected C. parvum proteins included those which had been previously identified as potential vaccine candidates (13–33). Open reading frames (ORFs) >3000 base pairs were cloned as overlapping segments to optimize in vitro translation. The array also included 15 genetically variant regions of the gp60 gene common in this Bangladeshi population (9). Proteins with conserved sequences in the different Cryptosporidium species that account for the majority of cryptosporidiosis in humans (C. hominis, C. parvum and C. meleagridis), and that were annotated as having a signal peptide, and thus potentially a membrane protein and accessible to human antibodies, were prioritized for inclusion (FIG.11). PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 The array was incubated with a 1:100 dilution of plasma collected at one year of age from 500 children in the cohort, and developed with anti-human IgG (DyLight650, Bethyl Laboratories) and Cy3 AffiniPure F(ab')₂ or anti-human IgA. The distribution of normalized fluorescence signal intensity (SI) values of each antigen was analyzed using a mixture modeling technique (FIG. 12A) to identify the antigen specific background component of the spot signal and hence the appropriate intensity (cut-off value) that was defined as seropositive (FIG.12B). Antigens were classified as seroreactive in this population if ≥ 10% of the children had either IgA (FIG.1A) or IgG (FIG.1B) antibodies against the antigen. Using this criterion, 36 antigens were seroreactive to both IgG and IgA (FIG.1), 57 antigens by IgA alone and 140 antigens by IgG alone (FIG.1). Antigens recognized varied greatly between children, with each antigen recognized by only a subset of the responding infants (FIG.2). Orthologues encoded by C. parvum and C. hominis generated similar signals; for example, the C. parvum Cp23 (cgd4_3620) and the C. hominis Cp23 orthologue (Chro.40414) signals were correlated (Pearson r value 0.844 p=2.11e-119)). In total there were 124 IgG-reactive proteins and 70 IgA-reactive C. parvum proteins. Antigens recognized were from multiple developmental stages of the Cryptosporidium parasite (34-38, 40) (FIG.10). Humoral immune response diminished with time from infection The anti-Cryptosporidium IgA and IgG antibody profiles were analyzed using t-distributed stochastic neighbor embedding (t-SNE) as an unsupervised data reduction method for visualization of the trends in the antibody profile, based on the number of days since the first Cryptosporidium positive diagnostic qPCR and whether the child had a documented prior Cryptosporidium infection (FIG.3A). The antibody profile of children with more recent infections mapped to a distinct region within the t-SNE plot (Region 1, “R1”), while children with prior infection did not cluster separately from children without a prior infection (FIG. 3A). By analyzing the most responsive antigens (top 100), the important factors which influenced the antibody profile of children in R1 of the t-SNE plot were the strength of the immune response (FIG.3B) and its breadth (the number of parasite antigens recognized by IgA and IgG) (FIG. 3C) (39). Diminishing antibody responses over time were confirmed by a linear regression analysis where most notably, the breadth of both the IgA and IgG anti-Cryptosporidium immune responses significantly decreased over time (FIG.3D). Impact of prior infection on antibody response While the effect of time since Cryptosporidium infection on antibody levels was significant, it did not completely explain the failure to generate an anti-Cryptosporidium immune response in all cases. To focus on the impact of prior exposure to the Cryptosporidium parasite, the data were analyzed using partial least squares discriminant analysis (PLS-DA) (FIG.3E and F). This analysis PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 demonstrated that a subset of children with prior infection differed from the population of children with no prior infection. but that a substantial proportion of children with prior infection had antibody profiles similar to children without a documented prior infection. It was concluded that some infections in this cohort were missed despite the active surveillance system in place. To explore whether malnutrition or inflammation impacted the humoral immune response, it was examined whether the immune profile correlated with growth failure (a measure of chronic malnutrition measured by child height-for-age Z scores (HAZ)) or biomarkers of systemic and local inflammation (sCD14, IL-1Beta, CRP) or immunoregulatory cytokines (IL-4), but no correlations were observed (FIG.14). Protection from reinfection was not associated with the breadth of the antibody response (i.e., number of antigens recognized by a given child) Children for whom a previous infection had been identified had a greater number of parasite antigens recognized by IgA and IgG (greater “breadth”) (FIG. 4A). However, no association was found between the breadth of the antibody response and resistance to reinfection using either a data set restricted to the infants with a qPCR verified Cryptosporidium infection prior to year one (FIG. 4B) or using the data from the entire study cohort (FIG.4C). Validation of the array by examining the data obtained from antigens previously associated with a protective immune response C. hominis Cp23 (Chro.40414) and Cp17, a conserved peptide encoded by the variable C. hominis gp60 gene (Chro.601380: variant IaA25R3), are both potential vaccine candidates and previously shown to be associated with a delay in reinfection in the study population (7, 8). A potential association with protection from reinfection between IgA antibodies recognizing C. hominis Cp23 (Chro.40414) and the C. hominis gp60 (Chro.601380) antigens was investigated on the Cryptosporidium array. As the IgA anti-Cp23 (Chro.40414) signal was low in the array data, only analysis of the anti-IgG Cp23 (Chro.40414) data was possible. As expected, a protective association was observed between both anti-IgA and IgG C. hominis Gp60 (Chro.601380) (FIG. 5A-5D) and anti-IgG C. hominis Cp23 (Chro.40414) (FIG. 5E and 5F). (Since Gp60 and Cp23 were a priori antigen candidates, p-values were not adjusted for the false discovery rate). Impact of the polymorphisms in the gp60 gene on immune reactivity The protein encoded by the gp60 gene is processed by the parasite into Gp40 and Gp15 proteins (FIG. 6A). The region of the gp60 gene that encodes the Gp40 protein has three variable domains: a SNP-based allelic family “type”; a variable number of trinucleotide repeats “subtypes”; and a repeat sequence “R” (34). In the Bangladeshi infant cohort 15 different variants of gp60 were identified (2 in C. parvum and 13 in C. hominis) (FIG.6A) all of which were included in the protein PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 array (9). The gp60 genotype of the infecting Cryptosporidium parasite was known in a subset of cases, and the data from the plasma collected from these children was examined to see if an allele- specific immune signal could be observed. With one exception, the infecting C. hominis genotype matched the Gp40 antigen variant recognized by the child’s plasma (Figures 6A and 6B, FIG.15). The number of trinucleotide repeats in the gp60 gene however did not impact antibody recognition: children infected with the IaA18R3 subtype bound equivalently to the Ia antigens on the array which had different numbers of trinucleotide repeats (IaA27R3, IaA26R3, IaA25R3, IaA22R3, IaA19R3 and IaA18R3 (FIG. 6A and 6B). It was concluded that humoral immunity to the variable Gp40 antigen was genotype specific. Antigens associated with protection from reinfection It was tested if a delay in the time to reinfection was associated with the development of anti- Cryptosporidium antibodies against specific antigens. This analysis was done for the children on follow-up to ages 2 and 3 years who had qPCR-verified cryptosporidiosis during the first year of life (Table 1; FIG.15). Table 1. Antibody responses associated with protection resulting from a Cryptosporidium infection Antibodies at one year of life associated with reduced risk of infection in year 2 (children with qPCR positive stool samples during the first year of life, n=104 children) IgG Gp60, sporozoite 0.41 (0.23- 0.003 (PFDR = Chro.601 52 / 104 (50%) antigen gp40 / 15 0.74) N / A) 38 IgA Gp60, sporozoite 37 / 104 0.47 (0.25- Chro.601 0.02 (PFDR= N / A) antigen gp40 / 15 (35.6%) 0.89) 38 IgG Cp23, 55 / 104 0.55 (0.31- 0.046 (PFDR = Chro.404 immunodominant (52.9%) 0.99) N / A) 14 antigen IgG CpMuc8, secreted 12 / 104 0.26 (0.09- 0.015 (PFDR= Cgd8_70 mucin (11.5%) 0.77) 0.066) 0 PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 CpSMP, small IgG membrane protein 33 / 104 0.45 (0.23- 0.018 (PFDR = Chro.301 (Signal peptide & (31.7%) 0.87) 0.066) 11 transmembrane domain) IgG Gp900, Cryptosporidial 57 / 104 0.53 (0.3- 0.032 (PFDR = Cgd7_40 mucin (54.8%) 0.95) 0.071) 20 Antibodies at one year of life associated with reduced risk of infection in year 2 (all children in the cohort, n=435 children) IgG Gp60, sporozoite antigen gp40 / 1588 / 4350.56 (0.37- 0.006 (PFDR= (20.2%) 0.85) N / A) IgA Gp60, sporozoite 50 / 435 0.56 (0.33- 0.028 (PFDR = Chro.601 antigen gp40 / 15 (11.5%) 0.94) N / A) 38 IgG Cp23, 89 / 435 0.58 (0.39- Chro.404 immunodominant 0.01 (PFDR= N / A) (20.5%) 0.88) 14 antigen IgG CorA, possible 76 / 435 0.55 (0.36- 0.034 (PFDR = Cgd2_15 magnesium transporter (17.5%) 0.83) 0.034) 20 IgG CpMuc8, secreted 0.018 (PFDR = Cgd8_70 mucin 0.045) 0 IgG CCDC, coiled-coil 67 / 435 0.58 (0.37- 0.019 (PFDR = Cgd8_83 domain-containing (15.4%) 0.92) 0.045) 0 protein Antibodies at one year of life associated with reduced risk of infection in years 2 and 3 (children with qPCR positive stool samples during the first year of life, n=104) PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 IgG Gp60, sporozoite 0.53 (0.33- 0.007 (PFDR = Chro.601 52 / 104 (50%) antigen gp40 / 15 0.84) N / A) 38 IgA Gp60, sporozoite 37 / 104 0.54 (0.33- 0.014 (PFDR= Chro.601 antigen gp40 / 15 (35.6%) 0.88) N / A) 38 IgG Cp23, 55 / 104 0.63 (0.39- 0.059 (PFDR= Chro.404 immunodominant (52.9%) 1.02) N / A) 14 antigen CpSMP, small IgG membrane protein 33 / 104 0.47 (0.28- 0.0042 (PFDR = Chro.301 (Signal peptide & (31.7%) 0.79) 0.025) 11 transmembrane domain) IgG Gp900, Cryptosporidial 57 / 104 0.53 (0.33- 0.0072 (PFDR = Cgd7_40 mucin (54.8%) 0.84) 0.025) 20 Antibodies at one year of life associated with reduced risk of infection in years 2 and 3 (all children in the cohort, n=435) IgG Gp60, sporozoite 88 / 435 0.68 (0.49- 0.016 (PFDR = Chro.601 antigen gp40 / 15 (20.2%) 0.93) N / A) 38 IgA Gp60, sporozoite 50 / 435 0.53 (0.35- 0.003 (PFDR = Chro.601 antigen gp40 / 15 (11.5%) 0.81) N / A) 38 IgG Cp23, 89 / 435 0.66 (0.48- 0.011 (PFDR = Chro.404 immunodominant (20.5%) 0.91) N / A) 14 antigen PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 IgG CCDC, coiled-coil 67 / 435 0.68 (0.48- 0.025 (PFDR = Cgd8_83 domain-containing (15.4%) 0.95) 0.11) 0 protein IgG CorA (possible 76 / 435 0.71 (0.52- 0.032 (PFDR= Cgd2_15 magnesium transporter) (17.5%) 0.97) 0.11) 20 * Gene ID from CryptoDB;†P-values computed from multivariable Cox proportional hazards models, and PFDRrepresents P-values adjusted for the false discovery rate among the subset of protective antibodies identified from Random Forest analysis (hazard ratios < 1). Antibodies against the a priori vaccine candidate antigens Gp60 and Cp23 were not adjusted for the FDR. HR: hazard ratio. Exemplary Novel Protein Candidates associated with genes in Table 1: >cgd8_700. MIFLRVLITCLTLLIVTYITLFISLNNEIGNHLNDEITKINSQAVFISFLEIPGLKRKKNYSKLSL TNINIKRMSLDQLNSLISRLLQQISELRKEINELEAKLKVLKSGLELEKCNDKNKKNKKKQK HLSKKCQNCESIQKEINSVESKLRKLRLKLNNDKNKLIKAKFRKSKLVSSSNEQEETEANE DTGADKINYSTGTSTGTSTSTSTVTTTCITSTSTHKTTTTTTISTTTSNITITPTISNKATPTHIP APTPTHTPTPTPTPNPNPNPNPNPNPSELNNSETNMVNEKLKLLDAKMEEIKKLAMGQRET VQLFFEKLLKVFAASELIELKCELGMVNKLFVVKLKIIKILQSAQNRNNESYRIDESTFLTTQ TEKGKQAIKEYEILLLLLKDLISYFSKLLELCEEIFHVSPKIKGKLEKLIINLNECKFEKFSPLL DLTRFLVQNYSKFPINSRYGSKIFLYLLTRLQGFTQIKECLSIKKLQKWVSLKNEYNNKILK YKLKLKSLKCNGHNHLNKPCTRNTCIIELKKYFLMEKIKTYNLIIELLISLLNNCDNLLKKD PSSLEIQAKIHSFSKECSYTYDITKSIKKLGIYKDLNQLQKKQVYQNMYQLIQSIGGFTFIFYS KDCNIETITELFQFISRINQIKELEENNKNLYEDPNLDEARKLKIISAKSLIKISLDLISFCLTYY QFEEEVTQKINLNKEIIKKMDINSELRADLKLFENLQILLSEKYIYSTLDCNFKNIMKIIQEKQ QSMELLNFYQKELKLKKHLHGKSGNQSIDKIIQKRNILLYGITMNNNHNCSICNSDNVKRN ILLEKYYMELLQFILNNCIKIKFPYINKFLDEEISKNNYKTIIGELFSGIIENLFSEEIILLLNLAN KIEMAILNTLLKRFSINMSGLKDCTVKKIIDFKKSLKEIKILQDRLEERINNNNNNYEEISYK NIKLEEMMNENELMITKRLHYRLKDILIVLILIIEDIIRRCENVIEIIKKDDENELSIKILKLPSP QYFTASIKKGLLLNKIEITSVFFKLTSNFDLFGHINSCLETNYLSLLLKYGKLSEEFNMILSNF LNKYSNGIDSSLEYNYNKEFLTLIGYSLALEYFFEAIYACILRVEGENGLGIIKKYDPFKKEG ENLILNKSINDILKQERWGYGLFQENVTIDGSHLLHRFTSNDKIKPESCTLSFIKELIQKIEEIE NLKRGLKNEELIEAKNLSSILSLHSSIIKFCFKFGIFYILKSQLNKKQEIITTGVVGWEFHPTL PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 MEFEFPSYPLEDGFLSNLELFGFDNLVSSGDYSQLFDLDSGDLISRTEMSVGMYINDSVDEN ERFDFEGFGVGMGAGAGTGAGTGAGVGIGTGAGTGPEQGPGTGIKTGTKAEGTGTGPEQ GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT GTGAEIKAEVKLEAGDEATKAEFPILTVMPELGPEQHVLDKLDLKTLMNYNLMNYLEMFI KELSNLLLPEILEKAFKFLTGCDLNLLYLINTRISTIEYLLIQMLKFNNNNKSDHNSVNYELL FETLRNLVFKLKSYLVKCQELNKFKYPWLHIPNLKNFKENIKSLLFSFFQQDKNIPKDCFLI NIEEVKKFISFQKLKVERLEDMVEKTKLFIQNRDGKNANFKSSSTIFHLELEKEIIISAITRNE QLTAICEEFLNYFQLNSHITIDILDVLENLFSSLVISDLQISQFNSRISQVFSLGASGAGVGTGS GVGTGSGVGTGADAGTGADAGTGVGAGVGAVYTPTPTPAPAYGESSGFNSPSIVLLSDIY TEGTEEPNLPIIQSKPISNISSQSNQENNDYSSFLKDPEVQNLYSLYLSLIEEPLTLKQLIESSG FDKELLIQMLLGFLEEN (SEQ ID NO: 4) >Chro.30111 Small Surface Protein MKLSFFLSLLVLFISYYQVNSQDAYHPFRSTALELADSKNQSSCNENCIQEKNDRSLQESSE NSNSGTSQGSNNSVGNIIQENINNLYKELADHSQEQAKNTWDSLSTGAKA GIIIAIVVVAIIIIAGIIHCLCICKLCCCC (SEQ ID NO: 5) >cgd2_1520 MSNNVNESFREIQQPPPSYLVSKDLDSIVVEESMEIFDDRIYDSETQKNEDSSKEMLENVDF LDRVVDQFYGNERTSSIRKVNDEMDEGNPLLFSNNMTRNTEIMNINKRHKIMDNNDQKLG GSREFLDAIQAKTRKYITFEIGRGYKRCLLLQTGELLRLVHSYNKECLLQDTVPGALKLRD LRQVVSMGSSQRPSIEVRRNCILVNVPHFRAIILHQKVLLIASGYSRSPLDYPSSGINYNYSS GNNNKSEKKEDFKEQNSCVNKNAFSLNDVQLEVPAPYLSSIDIPNSPSNYQCKNDVINEVN FDNSMTVQFDSSKVSSFPKTGIEYTPIEGLSDKQIYSKNCQFIPPGIEEGFPLLRKLEHISGIES STPFEYLVLETILVESCNIINRQVRPIRDSVLFILDSFPGRNRETRRLLDAVSELRRRLNAIEEL AQGLFKAITEMLGNEEDMQRLEISFYWNRPEAWEYPKNTPYHEEVENVLECYAQEVEMM LQQIESIGESLEDALEVLTLELSSLRNSIMKADLGLSIIATIVGFCGFFADCFGMNLRNGLEE VGPALFWFITWGLILLCAAGAIVVLTTFRKIDL (SEQ ID NO: 6) >cgd8_830 MSKGKFSFSLGKSKEKGPKSLGNVFLGEKVFESEKDENNSAEDLGSKNSDNFQSISTNYEY KKSIKFYNEHPELLKDFDRSNKVKRIEAEDEEEKKDEPKKASLGKSKYLSRIQEYVELRNIE KQEIQEEKIQKEIKEEGNTQVFITDAYKDVLEERKKLKNLLTNRKLSEGEDPRISGPSSIFEM RLSPSTNELNNEESDKQIASGSPKEELNIYNVNSTNSSTTKDYYVVNDDEVSKTSKDLKLIK IQQARERYLLRKQNKNSA (SEQ ID NO: 7) PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 The analysis was also performed including all the children in the cohort (Table 2; FIG.16). Table 2. Other antibody responses potentially associated with protection from Cryptosporidium reinfection cgd6_4 parvu (10 / 104); 1.07) characteriz N.S. N.S. 870 m IgG: 1.9% P=0.07 ed protein (PFDR= (2 / 104) 0.62) secreted β=0.65 protein (0.41- cgd8_3 parvu with 1.02) N.S. N.S. 520 m cysteine P=0.061 rich (P =0 (51 / FDR.6 104) repeats 1) PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 and a mucin like threonine rich repeat, signal peptide Un- IgA: 12.5% β=0.38 characteriz cgd3_1 parvu (13 / 104); (0.19-0.75) ed protein, N.S. N.S. N.S. 130 m IgG: 31.7% P=0.006 TM (33 / 104) (PFDR=0.4) domain Un- characteriz β=0.47 ed IgA: 10.6% (0.24- cgd1_6 parvu secreted (11 / 104); 0.91) N.S. N.S. N.S. 50 m Protein IgG: 21.2% P=0.025 (CpLSP (22 / 104) (PFDR=0.4 gene 9) family) IgA: 6.7% β=0.54 Un- (0.3-0.97) cgd8_6 parvu characteriz (7 / 104); N.S. N.S. P=0.04 60 m ed protein IgG: 23.1% (PFDR=0.5 (24 / 104) 4) Analysis using only the 104 children in the cohort known to be infected prior to year one by qPCR of stool samples. *Gene ID from CryptoDB; N.S.: Not significant; FDR: false discovery rate. Table 3. Other antibody responses associated with protection from Cryptosporidium infection among all children in the cohort PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 Uncharacteri IgA: 13.6% (0.45-0.89) zed (59 / 435); N.S. N.S. N.S. P=0.008 cgd4_197 parvu transmembra IgG: 22.1% (PFDR=0.3 0 m ne Protein (96 / 435) 6) β=0.57 β=0.61 (0.34- (0.41-0.91) IgA: 2.8% 0.95) N.S. N.S. P=0.016 Uncharacteri (12 / 435); P=0.03 (PFDR=0.36 cgd5_149 parvu zed Secreted IgG: 11.5% (PFDR=0. ) 0 m Protein (50 / 435) 58) β=0.69 (0.46- IgA: 10.3% 1.04) N.S. N.S. N.S. (45 / 435); P=0.073 cgd6_487 parvu Uncharacteri IgG: 0.7% (PFDR=0. 0 m zed protein (3 / 435) 99) β=0.57 β=0.58 (0.34- (0.39-0.88) IgA: 2.1% 0.96) N.S. N.S. P=0.009 (9 / 435); P=0.034 (PFDR=0.36 cgd7_215 parvu transmembra IgG: 11.3% (PFDR=0. ) 0** m ne protein (49 / 435) 59) secreted protein with β=0.71 cysteine rich (0.52-0.98) repeats and a N.S. N.S. N.S. (7 / 435); P=0.04 mucin like cgd8_352 parvu IgG: 20% (PFDR=0.5) threonine 0 m (87 / 435) rich repeat, PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 signal peptide very large probable mucin, β=0.65 11700 aa (0.45-0.94) long protein N.S. N.S. N.S. P=0.023 with signal (PFDR=0.39 peptide and IgA: 4.8% pronounced (21 / 435); cgd3_720 parvu Thr repeat IgG: 14% ** m (308 aa long) (61 / 435) Ubiquitin β=0.65 domain- IgA: 23.7% (0.44-0.95) containing (103 / 435); N.S. N.S. N.S. P=0.026 cgd2_120 parvu Steroid IgG: 11.7% (PFDR=0.39 0** m reductase (51 / 435) ) Analysis using all the children in the cohort (n=435). *Gene ID from CryptoDB; N.S.: Not significant; FDR: false discovery rate. Antigens associated with risk of Cryptosporidium reinfection The genes associated with increased risk of reinfection were cgd4_1910, Chro.10174, cgd8_3610 and cgd3_4190. Detected gene products of these candidates (the antigens presented in FIGS.16, 17, 18) are associated with increased risk of Cryptosporidium reinfection. Exemplary protein sequences translated from risk-associated genes cgd4_1910 and Chro.10174: >cgd4_1910 MISYKEQKLNNLPENKYKSSLGSNDSFLESPNEGMSLEITFLISSIIICIVVSLISIVTQGKNQIR VNCSDPNHIVVMTHGWAGTPANMDVLAERILNKYNILDNSQWTENNQIQKSECILIYKIHS NWGYFRSIFITSDGIENGALRMSKELQQVIIRTPSLEKISFIGHSLGGLYNRAVLPLMSNYPL EKEIQSKNSTGLIGGLKPMNFISIGTPHKGVLSDDCTFFGFEILKVLFPWKWISWLPTISQLLL MDKNKPLIADMMNNMNMINPLSWFKHRHTIGSLKGDLLVPPTSASLLPFCIDNENLSLVSF NIYEFERRYQTNNIYRLKNFKQNYQLYSKTNKNHSNFVPNIIKAKSGEKDNLIEWITVIDSG PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 NEKSYENKNEIYYRNIKNRKKLINLVKEKYHNFLNHKTLSDVFDKSPNGNLDKLVWMKTS VLFKSKIHRFFSHQLMMFCFENWGYFLLGNNFQLLDHIIENMKF (SEQ ID NO: 8) >Chro.10174 MHANMVAFIIIGEPKCRSLKIRKRILHLKMKLSFSVVLTLLIYTIGKPHGCEAGLLDTIAKAV GTYFKVFYPEVTTPRKDYSPDFELQDQLVVQSQEIMKGLVHIKNNITQIEDNWAGIKEFAE LRRNPKNIFAENSLGIVDNLSDVISKMSLSSAFKNMEAPIVFLEPPSVAIKQEEQAGTPCITC VGRLSLSQSEFKIFKSEINRLKRIHAKTLQEANQELLEAEALAKETLQQRSKIIENIQKLSNVI SLNEGVYGADNVELKFLQSDLAIAEQKHAALQQKQKALAKKIQELSSKKKSFWRK (SEQ ID NO: 9) To minimize false discoveries, as well as false exclusions, a feature selection antigen filtering step was employed using random forest (“RF”) models on survival data. For the RF models, the children were stratified into seropositive vs seronegative for each of the 233 IgA- and / or IgG-reactive antigens, and variables that were important to the models over 100 iterations were identified (FIG. 7A-B). Among antigens with an average variable importance metric (VIMP) greater than one standard deviation above the mean of all antigen VIMP scores and with positive VIMP scores (i.e., important to the model) in at least 80% of iterations, 7 antigens in addition to Gp60 and Cp23 had hazard ratios less than 1 (protective) in all four modeling groups (FIG. 7C). Additional RF comparisons are shown in FIG. 16) and are included in Table 1 along with the adjustment for the number of antigens tested. These were selected for evaluation in Cox proportional hazards models (FIG.7D-E) with adjustment for the false discovery rate. In addition to the Gp60 and Cp23 antigens, a significant association with protection from cryptosporidiosis was observed for antibodies against the Gp900 mucin (cgd7_4020), the potential mucin CpMuc8 (cgd8_700), the putative metal ion transporter CpCorA (cgd2_1520), a small membrane protein (Chro.30111) and the coiled coil domain protein CpCCDC (cgd8_830) (additional RF comparisons are shown in FIG. 16). Parenthetically, cgd8_830 seropositivity was associated with significantly lower incidence of infection, particularly during the first year of follow-up post-sampling, but was found to be more abundant in children that ultimately were infected at the end of follow-up. Likewise, Chro.30111 antibody responses showed evidence of protection during follow-up and at the end of the first year of follow-up post-sampling, but not at the end of 2 years of follow-up. A PLS-DA regression model was then used to evaluate the relative contribution of the selected antigens in defining the latent components (“loading weights”) that maximize discrimination of children by infection status (FIG. 8A). The end point metric was complete protection from PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 reinfection associated with antibody levels. The analysis was performed at age two (FIG. 8B) and age three (FIG.8C). The contribution of each antibody to the PLS-DA profile at age two (FIG.8D) and three years (FIG.8E) is also shown. Discussion Provided herein is the identification of seven cryptosporidial antigens to which a humoral immune response is associated with protection from reinfection. These included previously identified vaccine candidates, Cp23 and Cp17 proteins (7, 8, 10, 35, 36) the Gp900 mucin (15, 25, 30) as well as the novel proteins CpMuc8 (a potential mucin); CpSMP1 (small membrane protein); a coiled-coil protein CpCCDC, and a potential metal transporter CpCorA. The developmental stages of Cryptosporidium (37) include extracellular and intracellular forms that differ in protein repertoire (38, 39). It was considered a possibility that only antigens from proteins expressed at specific stages in the parasite's lifecycle were protective. Antibodies that target the early extracellular life stages in apicomplexans may be more effective at preventing infection (40). However, in this case, the protective antigens were present in more than one life-stage as assessed by mRNA transcripts (38, 39, 41). One drawback of using transcriptomics data is that post- transcriptional regulation may influence protein expression. The available proteomic data was examined, and peptides were found from four of the seven candidates in the sporozoites / oocyst proteome (39, 42). In summary, the protective antigens are not all highly expressed in sporozoites. The available information suggests that protective antigens may not be restricted to the cryptosporidial sporozoite (39, 42). While plasma IgG anti-Cp23 and Cp17 had not been previously observed to be protective in the cohort (7, 8), reanalysis of the IgG data in this study suggests that the use of the mixed models to determine the boundary of the positive response in the protein array data improved the specificity of the immunoassay results and accounted for the apparent difference in the study conclusions (FIG. 12) (44). The association observed between antibody levels and time since detection of Cryptosporidium infection suggests that anti-Cryptosporidium antibodies may be short-lived in this young age group. It is possible that multiple repeat infections are needed to generate a more durable antibody response (45, 46). In addition, a substantial proportion of the children with prior infection had largely undetectable antibody levels, similar to the larger population of immunologically naïve children. Failure to generate robust humoral immunity in infants has also been observed with infection with the apicomplexan parasite Plasmodium, with immunity to symptomatic disease developing only after repeated exposures to the pathogen (47). Also, in Plasmodium a short-lived PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 non-sterile immunity is common in infants, and in this case may involve defects in antibody affinity maturation in the host germinal centers (48–50). The immune mechanisms involved in the control of the Cryptosporidium parasite likely involve both the innate and adaptive arms of the immune system (1). The adaptive immune response consists of both cellular and humoral immunity. Pre-existing anti-Cryptosporidium IgG was shown to be associated with immunity in this work and earlier in experimentally infected adults (51). The importance of cellular immunity and in particular, interferon gamma is also evident (52–54). It remains to be determined the contribution of these seven antigens to cellular immune responses. In addition to the antibodies associated with protection, some anti-Cryptosporidium antigen- specific antibody responses were associated with an increased risk of reinfection (FIGS.7 and 16). These antibodies occurred in a distinct subset of children and their appearance was not correlated with that of the antibodies associated with the protective immune response (FIG. 17). This observation is in line with the earlier finding that not all antigen-antibody responses are associated with protection (FIG.17). Although investigated, there was no association between the appearance of the antibodies targeting these nonprotective antigens and biomarkers of inflammation or of IL-4 (which is involved in modulating the humoral immune response) (FIG. 19). Further studies are needed to identify the mechanism that promote a protective immune response. Provided herein is intensive surveillance undertaken for cryptosporidiosis from birth to three years of life and the use of a proteome array that enabled identification of novel protective antigens (55). In addition to the antigens discussed these included some antigens that although interesting were not statistically significant (FIG.17). Bibliography 1. Cohn IS, Henrickson SE, Striepen B, Hunter CA. Immunity to Cryptosporidium: Lessons from Acquired and Primary Immunodeficiencies. The Journal of Immunology 2022;209(12):2261–2268. 2. Kotloff KL et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case- control study. The Lancet 2013;382(9888):209–222. 3. Haque R et al. Prospective Case‐Control Study of the Association between Common Enteric Protozoal Parasites and Diarrhea in Bangladesh. Clinical Infectious Diseases 2009;48(9):1191–1197. 4. Sow SO et al. The Burden of Cryptosporidium Diarrheal Disease among Children < 24 Months of Age in Moderate / High Mortality Regions of Sub-Saharan Africa and South Asia, PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 Utilizing Data from the Global Enteric Multicenter Study (GEMS). PLoS Negl Trop Dis 2016;10(5):e0004729. 5. Korpe PS et al. Breast Milk Parasite-Specific Antibodies and Protection From Amebiasis and Cryptosporidiosis in Bangladeshi Infants: A Prospective Cohort Study. Clinical Infectious Diseases 2013;56(7):988–992. 6. Steiner KL et al. Species of cryptosporidia causing subclinical infection associated with growth faltering in rural and Urban Bangladesh: A birth cohort study. Clinical Infectious Diseases 2018;67(9):1347–1355. 7. Steiner KL et al. Fecal immunoglobulin a against a sporozoite antigen at 12 months is associated with delayed time to subsequent cryptosporidiosis in urban Bangladesh: A prospective cohort study. Clinical Infectious Diseases 2020;70(2):323–326. 8. Steiner KL et al. Delayed Time to Cryptosporidiosis in Bangladeshi Children is Associated with Greater Fecal IgA against Two Sporozoite-Expressed Antigens. Am J Trop Med Hyg 2021;104(1):229–232. 9. Gilchrist CA et al. Genetic Diversity of Cryptosporidium hominis in a Bangladeshi Community as Revealed by Whole-Genome Sequencing. J Infect Dis 2018;218(2):259–264. 10. Kabir M et al. Nonsterile immunity to cryptosporidiosis in infants is associated with mucosal IgA against the sporozoite and protection from malnutrition. PLoS Pathog 2021;17(6). doi:10.1371 / journal.ppat.1009445 11. Abrahamsen MS et al. Complete Genome Sequence of the Apicomplexan, Cryptosporidium parvum. Science (1979) 2004;304(5669):441–445. 12. Baptista RP et al. Long-read assembly and comparative evidence-based reanalysis of Cryptosporidium genome sequences reveal expanded transporter repertoire and duplication of entire chromosome ends including subtelomeric regions. Genome Res 2022;32(1):203– 213. 13. Putignani L et al. The thrombospondin-related protein CpMIC1 (CpTSP8) belongs to the repertoire of micronemal proteins of Cryptosporidium parvum. Mol Biochem Parasitol 2008;157(1):98–101. 14. Wanyiri JW et al. Role of CpSUB1, a Subtilisin-Like Protease, in Cryptosporidium parvum Infection In Vitro. Eukaryot Cell 2009;8(4):470–477. 15. Li X et al. The mucin-like, secretory type-I transmembrane glycoprotein GP900 in the apicomplexan Cryptosporidium parvum is cleaved in the secretory pathway and likely plays a lubrication role. Parasit Vectors 2022;15(1):170. PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 16. Spano F et al. Molecular cloning and expression analysis of a Cryptosporidium parvum gene encoding a new member of the thrombospondin family. Mol Biochem Parasitol 1998;92(1):147–62. 17. Tosini F, Agnoli A, Mele R, Gomez Morales MA, Pozio E. A new modular protein of Cryptosporidium parvum, with ricin B and LCCL domains, expressed in the sporozoite invasive stage. Mol Biochem Parasitol 2004;134(1):137–47. 18. O’Hara SP, Yu J-R, Lin JJ-C. A novel Cryptosporidium parvum antigen, CP2, preferentially associates with membranous structures. Parasitol Res 2004;92(4):317–327. 19. Matsubayashi M et al. Elongation Factor-1α Is a Novel Protein Associated with Host Cell Invasion and a Potential Protective Antigen of Cryptosporidium parvum. Journal of Biological Chemistry 2013;288(47):34111–34120. 20. Yu Q et al. Induction of immune responses in mice by a DNA vaccine encoding Cryptosporidium parvum Cp12 and Cp21 and its effect against homologous oocyst challenge. Vet Parasitol 2010;172(1–2):1–7. 21. Nesterenko M v, Woods K, Upton SJ. Receptor / ligand interactions between Cryptosporidium parvum and the surface of the host cell. Biochim Biophys Acta 1999;1454(2):165–73. 22. Manque PA et al. Identification and immunological characterization of three potential vaccinogens against Cryptosporidium species. Clin Vaccine Immunol 2011;18(11):1796– 802. 23. Panda C, Mahapatra RK. Identification of novel therapeutic candidates in Cryptosporidium parvum: an in silico approach. Parasitology 2018;145(14):1907–1916. 24. O’Connor RM et al. Polymorphic mucin antigens CpMuc4 and CpMuc5 are integral to Cryptosporidium parvum infection in vitro. Eukaryot Cell 2009;8(4):461–9. 25. Chatterjee A et al. Evidence for mucin-like glycoproteins that tether sporozoites of Cryptosporidium parvum to the inner surface of the oocyst wall. Eukaryot Cell 2010;9(1):84– 96. 26. Allison GM et al. Antibody responses to the immunodominant Cryptosporidium gp15 antigen and gp15 polymorphisms in a case-control study of cryptosporidiosis in children in Bangladesh. Am J Trop Med Hyg 2011;85(1):97–104. 27. Preidis GA et al. Seropositive human subjects produce interferon gamma after stimulation with recombinant Cryptosporidium hominis gp15. Am J Trop Med Hyg 2007;77(3):583–5. 28. Ajjampur SSR et al. Serum IgG Response to Cryptosporidium Immunodominant Antigen gp15 and Polymorphic Antigen gp40 in Children with Cryptosporidiosis in South India. Clinical and Vaccine Immunology 2011;18(4):633–639. PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 29. Askari N et al. Evaluation of recombinant P23 protein as a vaccine for passive immunization of newborn calves against Cryptosporidium parvum. Parasite Immunol 2016;38(5):282–289. 30. Haserick JR, Klein JA, Costello CE, Samuelson J. Cryptosporidium parvum vaccine candidates are incompletely modified with O-linked-N-acetylgalactosamine or contain N- terminal N-myristate and S-palmitate. PLoS One 2017;12(8):e0182395. 31. Bouzid M, Hunter PR, Chalmers RM, Tyler KM. Cryptosporidium Pathogenicity and Virulence. Clin Microbiol Rev 2013;26(1):115–134. 32. Priest JW et al. Cloning and Characterization of the Acidic Ribosomal Protein P2 of Cryptosporidium parvum, a New 17-Kilodalton Antigen. Clinical and Vaccine Immunology 2010;17(6):954–965. 33. Benitez A, Priest JW, Ehigiator HN, McNair N, Mead JR. Evaluation of DNA encoding acidic ribosomal protein P2 of Cryptosporidium parvum as a potential vaccine candidate for cryptosporidiosis. Vaccine 2011;29(49):9239–9245. 34. Chalmers RM, Robinson G, Elwin K, Elson R. Analysis of the Cryptosporidium spp. and gp60 subtypes linked to human outbreaks of cryptosporidiosis in England and Wales, 2009 to 2017. Parasit Vectors 2019;12(1):95. 35. Allison GM et al. Antibody Responses to the Immunodominant Cryptosporidium gp15 Antigen and gp15 Polymorphisms in a Case–Control Study of Cryptosporidiosis in Children in Bangladesh (Internet). Am J Trop Med Hyg 2011;85(1):97–104. 36. Ajjampur SSR et al. Serum IgG Response to Cryptosporidium Immunodominant Antigen gp15 and Polymorphic Antigen gp40 in Children with Cryptosporidiosis in South India. Clinical and Vaccine Immunology 2011;18(4):633–639. 37. Truong Q, Ferrari BC. Quantitative and qualitative comparisons of Cryptosporidium faecal purification procedures for the isolation of oocysts suitable for proteomic analysis. Int J Parasitol 2006;36(7):811–819. 38. Snelling WJ et al. Proteomics Analysis and Protein Expression during Sporozoite Excystation of Cryptosporidium parvum (Coccidia, Apicomplexa). Molecular & Cellular Proteomics 2007;6(2):346–355. 39. Urrea-Quezada A, Balmaceda-Baca R, Garibay A, Hernández J, Valenzuela O. Serum IgG Responses to gp15 and gp40 Protein-Derived Synthetic Peptides from Cryptosporidium parvum. Front Cell Infect Microbiol 2022;11. doi:10.3389 / fcimb.2021.810887 40. Leitch GJ, He Q. Cryptosporidiosis-an overview. J Biomed Res 2012;25(1):1–16. 41. Tandel J et al. Life cycle progression and sexual development of the apicomplexan parasite Cryptosporidium parvum. Nat Microbiol 2019;4(12):2226–2236. PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 42. Hoffman SL, Vekemans J, Richie TL, Duffy PE. The March Toward Malaria Vaccines. Am J Prev Med 2015;49(6):S319–S333. 43. Warrenfeltz S, Kissinger JC. Accessing Cryptosporidium Omic and Isolate Data via CryptoDB.org. In: 2020:139–192 44. Sanderson SJ et al. Determining the protein repertoire of Cryptosporidium parvum sporozoites. Proteomics 2008;8(7):1398–1414. 45. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4. J Stat Softw 2015;67(1). doi:10.18637 / jss.v067.i01 46. de Angelis ML et al. Repeated Exposure to Subinfectious Doses of SARS-CoV-2 May Promote T Cell Immunity and Protection against Severe COVID-19. Viruses 2021;13(6):961. 47. Fallet B et al. Chronic Viral Infection Promotes Efficient Germinal Center B Cell Responses. Cell Rep 2020;30(4):1013-1026.e7. 48. Theander TG. Defence mechanisms and immune evasion in the interplay between the humane immune system and Plasmodium falciparum. Dan Med Bull 1992;39(1):49–63. 49. Visweswaran GRR et al. Germinal center activity and B cell maturation are associated with protective antibody responses against Plasmodium pre-erythrocytic infection. PLoS Pathog 2022;18(7):e1010671. 50. O’Neal KA, Latham LE, Ntirandekura E, Foscue CL, Stumhofer JS. ICOS Expression Is Required for Maintenance but Not the Formation of Germinal Centers in the Spleen in Response to Plasmodium yoelii Infection. Infect Immun 2022;90(3). doi:10.1128 / iai.00468- 21 51. Lee MSJ et al. B cell intrinsic TBK1 is essential for germinal center formation during infection and vaccination in mice. Journal of Experimental Medicine 2022;219(2). doi:10.1084 / jem.20211336 52. Okhuysen PC et al. Infectivity of Cryptosporidium parvum in healthy adults with pre-existing anti-C. parvum serum immunoglobulin G. Am J Trop Med Hyg 1999;60(1):157–164. 53. Choudhry N, Petry F, van Rooijen N, McDonald V. A Protective Role for Interleukin 18 in Interferon γ–Mediated Innate Immunity to Cryptosporidium parvum That Is Independent of Natural Killer Cells. J Infect Dis 2012;206(1):117–124. 54. Ungar BL, Kao TC, Burris JA, Finkelman FD. Cryptosporidium infection in an adult mouse model. Independent roles for IFN-gamma and CD4+ T lymphocytes in protective immunity. J Immunol 1991;147(3):1014–22. 55. Gullicksrud JA et al. Enterocyte–innate lymphoid cell crosstalk drives early IFN-γ-mediated control of Cryptosporidium. Mucosal Immunol 2022;15(2):362–372. PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 56. Obiero JM et al. Antibody Biomarkers Associated with Sterile Protection Induced by Controlled Human Malaria Infection under Chloroquine Prophylaxis. mSphere 2019;4(1). doi:10.1128 / mSphereDirect.00027-19 57. Mazurie AJ et al. Comparative genomics of Cryptosporidium. Int J Genomics 2013;2013. doi:10.1155 / 2013 / 832756 58. Arias-Agudelo LM, Garcia-Montoya G, Cabarcas F, Galvan-Diaz AL, Alzate JF. Comparative genomic analysis of the principal Cryptosporidium species that infect humans. PeerJ 2020;8. doi:10.7717 / peerj.10478 59. Amos B et al. VEuPathDB: the eukaryotic pathogen, vector and host bioinformatics resource center. Nucleic Acids Res 2022;50(D1):D898–D911. 60. Heiber A et al. Identification of New PNEPs Indicates a Substantial Non-PEXEL Exportome and Underpins Common Features in Plasmodium falciparum Protein Export. PLoS Pathog 2013;9(8):e1003546. 61. Pool MR, Russo I. The perplexing PEXEL protein secretory pathway. Nat Microbiol 2018;3(9):969–970. 62. Kessler A et al. Convalescent Plasmodium falciparum-specific seroreactivity does not correlate with paediatric malaria severity or Plasmodium antigen exposure. Malar J 2018;17(1):178. 63. Davies DH et al. Profiling the humoral immune response to infection by using proteome microarrays: High-throughput vaccine and diagnostic antigen discovery. Proceedings of the National Academy of Sciences 2005;102(3):547–552. 64. Smith LM, Priest JW, Lammie PJ, Mead JR. Human T and B cell immunoreactivity to a recombinant 23-kDa Cryptosporidium parvum antigen. J Parasitol 2001;87(3):704–7. 65. de Onis M, Branca F. Childhood stunting: a global perspective. Matern Child Nutr 2016;12:12–26. 66. RStudio Team. RStudio: Integrated Development for R. (Internet)2015; rstudio.com / . cited August 7, 2022 67. Benaglia T, Chauveau D, Hunter DR, Young D. mixtools^: An R Package for Analyzing Finite Mixture Models. J Stat Softw 2009;32(6). doi:10.18637 / jss.v032.i06 68. Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 2016;32(18):2847–9. 69. van der Maaten L, Courville A, Fergus R, Manning C. Accelerating t-SNE using Tree-Based Algorithms (Internet).2014: 70. van der Maaten L, Hinton G. Visualizing Data using t-SNE.2008: PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 71. Pérez-Enciso M, Tenenhaus M. Prediction of clinical outcome with microarray data: a partial least squares discriminant analysis (PLS-DA) approach. Hum Genet 2003;112(5–6):581–92. 72. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society: Series B (Methodological) 1995;57(1):289–300. 73. Ishwaran H, Kogalur UB, Blackstone EH, Lauer MS. Random survival forests (published online ahead of print: November 11, 2008); doi:10.1214 / 08-AOAS169 74. Camero L, Shulaw WP, Xiao L. Characterization of a Cryptosporidium parvum Gene Encoding a Protein with Homology to Long Chain Fatty Acid Synthetase. J Eukaryot Microbiol 2003;50(s1):534–538. 75. Bhat N, Joe A, PereiraPerrin M, Ward HD. Cryptosporidium p30, a Galactose / N- Acetylgalactosamine-specific Lectin, Mediates Infection In Vitro. Journal of Biological Chemistry 2007;282(48):34877–34887. 76. Avendaño C et al. Cryptosporidium spp. CP15 and CSL protein-derived synthetic peptides’ immunogenicity and in vitro seroneutralisation capability. Vaccine 2018;36(45):6703–6710. 77. Sanderson SJ et al. Determining the protein repertoire of Cryptosporidium parvum sporozoites. Proteomics 2008;8(7):1398–1414. 78. PlasmoDB: An integrative database of the Plasmodium falciparum genome. Tools for accessing and analyzing finished and unfinished sequence data. Nucleic Acids Res 2001;29(1):66–69. EXAMPLE 2 Introduction Cryptosporidium infection is one of the top causes of diarrhea and growth faltering in Bangladeshi infants. Scientists previously carried out a natural history study of cryptosporidiosis of infants living in lower-income neighborhoods within Dhaka, Bangladesh, tracking infants’ infections from birth until they reached 3 years of age (National Clinical Trial Identifier: NCT02764918) (1– 4). The intensive surveillance undertaken during years 1-3 of their lives, combined with the high exposure to cryptosporidiosis in this population, allowed for analysis of the impact of repeated infections (sub-clinical and symptomatic) on Bangladeshi child health (5). The children’s immunity to repeated infection was non-sterile at one year old, and most children were reinfected during subsequent years. The humoral response against cryptosporidiosis has been postulated to be non-essential for a protective immune response (6). The case for the important role that T cells play in anti- PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 Cryptosporidium immunity is perhaps most compelling in patients with advanced HIV infection where chronic cryptosporidiosis occurs upon CD4+T cell deficiency. A role for IFNγ in protection is supported by its detection in jejunal biopsies of experimentally challenged volunteers but not in AIDS patients (7). In mouse models of cryptosporidiosis IFNγ- / -mice are more susceptible than WT mice (8). In addition, treatment with anti-IFNγ and anti-CD4 antibodies render mice more susceptible to cryptosporidiosis (9). The susceptibility of Rag1- / -mice (which lack B and T cells) was ascribed to the lack of T cells, as muMT- mice (lacking IgM on B cells although capable of producing IgG and IgE) remained resistant (9). Rag1- / -mice susceptibility and the impact of anti-CD4 depletion may however reflect in part the need for CD4+Tfh help in antibody production and the resistance of muMT- mice might be due to the ability of these mice to produce IgG and IgE (10). In additional studies the presence of anti-Cryptosporidium antibodies in human volunteers challenged with the parasites was associated with resistance to diarrhea (11,12). To investigate the potential role of adaptive immunity in this cohort, scientists followed a subset of the children until 4 years of age. During this time the amount of cryptosporidial diarrheal greatly decreased and the duration of infection (as determined by fecal DNA) declined. Previous studies have shown that the Cryptosporidium antigens Cp17 and Cp23 are associated with protection from reinfection in children through 3 years of life (5). To explore whether anti-Cryptosporidium antibodies play a role in mucosal and systemic immunity to cryptosporidiosis in ages 1-4, samples from a subgroup of 54 children previously infected before 1 year of age were examined. Antibodies against the Cryptosporidium antigens Cp23 and Cp17 were measured in surveillance fecal samples collected between 0-3 years of age (IgA only) and in the plasma samples collected between 1-4 years (both IgA and IgG). The avidity of the anti-Cp23 and anti-Cp17 antibodies in infants infected prior to one year of age were measured at one or one and half years and four years of age. Materials and Methods Child cohort 500 children were enrolled within 1 week of birth in an impoverished neighborhood of Dhaka, Bangladesh between June 2014 and March 2016 (FIG. 21). These children were monitored for diarrhea through bi-weekly visits to their home by trained field investigators (“Cryptosporidiosis and Enteropathogens in Bangladesh”; ClinicalTrials.gov identifier NCT02764918). Fecal samples collected from both all diarrheal episodes and asymptomatic surveillance were processed to extract fecal DNA to run a diagnostic qPCR assay to detect the protozoan parasites Cryptosporidium spp., Giardia lamblia and Entamoeba histolytica (1). At the Bangladesh study site, disease caused by the protozoan parasites was expected to be common, and a particular cause of concern during the post- neonatal period (1, 54–57). However, in 2019 when most of the children were close to completing PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 the third year of study the protocol was modified to extend the follow-up beyond 3 years. This resulted in a) Sub-Group1 of children with uninterrupted bi-weekly diarrheal surveillance and monthly asymptomatic stool collection and b) Sub-Group2 with collection of diarrheal samples available during clinic visit during the episode and bi-annual asymptomatic stool collection. To study the potential role of mucosal and systemic immunity, 54 children were randomly selected from among the children who had at least one Cryptosporidium infection prior to 1 year of age (FIG.21, 23). In accordance with WHO polio eradication protocols, stool samples collected prior to May 2016 were discarded after molecular diagnostic assays were performed to identify symptomatic and asymptomatic infections of polio. These sample were therefore not therefore available for fecal IgA analysis (Poliovirus Containment Advisory Group 2022). Plasma samples were also collected from the children bi- annually for later antibody level analysis. Human Sampling and Specimen Testing Stool samples collected fresh in the field were placed in ice and deposited into the International Centre for Diarrhoeal Disease Research (icddr,b) laboratory by the end of the same day, where they were subsequently frozen at -80 degrees C within 6 hours of collection. Blood samples collected at the Study Clinic were brought to the lab biobank for processing, freezing and storage. A subset of 54 children (FIG.21, 23), who were identified as infected with the Cryptosporidium parasite prior to one year in age, were selected for anti-Cp23 and Cp27 IgA and IgG immune profiles using the fecal samples collected after May 2016 and the plasma samples. Blood samples were collected biannually from the children during years 1-3 and annually at years 4 and 5 of age (FIG.21). ELISA Protocol to detect anti-Cp23 and Cp27 IgG and IgA antibodies Fecal dilution buffer was first prepared consisting of PBS mixed with 0.5M EDTA pH 8, 50µg / ml of soybean trypsin inhibitor, and 666µL of 100mM PMSF. Fecal samples were then thawed, and a single 100 mg aliquot of stool was combined 1:10 in Fecal Dilution Buffer. One Eppendorf capful of glass beads was added (~, and the sample was homogenized in a Qiagen TissueLyser II for 10 minutes. Samples were then centrifuged at 10,000 g for 5 minutes. Supernatants were collected and stored for ELISA antibody testing. ELISA plates were coated with 50µL per well of the CP17 or CP23 antigen solution at a concentration of 5 µg / mL, diluted in PBS. The plate was covered and left to incubate overnight on a shaker at 4 degrees. The plate was then washed 3 times with PBS mixed with 0.05% Tween 20 (PBST) wash buffer to remove any non-adhered coating buffer.150 µL of ELISA blocking solution was added to each well, and the plate was allowed to incubate for 1 hour at 37 degrees in a shaking incubator. The wells were then washed one more time.50 µL of fecal sample diluted 1:4 in blocking PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 buffer were added to each well on the plate. The plate was again incubated for an hour at 37 degrees in the shaking incubator. If antibody avidity was being assayed the plate was then washed 3 times in PBST wash buffer and 50 µL of either PBS or a 0.5M NH4SCN -PBS solution was added to one of two paired wells. The plate was incubated at room temperature for 15 min. These latter two steps were however omitted if only antibody levels were being determined. The plate was then washed 3 times in PBST wash buffer and 50 µL of HRP antihuman conjugated secondary antibody (Southern Biotechnology) was added per well, and it was left to incubate for 1 hour at 37 degrees. The plate was then washed 3 times with PBST and 50 µL per well of TMB Turbo ELISA Substrate (Fisher ThermoScientific) was added. The plates were incubated at room temperature (RT) for 7.5 minutes, then 50 µL of stop solution (2N H2SO4) was added to each well. Absorbance was measured at 450 nm (corrected with absorbance at 570 nm). For plasma samples, the same procedure was carried out except that the dilution of the primary samples was 1500x for IgG and 150x for IgA. In all plates, a dilution series of a pool of strong positive samples was used to generate a standard curve and determine the relative antibody values and negative control samples were used to determine a positive cutoff value. Statistical Analysis Analysis of infection frequency and the impact of repeat infections on parasite burden and antibody levels was performed using the Prism 10 computer program using either the Brown and Wilson Chi-square test for trend or the Kruskal-Wallis test with the Dunn’s test for multiple comparisons of nonparametric data as appropriate (GraphPad) (58,59). All other analyses were performed using R (version 4.3.0), with packages tidyverse (version 2.0.0) and readxl (version 1.4.2) used for data organization and visualization (RStudio Team 2015). The strength of the antibody associations with time was analyzed using Pearson’s correlation test and linear regression analysis. All code used for these analyses will be made public with the publication of the paper through GitHub at github.com / wikipetria / Cryptosporidium / blob / main / Petri_et_al. Results Diarrheal disease is associated with Cryptosporidium infection declines beginning at two years of age. Five hundred children were enrolled within the first week of birth, and of these 360 completed four full years of observation (FIG. 21). Although diarrheal samples continued to be collected from all children enrolled in the 4 years of the study monthly surveillance was only continued for children in Sub-Group 1, while surveillance samples were collected only at 6-month intervals in Sub-Group 2 (FIG.21). The Sub-Group 1 dataset where the field workers made biweekly study visits was analyzed to study changes in Cryptosporidium infection frequency in years 0-4, and the collection of both monthly stool samples and yearly blood samples continued to year 4 (Table 1). PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 Cryptosporidium-associated diarrheal infections were defined as an episode of diarrhea associated with the first parasite PCR positive sample collected in a new Cryptosporidium infection, indicated by stool sample(s), testing negative for Cryptosporidium for at least 65 of the preceding days (ensuring at least two samples that were qPCR negative for Cryptosporidium parasite had been 5 collected before the new positive sample) (1). Table 1: Incidence of Cryptosporidiosis in the Mirpur cohort. Range Episodes Cryptosporidium of sub- (days in infections Episodes of age)clinica YearsCo Participating l llected diarrheal Ch disease of surveillance ildren cryptosporidiosis per samples sub- (calculated)* per child per 6 diarrheal child Start End clinical months infections per 6 infections months 0 183 0.5 1099 1 11 183 0.01 0.06 183 365 1 1052 14 31 175 0.08 0.18 365 548 1.5 1017 13 28 170 0.08 0.17 548 731 2 992 20 41 165 0.12 0.25 731 913 2.5 967 14 56 161 0.09 0.35 913 1096 3 925 15 60 154 0.10 0.39 1096 1278 3.5 333 3 19 56 0.05 0.34 1278 1461 4 829 2 46 138 0.01 0.33 *This number is calculated on the basis that six surveillance stools should have been collected from each child in the study during the 6-month time period (Bin width:182.625 days; centered on 90.3125 days). Actual child numbers varied due to children that missed a surveillance stool collection time0 point and the fact that some children were lost to study follow-up during each of the six-month periods. In line with previous observations, the frequency of diarrheal cryptosporidiosis significantly declined in years 3-4 (FIG.22) (5). This was highest in children between 1.5 and 2 years of age when5 there were 0.12 diarrheal episodes per child and thereafter it occurred less frequently (i.e., falling to 0.01 episodes per child between 3.5-4 years). Sub-clinical disease did not decline in frequency over PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 the same time period (2-4 years of life) and remained at 0.33 ± 0.05 episodes per child in each 6 months (183 days) of life (FIG.22, Table 2). This suggested that in these children >6 months of age exposure to the Cryptosporidium parasite remained constant while the frequency of diarrheal disease declined. A rapid decline in diarrhea-associated cryptosporidiosis also occurred in Sub-Group 2 (FIG. 26). The duration of Cryptosporidium stool positivity is shorter in children with repeat infections. Total infection length (defined as a continuing collection of Cryptosporidium qPCR positive stool even in the absence of overt diarrhea) was examined to assess the possible impact of repeat infections on the duration of infection (including both symptomatic and sub-clinical infection periods). Cryptosporidium-positive infections (diarrheal and sub-clinical) were classified into two groups, cases where only one diagnostic qPCR-positive fecal sample (± 65day interval) was collected or into a longer infection group where more than one temporally linked positive sample in the same child was detected. A significant decrease in the proportion of longer infections was evident in repeatedly infected children (Table 2; Chi-square test for trend p<0.0001). Table 2: The ratio of Chronic versus Single sample Cryptosporidium Infections declined during repeat infections. group with longer infections was defined as where more than one temporally linked positive sample in the same child was detected. The data were further analyzed to determine if the duration of diarrheal symptoms was affected by the child's infection history. However, scientists did not find that this was significantly impacted by either the child's age or the number of previous Cryptosporidium infections a child had experienced (data not shown). PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 Anti-Cryptosporidium Cp23 and Cp17 IgA and IgG Antibody Profiles Throughout the study period a significant proportion of pediatric subjects remained serologically positive for CP17 and Cp23 antibodies (Table 3; (13)). Anti-Cp17 and anti-Cp23 antibodies were common in ≥1 year-olds (Anti-Cp17 IgG 77%±8: Anti-Cp17 IgA 61%±6: Anti- Cp23 IgG 86%±5: Anti-Cp23 IgA 46%± 6) but, with the exception Anti-Cp23 IgA, antibody levels appeared to decline with age (RAU: Anti-Cp17 IgG one-year-olds versus 172.7 ± 190.0 in 4-year- olds 89.84 ± 103.8; Anti-Cp17 IgA one-year-olds 1697 ± 2083 versus in 4-year-olds 1135 ± 1176 ; Anti-Cp23 IgG one-year-olds 911.4 ± 1009 versus in 4-year-olds 609.8 ± 565.1; Anti-Cp23 IgA one- year-olds 1243 ± 1675, 4-year-olds 1603 ± 2051). Table 3: Prevalence of seropositive samples. This table shows time post birth of the plasma collection, and the percent of children with a positive signal via ELISA for Cp17 IgG and IgA antibody (% positive is shown in the brackets). PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 To examine the serological response in conjunction with potential confounders 345 plasma samples were assayed for anti-Cp17 and Cp23 IgA and IgG antibody levels between years 1-4 of age. As only 39 children in Sub-Group 1 had at least one Cryptosporidium infection before one year in age and had completed 4 years of the study (and so had the potential to be seropositive at age one) an additional 11 children were added from Sub-Group 2 (n=54). The children had a median of 3 Cryptosporidium infections over the 4 years tracked, with a range of 1 to 6 infections (FIG. 26). Surveillance fecal samples collected at <3 years of age from the same children were also available to analyze fecal IgA, however due to the discontinuation of some children from the study (FIG.21) and the discarding of some samples because of the possibility of cVDPV2 polio virus emergence (14), only a subset of the collected samples were available in the study database for further analyses (n=1308; year 1 n=209; year 2 n=482, year 3 n=649). Linear mixed effects modeling was used to examine associations between antibody levels and factors previously associated with susceptibility to cryptosporidiosis (household income, proximity to open drains, child HAZ and rainy season in Bangladesh (June to October)) as well as the impact of child age and the number of previous Cryptosporidium infections (FIG.24) (1,5). An increase in the number of Cryptosporidium infections a child had experienced was associated with a concordant increase in antibody levels (fecal anti-Cp17 IgA and plasma anti-Cp23 IgG (FIG.24 A, F), but this correlation was not always statistically significant (FIG.24 B, C, D, E). Scientists also discovered a noticeable association with increased anti-Cryptosporidium levels in child plasma during the rainy season in younger children (FIG. 24B, C, F). This may reflect both the greater intestinal-barrier permeability in young infants, and the greater number of Cryptosporidium infections occurring in the rainy season (2,15–19). In fecal samples this effect was either not observed (FIG. 24A) or not statistically significant (FIG. 24D). The observed differences in statistical significance may reflect the complex mix of potential confounding variables (e.g., gut microbiota, maternal breast milk composition and infant delivery methods) that contribute to fecal IgA levels, and which may not able to be completely compensated for using the data collected during this study (20–28). Anti-Cp17 antibody avidity increases with age. In line with earlier observations, anti-Cryptosporidium antibody levels continued to decline as the children got older (FIG. 27A, C, D, F) (13). This was most pronounced with fecal IgA antibodies, which had a significant negative correlation with age (FIG. 27). The adaptive immune system gradually matures over the first decade of life (29,30). Antibody affinity maturation increases antibody activity through multiple rounds of somatic hypermutation and selection in the germinal center (31). It is hypothesized that an increase of anti-Cryptosporidium antibody avidity after repeated infections tempers the requirement for high levels of anti-Cp17 and Cp23 antibodies. To PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 measure the functional affinity of the antibodies a modification of the standard ELISA assay was developed that included an incubation with the chaotropic reagent ammonium thiocyanate (NH4SCN) (32,33). This assay was then used to compare the avidity of human antibodies in plasma collected from previously infected one or one and a half year old infants with the avidity of the IgG plasma antibodies in the samples collected from the same infants at 4 years of age (n=56). A significant increase in anti-Cp17 antibody affinity was observed in the older children (paired samples; p<0.0001) (FIG.25A). However, no change was observed in the avidity of the anti-Cp23 IgG antibodies against recombinant Cp23 in older children (FIG.25B p=0.95; paired samples n=28). This may reflect the use of the recombinant Cp23 expressed in bacteria in these assays does not incorporate any of the secondary protein modifications of Cryptosporidium proteins (34). Discussion Provided herein is the observation that the number of diarrheal Cryptosporidium infections peaked at age 2 but steadily declined over the next two years. The length of time a child remained infected also decreased (Table 1; Chi-square test for trend p<0.0001). However, the frequency of sub-clinical asymptomatic infections remained constant and the level of antibodies to Cp17 and Cp23 were higher in fecal material earlier in life. This observation suggests that the systemic antibody elevation when first infections were common was short-lived and that infection could be controlled with lower antibody levels in older children (15,30,31). Adaptive immunity may not be fully developed in the younger children experiencing their first infection due either to the age of the child or the transient nature of the parasitic infection (35–37). A key aspect of antibody maturation— antibody avidity, was examined in a subset of plasma samples collected before one and a half and four years of age from the same Bangladeshi infants (32). Scientists found that the avidity of the anti-Cp17 IgG antibodies was indeed higher in the samples collected when the children were 4 years old. However, the avidity of the anti-Cp23 antibodies appeared unchanged in these assays. Both Gp15 (which encompasses the Cp17 peptide) and Cp23 undergo secondary modifications in the native Cryptosporidium proteins, however the lipidation of the native Cp23 protein may have a larger impact on high-affinity antibody recognition (38,39). While the unmodified Cp17 peptide and Cp23 worked well in these ELISAs, a correctly lipidated Cp23 protein may be required to observe an increase in anti-Cp23 antibody avidity (39). The mechanisms involved in the selection of high-affinity antibodies are however also complex (33). Differences have been observed in the timing of the acquisition of increased anti-T. gondi antibody avidity to different antigen targets after an infection (32). The Cryptosporidium Cp23 protein is also a microneme protein and hence is involved early in host cell infection and during autoinfection (40). However, while the Gp40 / Gp15 protein (which encompasses the Cp17 peptide) PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 complex has been found in the microneme vesicles, it has also been found on the sporozoite surface, and in the parasitophorous vacuole membranes (41–43). It may therefore be more exposed to the host immune system. These results are consistent with the hypothesis that in repeat infections, lower levels of anti- Cp17 antibodies with higher affinity for the parasite can control disease outcome. Higher avidity antibodies would enable the host to respond more quickly and overcome the infection faster, resulting in a decline in disease severity and a decrease in infection length. Preliminary studies observed that the decline in the proportion of diarrheal cases happened sooner in children who had the greater anti- Cp17 avidity at one year in age (3rdinfection: upper half of the data set p=0.04) and parasite burden declined (5). There was an observed decrease in total infection length in this data set. These findings are consistent with the development of a protective immune response. A vaccine against cryptosporidiosis can significantly reduce post-neonatal cryptosporidiosis and improve child health by reducing the burden of diarrheal disease (47). This parasite has a complex lifecycle with both intracellular and extracellular life stages (48,49). While the cellular immunity regulated by IFNγ is undoubtedly an important component of the anti-Cryptosporidium immune response and is essential to resolve the parasitic infection (6,50,51) the work reported here was focused on the humoral antibody response to the Cryptosporidium pathogen. The data provided herein suggests that increases in antibody affinity to key parasite antigens over time could lead to a reduction in the amount of diarrheal disease and a decline in infection length (52,53). More work is needed but this work supports roles for both arms of the immune system (cellular and humoral) in an immune response that protects children from infection with this parasite. Bibliography 1. Steiner KL, Ahmed S, Gilchrist CA, et al. Species of cryptosporidia causing subclinical infection associated with growth faltering in rural and Urban Bangladesh: A birth cohort study. Clinical Infectious Diseases 2018; 67:1347–1355. 2. Gilchrist CA, Cotton JA, Burkey C, et al. Genetic Diversity of Cryptosporidium hominis in a Bangladeshi Community as Revealed by Whole-Genome Sequencing. J Infect Dis 2018; 218:259–264. 3. Steiner KL, Kabir M, Hossain B, et al. Delayed Time to Cryptosporidiosis in Bangladeshi Children is Associated with Greater Fecal IgA against Two Sporozoite-Expressed Antigens. Am J Trop Med Hyg 2021; 104:229–232. 4. Steiner KL, Kabir M, Priest JW, et al. Fecal immunoglobulin a against a sporozoite antigen at 12 months is associated with delayed time to subsequent cryptosporidiosis in urban Bangladesh: A prospective cohort study. Clinical Infectious Diseases 2020; 70:323–326. PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 5. Kabir M, Alam M, Nayak U, et al. Nonsterile immunity to cryptosporidiosis in infants is associated with mucosal IgA against the sporozoite and protection from malnutrition. PLoS Pathog 2021; 17. 6. Cohn IS, Henrickson SE, Striepen B, Hunter CA. Immunity to Cryptosporidium: Lessons from Acquired and Primary Immunodeficiencies. The Journal of Immunology 2022; 209:2261– 2268. 7. White AC, Robinson P, Okhuysen PC, et al. Interferon‐γ Expression in Jejunal Biopsies in Experimental Human Cryptosporidiosis Correlates with Prior Sensitization and Control of Oocyst Excretion. J Infect Dis 2000; 181:701–709. 8. Sateriale A, Šlapeta J, Baptista R, et al. A Genetically Tractable, Natural Mouse Model of Cryptosporidiosis Offers Insights into Host Protective Immunity. Cell Host Microbe 2019; 26:135-146.e5. 9. Chen W, Harp JA, Harmsen AG. Cryptosporidium parvum infection in gene-targeted B cell- deficient mice. J Parasitol 2003; 89:391–3. 10. Ghosh S, Hoselton SA, Schuh JM. μ-Chain–Deficient Mice Possess B-1 Cells and Produce IgG and IgE, but Not IgA, following Systemic Sensitization and Inhalational Challenge in a Fungal Asthma Model. The Journal of Immunology 2012; 189:1322–1329. 11. Okhuysen PC, Jakubowski W, Dupont HL, Sterling CR, Wang C, Chappell CL. Infectivity of Cryptosporidium parvum in healthy adults with pre-existing anti-C. parvum serum immunoglobulin G. Am J Trop Med Hyg 1999; 60:157–164. 12. Moss DM, Chappell CL, Okhuysen PC, et al. The Antibody Response to 27‐, 17‐, and 15‐kDa Cryptosporidium Antigens following Experimental Infection in Humans. J Infect Dis 1998; 178:827–833. 13. Gilchrist CA, Campo JJ, Pablo J V., et al. Specific Cryptosporidium antigens associate with reinfection immunity and protection from cryptosporidiosis. Journal of Clinical Investigation 2023; 133. 14. Poliovirus Containment Advisory Group. WHO Global Action Plan for Poliovirus Containment (GAPIV).2022. Available at: http: / / www.wipo.int / amc / en / mediation / rules / . 15. Crompton PD, Kayala MA, Traore B, et al. A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proceedings of the National Academy of Sciences 2010; 107:6958–6963. 16. Jagai JS, Castronovo DA, Monchak J, Naumova EN. Seasonality of cryptosporidiosis: A meta- analysis approach. Environ Res 2009; 109:465–478. PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 17. Palomino-Kobayashi LA, Ymaña B, Ruiz J, Mayanga-Herrera A, Ugarte-Gil MF, Pons MJ. Zonulin, a marker of gut permeability, is associated with mortality in a cohort of hospitalised peruvian COVID-19 patients. Front Cell Infect Microbiol 2022; 12. 18. Osman M, Kassem II, Dabboussi F, Cummings KJ, Hamze M. The indelible toll of enteric pathogens: Prevalence, clinical characterization, and seasonal trends in patients with acute community-acquired diarrhea in disenfranchised communities. PLoS One 2023; 18:e0282844. 19. Łoniewska B, Adamek K, Węgrzyn D, et al. Analysis of Faecal Zonulin and Calprotectin Concentrations in Healthy Children During the First Two Years of Life. An Observational Prospective Cohort Study. J Clin Med 2020; 9:777. 20. Huus KE, Rodriguez-Pozo A, Kapel N, et al. Immunoglobulin recognition of fecal bacteria in stunted and non-stunted children: findings from the Afribiota study. Microbiome 2020; 8:113. Available at: https: / / microbiomejournal.biomedcentral.com / articles / 10.1186 / s40168-020- 00890-1. 21. Chen YY, Tun HM, Field CJ, et al. Impact of Cesarean Delivery and Breastfeeding on Secretory Immunoglobulin A in the Infant Gut Is Mediated by Gut Microbiota and Metabolites. Metabolites 2023; 13:148. 22. Matos YAS, Cano J, Shafiq H, Williams C, Sunny J, Cowardin CA. Colonization during a key developmental window reveals microbiota-dependent shifts in growth and immunity during undernutrition. bioRxiv 2024; Available at: https: / / doi.org / 10.1101 / 2023.07.07.547849. 23. Hares MF, Griffiths BE, Johnson F, et al. Specific pathway abundances in the neonatal calf faecal microbiome are associated with susceptibility to Cryptosporidium parvum infection: a metagenomic analysis. Anim Microbiome 2023; 5:43. Available at: https: / / animalmicrobiome.biomedcentral.com / articles / 10.1186 / s42523-023-00265-5. 24. Hurle GeorginaR, Brainard J, Tyler KevinM. Microbiome diversity is a modifiable virulence factor for cryptosporidiosis. Virulence 2023; 14. Available at: https: / / www.tandfonline.com / doi / full / 10.1080 / 21505594.2023.2273004. 25. Funkhouser-Jones LJ, Xu R, Wilke G, et al. Microbiota-produced indole metabolites disrupt mitochondrial function and inhibit Cryptosporidium parvum growth. Cell Rep 2023; 42:112680. 26. Carey MA, Medlock GL, Alam M, et al. Megasphaera in the Stool Microbiota Is Negatively Associated with Diarrheal Cryptosporidiosis. Clinical Infectious Diseases 2021; 73:e1242– e1251. 27. Widmer G, Creasey HN. Fecal microbiota impacts development of Cryptosporidium parvum in the mouse. Sci Rep 2024; 14:5498. PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 28. Ye X, Li H, Anjum K, et al. Dual Role of Indoles Derived from Intestinal Microbiota on Human Health. Front Immunol 2022; 13:903526. 29. Moraes-Pinto MI de, Suano-Souza F, Aranda CS. Immune system: development and acquisition of immunological competence. J Pediatr (Rio J) 2021; 97:S59–S66. 30. Basha S, Surendran N, Pichichero M. Immune responses in neonates. Expert Rev Clin Immunol 2014; 10:1171–1184. Available at: http: / / www.tandfonline.com / doi / full / 10.1586 / 1744666X.2014.942288. 31. Gatto D, Brink R. The germinal center reaction. Journal of Allergy and Clinical Immunology 2010; 126:898–907. 32. Holec-Gąsior L, Sołowińska K. IgG Avidity Test as a Tool for Discrimination between Recent and Distant Toxoplasma gondii Infection—Current Status of Studies. Antibodies 2022; 11:52. 33. Nakagama Y, Candray K, Kaku N, et al. Antibody Avidity Maturation Following Recovery From Infection or the Booster Vaccination Grants Breadth of SARS-CoV-2 Neutralizing Capacity. J Infect Dis 2023; 227:780–787. 34. Haserick JR, Klein JA, Costello CE, Samuelson J. Cryptosporidium parvum vaccine candidates are incompletely modified with O-linked-N-acetylgalactosamine or contain N- terminal N-myristate and S-palmitate. PLoS One 2017; 12:e0182395. 35. Taylor DW, Bobbili N, Kayatani A, Tassi Yunga S, Kidima W, Leke RFG. Measuring antibody avidity to Plasmodium falciparum merozoite antigens using a multiplex immunoassay approach. Malar J 2020; 19:171. 36. Tassi Yunga S, Bobbili N, Lloyd YM, et al. Does Antibody Avidity to Plasmodium falciparum Merozoite Antigens Increase with Age in Individuals Living in Malaria-Endemic Areas? Infect Immun 2021; 89. 37. Correa VA, Rodrigues TS, Portilho AI, Trzewikoswki de Lima G, De Gaspari E. Modified ELISA for antibody avidity evaluation: The need for standardization. Biomed J 2021; 44:433– 438. 38. Haserick JR, Klein JA, Costello CE, Samuelson J. Cryptosporidium parvum vaccine candidates are incompletely modified with O-linked-N-acetylgalactosamine or contain N- terminal N-myristate and S-palmitate. PLoS One 2017; 12:e0182395. 39. Chiang C-Y, Pan C-H, Hsieh C-H, et al. Lipidated Dengue-2 Envelope Protein Domain III Independently Stimulates Long-Lasting Neutralizing Antibodies and Reduces the Risk of Antibody-Dependent Enhancement. PLoS Negl Trop Dis 2013; 7:e2432. 40. Guérin A, Strelau KM, Barylyuk K, et al. Cryptosporidium uses multiple distinct secretory organelles to interact with and modify its host cell. Cell Host Microbe 2023; 31:650-664.e6. PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 41. O’Connor RM, Wanyiri JW, Cevallos AM, Priest JW, Ward HD. Cryptosporidiu parvum glycoprotein gp40 localizes to the sporozoite surface by association with gp15. Mol Biochem Parasitol 2007; 156:80–83. 42. Cui Z, Wang L, Wang Y, et al. Cryptosporidium parvum gp40 / 15 Is Associated with the Parasitophorous Vacuole Membrane and Is a Potential Vaccine Target. Microorganisms 2020; 8:363. 43. Li M, Sun X, Chen H, et al. Stable expression of mucin glycoproteins GP40 and GP15 of Cryptosporidium parvum in Toxoplasma gondii. Parasit Vectors 2024; 17:65. 44. Taniuchi M, Sobuz SU, Begum S, et al. Etiology of Diarrhea in Bangladeshi Infants in the First Year of Life Analyzed Using Molecular Methods. Journal of Infectious Diseases 2013; 208:1794–1802. 45. Liu J, Platts-Mills JA, Juma J, et al. Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study. The Lancet 2016; 388:1291–1301. 46. Platts-Mills JA, Babji S, Bodhidatta L, et al. Pathogen-specific burdens of community diarrhoea in developing countries: a multisite birth cohort study (MAL-ED). Lancet Glob Health 2015; 3:e564–e575. 47. Wutor BM, Osei I, Babila Galega L, et al. Verbal autopsy analysis of childhood deaths in rural Gambia. PLoS One 2023; 18:e0277377. 48. Tandel J, English ED, Sateriale A, et al. Life cycle progression and sexual development of the apicomplexan parasite Cryptosporidium parvum. Nat Microbiol 2019; 4:2226–2236. 49. Guérin A, Striepen B. The Biology of the Intestinal Intracellular Parasite Cryptosporidium. Cell Host Microbe.2020; 28:509–515. 50. Pardy RD, Wallbank BA, Striepen B, Hunter CA. Immunity to Cryptosporidium: insights into principles of enteric responses to infection. Nat Rev Immunol.2023; 51. Gullicksrud JA, Sateriale A, Engiles JB, et al. Enterocyte–innate lymphoid cell crosstalk drives early IFN-γ-mediated control of Cryptosporidium. Mucosal Immunol 2022; 15:362–372. 52. Li K, Horn GQ, Abraha M, et al. Higher antigen occupancy of high avidity CSP serum antibodies associate with protection against human malaria. Biophys J 2023; 122:144a–145a. Available at: https: / / linkinghub.elsevier.com / retrieve / pii / S0006349522018598. 53. Ssewanyana I, Arinaitwe E, Nankabirwa JI, et al. Avidity of anti-malarial antibodies inversely related to transmission intensity at three sites in Uganda. Malar J 2017; 16:67. Available at: https: / / malariajournal.biomedcentral.com / articles / 10.1186 / s12936-017-1721-3. PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 54. Black RE, Victora CG, Walker SP, et al. Maternal and child undernutrition and overweight in low-income and middle-income countries. Lancet 2013; 382:427–451. 55. Haque R, Mondal D, Karim A, et al. Prospective Case‐Control Study of the Association between Common Enteric Protozoal Parasites and Diarrhea in Bangladesh. Clinical Infectious Diseases 2009; 48:1191–1197. 56. Korpe PS, Haque R, Gilchrist C, et al. Natural History of Cryptosporidiosis in a Longitudinal Study of Slum-Dwelling Bangladeshi Children: Association with Severe Malnutrition. PLoS Negl Trop Dis 2016; 10:e0004564. 57. Mondal D, Minak J, Alam M, et al. Contribution of enteric infection, altered intestinal barrier function, and maternal malnutrition to infant malnutrition in Bangladesh. Clin Infect Dis 2012; 54:185–92. 58. Brown LD, Cai TT, Dasgupta A. Interval Estimation for a Binomial Proportion. Statistical Science 2001; 16:101–117. Available at: https: / / www.jstor.org / stable / 2676784. Accessed 10 July 2023. 59. McKight PE, Najab J. Kruskal‐Wallis Test. In: The Corsini Encyclopedia of Psychology. Wiley, 2010: 1–1. EXAMPLE 3 Introduction This work was based on the previous discovery that fecal IgA against the Cryptosporidium Cp23 and Cp17 antigens were associated with protection from re-infection. The proposal tests in a mouse model, whether a vaccine based on these proteins combined with the mucosal adjuvant GLA- 3M052 is protective. In addition to using the adjuvanted protein vaccine, a self-amplifying RNA (saRNA) formulated with a nanostructured lipid carrier (NLC) vaccine construct ± QS21 adjuvant resulted in a protective immune response. Materials and Methods Wild-type mice were infected and later challenged with Cryptosporidium. Metrics include fecal parasite burden (qPCR) and ELISA determination of antibody levels in fecal and plasma samples. Vaccinations against Cryptosporidium in mice utilize previously identified antigens (namely Cp17 and Cp23) that have been known to trigger immunoprotective antibody responses. Adjuvanted (GLA-3M052) protein and saRNA forms of these antigens were administered during experiments in isolation or combination, to ascertain whether vector-type could influence immunity against Cryptosporidium. Results PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 Infection of naïve wild-type mice with Cryptosporidium (FIG.28) demonstrates a relationship between the eventual decrease in parasite burden (days 8-15 post-infection) and the onset of adaptive immunity in the form of elevated anti-Cp17 antibodies (FIG.29). Experiment I After vaccination of infected mice with saRNA (Cp17 / Cp23), elevated anti-Cp23 levels were apparent in comparison to mice administered either a protein control or a mock vaccination (FIG. 33). Parasitic burden in infected and vaccinated mice peaked during days 11 and 14 post-infection (FIG. 34). Interestingly, on day 14 there a significant decrease in Crypto. burden in animals intramuscularly vaccinated with the Cp17 / Cp23 saRNA compared to animals injected with control saRNA or intranasal Cp17 / Cp23 saRNA (FIG.34). Experiment II Vaccination with the Cryptosporidium saRNA vaccine constructs produced a good anti-Cp23 IgG immune response in serum (FIG.36). Antibodies to the Cp17 were not however detected (FIG. 37). The inclusion of the QS21 adjuvant did not have a significant impact on the immune response (FIGS. 36 and 37). After challenge with the Cryptosporidium parvum parasite, no measurable decrease in the parasite burden was observed (FIG.39). Anti-Cp17 IgG was only detected after the GLA-3M052 Cp17 / Cp23 (adjuvanted protein) vaccination (FIG. 37). Intramuscular injection of the anti-Cryptosporidium saRNA which encoded Cp17 in tandem with the Cp23 sequence did not result in a strong immune response – suggesting that for the Cp17 target this expression vector was ineffective (FIG. 37). Interestingly the prime-boost vaccination regime (saRNA vaccination priming followed by a protein vaccination boost, Gp4) resulted in similar levels of Anti-Cp17 IgG as conventional vaccination strategies (repeated vaccination with the adjuvanted protein). However, neither approach generated detectable levels of fecal Anti-Cp17 IgA prior to parasite challenge (FIG.39). In challenge experiments, the mice vaccinated with the adjuvanted protein had a lower parasite burden than control animals at 10 days post challenge (FIG.38). This was associated with an increase in the amount of fecal Anti-CP17 IgA (FIG. 39). The parasite burden was inversely related to the amount of fecal anti-Cp17 IgA (FIG.39). Outcomes provided herein are: 1) Vaccination with both the GLA-3M052 Cp17 / Cp23 protein complex and the saRNA vaccine generated anti-Cryptosporidium IgG responses, 2) Anti-Cp17 IgG was only detected after the GLA-3M052 Cp17 / Cp23 (adjuvanted protein) vaccine, and 3) In challenge experiments, the mice vaccinated with the adjuvanted protein had a lower parasite burden than control animals at 10 days post-challenge. The parasite burden was inversely related to the amount of fecal anti-Cp17 IgA. PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 Discussion The Cryptosporidium parasite has a complex life cycle within the host gastrointestinal tract, cycling between the invasive extracellular (sporozoite and merozoites) and intracellular life stages. The saRNA vaccine evoked an immune response against the Cp23 protein. This is a microneme protein and is potentially secreted during sporozoite gliding motility (a process that moves the extracellular parasite) and invasion. The saRNA is effective at generating a cellular immune response therefore other antigens associated with the protective immune response (e.g., CpMuc8 & CpCCDC1) are good antigens to targets using this approach. A new saRNA vector construct is required to test the utility of using this technique to generate anti-Cp17 immune responses. The inclusion of retinoic acid in previous vaccine formulations has been shown to increase the mucosal IgA responses after vaccination. All-trans retinoic acid (all- transRA) pre-vaccination treatment has also been shown to increase the amount of high-affinity IgA antibodies in mice (Christensen et al.2019). Improvements in vaccination strategy include producing a multivalent vaccine incorporating the panel of protective antigens identified in previous studies (Gp900 (the Cryptosporidium mucin) and four additional antigens (CpSMP1, CpMuc8, CpCorA and CpCCDC1), as well as testing whether the lipidated Cp23 protein provides a better target antigen. Testing the alternative adjuvants funded for global access by the NIAID may also yield better vaccine formulations. Embodiments 1. A method to inhibit or prevent a Cryptosporidium infection, including a reinfection, comprising administering an effective amount of a cryptosporidial antigen to a subject, wherein said cryptosporidial antigen comprises one or more of Gp900, CpMuc8, CpSMP1, CpCCDC and / or CpCorA or portion thereof which elicits an immune response. 2. The method of embodiment 1, wherein the cryptosporidial antigen further comprises Cp23 and / or Cp17. 3. The method of embodiment 1 or 2, wherein RNA encoding the cryptosporidial antigen, DNA encoding the cryptosporidial antigen, or cryptosporidial antigen protein is administered. 4. The method of embodiment 3, wherein the RNA is self-replicating / self-amplifying RNA. 5. The method of embodiment 3 or 4, wherein the DNA and / or RNA encode two more cryptosporidial antigen proteins. 6. The method of any one of embodiments 1 to 5, further comprising administering an adjuvant. 7. The method of embodiment 6, wherein the adjuvant is GLA-3M052. PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 8. The method of any one of embodiments 1 to 8, wherein the cryptosporidial antigen is administered more than once. 9. A method for inducing protective immunity against Cryptosporidium infection in a human comprising administering an effective amount of cryptosporidial antigen to the human, wherein said cryptosporidial antigen comprises one or more of Gp900, CpMuc8, CpSMP1, CpCCDC and / or CpCorA or portion thereof which elicits an immune response. 10. The method of embodiment 9, wherein the cryptosporidial antigen further comprises Cp23 and / or Cp17. 11. The method of embodiment 9 or 10, wherein the RNA encoding the cryptosporidial antigen, DNA encoding the cryptosporidial antigen, or cryptosporidial antigen protein is administered. 12. The method of embodiment 11, wherein the RNA is self-replicating / self-amplifying RNA. 13. The method of embodiment 11 or 12, wherein the DNA and / or RNA encode two more cryptosporidial antigen proteins. 14. The method of any one of embodiments 9 to 13, further comprising administering an adjuvant. 15. The method of embodiment 14, wherein the adjuvant is GLA-3M052. 16. The method of any one of embodiments 9 to 15, wherein the cryptosporidial antigen is administered more than once. 17. The method of any one of embodiments 9 to 16, wherein the protective immunity reduces a risk of Cryptosporidium infection. 18. The method of any one of embodiments 9 to 16, wherein the protective immunity delays onset of Cryptosporidium infection and / or reduces the severity of Cryptosporidium infection. 19. A composition comprising at least one of Gp900, CpMuc8, CpSMP1, CpCCDC and / or CpCorA or portion thereof and an adjuvant, and optionally comprising Cp23 and / or Cp17. 20. The method of any one of embodiments 1 to 18 or the composition of embodiment 19, wherein cryptosporidial antigen protein is any one of SEQ ID NOs: 10 to 23 or a sequence that has at least about 80% sequence identity thereto. All publications, patents, and patent applications, Genbank sequences, websites and other published materials referred to throughout the disclosure herein are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application, Genbank sequences, websites and other published materials was specifically and individually indicated to be incorporated by reference. In the event that the definition of a term incorporated by reference conflicts with a term defined herein, this specification shall control.

Claims

PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 WHAT IS CLAIMED IS:

1. A method to inhibit or prevent a Cryptosporidium infection, including a reinfection, comprising administering an effective amount of a cryptosporidial antigen to a subject, wherein said cryptosporidial antigen comprises one or more of Gp900, CpMuc8, CpSMP1, CpCCDC and / or CpCorA or portion thereof which elicits an immune response.

2. The method of claim 1, wherein the cryptosporidial antigen further comprises Cp23 and / or Cp17.

3. The method of claim 1, wherein RNA encoding the cryptosporidial antigen, DNA encoding the cryptosporidial antigen, or cryptosporidial antigen protein is administered.

4. The method of claim 3, wherein the RNA is self-replicating / self-amplifying RNA.

5. The method of claim 3, wherein the DNA and / or RNA encode two more cryptosporidial antigen proteins.

6. The method of claim 1, further comprising administering an adjuvant.

7. The method of claim 6, wherein the adjuvant is GLA-3M052.

8. The method of claim 1, wherein the cryptosporidial antigen is administered more than once.

9. A method for inducing protective immunity against Cryptosporidium infection in a human comprising administering an effective amount of cryptosporidial antigen to the human, wherein said cryptosporidial antigen comprises one or more of Gp900, CpMuc8, CpSMP1, CpCCDC and / or CpCorA or portion thereof which elicits an immune response.

10. The method of claim 9, wherein the cryptosporidial antigen further comprises Cp23 and / or Cp17.

11. The method of claim 9, wherein the RNA encoding the cryptosporidial antigen, DNA encoding the cryptosporidial antigen, or cryptosporidial antigen protein is administered.PETRI-CRYPTO3 (02939-02) / / 1036.364WO1 12. The method of claim 11, wherein the RNA is self-replicating / self-amplifying RNA.

13. The method of claim 11, wherein the DNA and / or RNA encode two more cryptosporidial antigen proteins.

14. The method of any one of claims 9 to 13, further comprising administering an adjuvant.

15. The method of claim 14, wherein the adjuvant is GLA-3M052.

16. The method of claim 9, wherein the cryptosporidial antigen is administered more than once.

17. The method of claim 9, wherein the protective immunity reduces a risk of Cryptosporidium infection.

18. The method of claim 9, wherein the protective immunity delays onset of Cryptosporidium infection and / or reduces the severity of Cryptosporidium infection.

19. A method to provide passive immunity to a subject comprising administering one or more antibodies to said subject, wherein said one or more antibodies are directed to at least one of Gp900, CpMuc8, CpSMP1, CpCCDC, CpCorA or portion thereof or optionally comprising Cp23, Cp17 or portion thereof.

20. The method of claim 19, wherein the antibody is a monoclonal antibody.

21. A composition comprising at least one of Gp900, CpMuc8, CpSMP1, CpCCDC, CpCorA or portion thereof and an adjuvant, and optionally comprising Cp23 and / or Cp17.

22. The method of any one of claims 1 to 20, or the composition of claim 21, wherein cryptosporidial antigen protein is any one of SEQ ID NOs: 10 to 23 or a sequence that has at least about 80% sequence identity thereto.

Citation Information

Patent Citations

  • Cryptosporidium parvum Gp40 / 15 protein epitope polypeptide and adenovirus vector vaccine thereof

    CN113754749A

  • Recombinant cryptosporidium parvum antigen and detection of antibodies thereto

    US20020081312A1

  • Vaccines, antibodies, proteins, glycoproteins, DNAS and RNAS for prophylaxis and treatment of cryptosporidium parvum infections

    WO1998006430A1

  • Neutralization-sensitive epitopes of cryptosporidium parvum

    WO1998007320A1

  • METHODS FOR DETECTION OF CRYPTOSPORIDIUM SPECIES AND ISOLATES AND FOR DIAGNOSIS OF CRYPTOSPORIDIUMINFECTIONS

    WO2001094631A1